VOLUME FOUR HUNDRED AND EIGHT Y-NINE
METHODS
IN
ENZYMOLOGY The Unfolded Protein Response and Cellular Stress, Part A...
33 downloads
1522 Views
5MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
VOLUME FOUR HUNDRED AND EIGHT Y-NINE
METHODS
IN
ENZYMOLOGY The Unfolded Protein Response and Cellular Stress, Part A
METHODS IN ENZYMOLOGY Editors-in-Chief
JOHN N. ABELSON AND MELVIN I. SIMON Division of Biology California Institute of Technology Pasadena, California Founding Editors
SIDNEY P. COLOWICK AND NATHAN O. KAPLAN
VOLUME FOUR HUNDRED AND EIGHT Y-NINE
METHODS
IN
ENZYMOLOGY The Unfolded Protein Response and Cellular Stress, Part A EDITED BY
P. MICHAEL CONN Divisions of Reproductive Sciences and Neuroscience (ONPRC) Departments of Pharmacology and Physiology Cell and Developmental Biology, and Obstetrics and Gynecology (OHSU) Beaverton, OR, USA
AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier
Academic Press is an imprint of Elsevier 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 32 Jamestown Road, London NW1 7BY, UK First edition 2011 Copyright # 2011, Elsevier Inc. All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@ elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at http://elsevier.com/locate/permissions, and selecting Obtaining permission to use Elsevier material Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made For information on all Academic Press publications visit our website at elsevierdirect.com ISBN: 978-0-12-385116-1 ISSN: 0076-6879 Printed and bound in United States of America 11 12 13 10 9 8 7 6 5 4 3 2 1
CONTENTS
Contributors Preface Volumes in Series
Section I. UPR and Cell Stress in Normal and Diseased Cells 1. The Unfolded Protein Response in Mouse Cerebral Cortex
xi xvii xix
1 3
Nirinjini Naidoo 1. Introduction: The UPR 2. Transduction of the UPR Signal by PERK, IRE1, and ATF6 3. UPR and Apoptosis 4. The UPR in Health and Disease 5. Induction of the UPR by Sleep Deprivation 6. Experimental Protocols 7. Concluding Remarks Acknowledgments References
2. Immunohistochemical Detection of the Unfolded Protein Response in Atherosclerotic Plaques
3 4 5 6 6 7 18 19 19
23
Sˇa´rka Lhota´k, Ji Zhou, and Richard C. Austin 1. Endoplasmic Reticulum and the Unfolded Protein Response 2. Atherosclerosis 3. UPR in the Atherosclerotic Lesion 4. Mouse Models of Atherosclerosis 5. Methods Acknowledgments References
3. The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
24 24 25 27 29 44 44
47
Stefano Toldo, Anna Severino, Antonio Abbate, and Alfonso Baldi 1. Introduction 2. Identification of PDI as Cardio-Protective Factor
48 50 v
vi
Contents
3. Conclusions References
4. Measurement of the Increase in Endoplasmic Reticulum Stress-Related Proteins and Genes in Adipose Tissue of Obese, Insulin-Resistant Individuals
62 62
67
Guenther Boden and Salim Merali 1. Introduction 2. Study Subjects and Fat Biopsies 3. Proteomic Analysis 4. Western Blot Analysis 5. RT-PCR Analysis Acknowledgments References
5. Measurement of the Unfolded Protein Response (UPR) in Monocytes
68 69 70 79 80 81 82
83
Toma´s P. Carroll, Catherine M. Greene, and Noel G. McElvaney 1. Introduction 2. Investigating UPR Activation in the Monocyte Acknowledgments References
6. Assessment of Endurance Exercise Training in Hepatic Endoplasmic Reticulum Stress
84 86 93 93
97
Natalie Ann Chapados 1. Introduction 2. Assessment of an Endurance-Training Program 3. “Dietary-Inducible” Hepatic ER Stress 4. Assessment of Hepatic ER Stress Molecular Markers 5. Required Materials Acknowledgments References
7. Discovery Approaches to UPR in Athero-Susceptible Endothelium In Vivo
98 99 104 105 105 106 106
109
Mete Civelek, Elisabetta Manduchi, Gregory R. Grant, Christian J. Stoeckert Jr., and Peter F. Davies 1. Introduction 2. Procedures for the Isolation of Endothelial Cells and Preparation of RNA for Microarray Hybridization 3. Microarray Hybridization and Feature Extraction
110 112 116
Contents
4. Bioinformatics Analysis 5. Another Approach to Gene Connectivity: Weighted Gene Coexpression Network Analysis 6. Validation and Follow-up Acknowledgments References
8. Assessment of Endoplasmic Reticulum Stress and the Unfolded Protein Response in Endothelial Cells
vii 117 122 124 125 125
127
Ines Witte and Sven Horke 1. Introduction 2. The Acute Phase of ER Stress 3. The Adaptive Reaction Phase: Unfolded Protein Response in Endothelial Cells 4. The Final Phase: Cell Death Signaling Acknowledgments References
9. Measuring the Impact of Cigarette Smoke on the UPR
128 129 131 140 145 145
147
Hong Zhao, Jin Yang, Lin Shan, and Ellen D. Jorgensen 1. Introduction 2. Preparing Samples for Analysis 3. Analysis of Activation of the PERK Pathway 4. ATF6 Pathway 5. IRE1 Pathway 6. Using LSC to Measure UPR Activation Acknowledgments References
10. Induction and Measurement of UPR and Osmotic Stress in the Yeast Pichia pastoris
148 149 155 158 159 159 161 162
165
Martin Dragosits, Diethard Mattanovich, and Brigitte Gasser 1. Introduction 2. Measuring UPR Induction in P. pastoris 3. Inducing and Measuring Osmotic Stress in P. pastoris Acknowledgments References
11. Induction of ER Stress Response Leading to Programmed Cell Death in Trypanosoma brucei
166 169 179 186 186
189
Hanoch Goldshmidt and Shulamit Michaeli 1. Introduction 2. Induction of ER Stress in Trypanosomes
190 193
viii
Contents
3. Measurements of ER Stress in Trypanosomes Cells 4. Measurements of ER Stress-Induced Cell Death Acknowledgments References
12. Measurement of Activation of the Endoplasmic Reticulum Stress Response in Autoimmune Myositis
194 201 203 203
207
Heather M. Alger, Sree Rayavarapu, and Kanneboyina Nagaraju 1. Introduction 2. Measuring Endoplasmic Reticulum Stress Response in Skeletal Muscle Tissues Using Western Blotting 3. Immunohistochemical Detection of ER Stress Markers in Muscle Tissues 4. Determination of mRNA Levels of ER Stress Targets 5. Concluding Remarks Acknowledgments References
13. Activation of the Unfolded Protein Response in Human Acute Myeloid Leukemia
208 209 216 221 223 223 223
227
Julian A. Schardt, Beatrice U. Mueller, and Thomas Pabst 1. Introduction 2. Technical Aspects 3. Discussion References
14. Modulation of the Unfolded Protein Response by GRP78 in Prostate Cancer
228 232 239 241
245
Gustaaf de Ridder, Rupa Ray, Uma K. Misra, and Salvatore V. Pizzo 1. Introduction 2. Methods for Monitoring UPR Modulation 3. Conclusions References
15. Endoplasmic Reticulum Stress in Brain Damage
246 248 256 256
259
Ram Raghubir, Venkata Prasuja Nakka, and Suresh L. Mehta 1. Introduction 2. ER Stress and Unfolded Protein Response 3. Cross Talk Between ER and Mitochondria 4. Experimental Approaches for the Detection of ER Stress Acknowledgment References
260 261 267 269 271 272
Contents
16. Methods and Models for Monitoring UPR-Associated Macrophage Death During Advanced Atherosclerosis
ix
277
Edward B. Thorp 1. Introduction to ER Stress in Atherosclerosis 2. Significance of Macrophage ER Stress and Apoptosis in Advanced Atherosclerosis 3. Modeling Atherosclerosis-Relevant ER Stress-Induced Apoptosis 4. The UPR and Macrophage Death at the Murine Aortic Root 5. Conclusion and Future Methodological Advances Acknowledgments References
278 279 281 285 293 293 293
17. Detecting Autophagy in Response to ER Stress Signals in Cancer 297 Marı´a Salazar, Sonia Herna´ndez-Tiedra, Sofı´a Torres, Mar Lorente, Manuel Guzma´n, and Guillermo Velasco 1. Introduction 2. Monitoring Autophagy Upon ER Stress 3. Monitoring Autophagy Upon ER Stress In Vivo References
18. The Unfolded Protein Response Induced by Salt Stress in Arabidopsis
298 299 309 317
319
Miaoying Wang, Qiangyi Xu, and Ming Yuan 1. Introduction 2. The Treatment of Arabidopsis Seedlings 3. The Analysis of Unfolded Protein Response Acknowledgments References
19. Measurement of ER Stress Response and Inflammation in the Mouse Model of Nonalcoholic Fatty Liver Disease
319 320 322 327 327
329
Ze Zheng, Chunbin Zhang, and Kezhong Zhang 1. Introduction 2. Methods to Measure ER Stress Response and Hepatic Inflammation in the Mouse Model of NAFLD 3. Visualizing ER Stress Response Associated with Liver Pathology in the Mouse Model of NAFLD Acknowledgments References Author Index Subject Index
330 332 341 345 345 349 365
CONTRIBUTORS
Antonio Abbate Victoria Johnson Research Center and VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA Heather M. Alger Research Center for Genetic Medicine, Children’s National Medical Center, Washington, DC, USA Richard C. Austin Department of Medicine and Division of Nephrology, St. Joseph’s Hospital and McMaster University, Hamilton, Ontario, Canada Alfonso Baldi Department of Biochemistry and Biophysics F. Cedrangolo, Second University of Naples, Italy Guenther Boden Department of Medicine and the Clinical Research Center, Temple University School of Medicine, Philadelphia, PA, USA Toma´s P. Carroll Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland Natalie Ann Chapados Institut de Recherche de l’Hoˆpital Montfort/Montfort Hospital, Research Institute, Ottawa, Ontario, Canada Mete Civelek Institute for Medicine and Engineering, and Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiology, Department of Medicine, University of California, Los Angeles, California, USA Peter F. Davies Institute for Medicine and Engineering, and Department of Bioengineering; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA Gustaaf de Ridder Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA xi
xii
Contributors
Martin Dragosits Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, Vienna, Austria, and UC Davis Genome Center, University of California Davis, One Shields Avenue, Davis, USA Brigitte Gasser Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, and Austrian Centre of Industrial Biotechnology (ACIB GmbH), Muthgasse 18, Vienna, Austria Hanoch Goldshmidt The Mina and Everard Goodman Faculty of Life Sciences, and Advanced Materials and Nanotechnology Institute, Bar-Ilan University, Ramat-Gan, Israel Gregory R. Grant Center for Bioinformatics, and Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA Catherine M. Greene Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland Manuel Guzma´n Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, and Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain Sonia Herna´ndez-Tiedra Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain Sven Horke Institute of Pharmacology, University Medical Center of the Johannes Gutenberg University Mainz, Germany Ellen D. Jorgensen Department of Pathology, New York Medical College, Valhalla, New York, USA Sˇa´rka Lhota´k Department of Medicine and Division of Nephrology, St. Joseph’s Hospital and McMaster University, Hamilton, Ontario, Canada Mar Lorente Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain Elisabetta Manduchi Center for Bioinformatics, and Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Contributors
xiii
Diethard Mattanovich Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, and Austrian Centre of Industrial Biotechnology (ACIB GmbH), Muthgasse 18, Vienna, Austria Noel G. McElvaney Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland Suresh L. Mehta Department of Pharmaceutical Sciences/BRITE, North Carolina Central University, Durham, North Carolina, USA Salim Merali Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA, USA Shulamit Michaeli The Mina and Everard Goodman Faculty of Life Sciences, and Advanced Materials and Nanotechnology Institute, Bar-Ilan University, Ramat-Gan, Israel Uma K. Misra Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA Beatrice U. Mueller Department of Internal Medicine, University Hospital, Bern, Switzerland Kanneboyina Nagaraju Research Center for Genetic Medicine, Children’s National Medical Center, and Department of Pediatrics, The George Washington University Medical Center, Washington, DC, USA Venkata Prasuja Nakka Department of Neurological Surgery, School of Medicine & Public Health, University of Wisconsin, Madison, Wisconsin, USA Nirinjini Naidoo Center for Sleep and Circadian Neurobiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA Thomas Pabst Department of Medical Oncology, University Hospital, Bern, Switzerland Salvatore V. Pizzo Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
xiv
Contributors
Ram Raghubir Division of Pharmacology, Central Drug Research Institute, (CSIR), Chatter Manzil Palace, Lucknow, India Rupa Ray Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA Sree Rayavarapu Research Center for Genetic Medicine, Children’s National Medical Center, and Institute of Biomedical Sciences, The George Washington University, Washington, DC, USA Marı´a Salazar Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, and Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain Julian A. Schardt Department of Medical Oncology, University Hospital, Bern, Switzerland Anna Severino Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy Lin Shan Pathology Department, Duke University Medical Center, Durham, North Carolina, USA Christian J. Stoeckert Jr. Center for Bioinformatics, and Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA Edward B. Thorp Department of Medicine, Division of Molecular Medicine, Columbia University, New York, USA Stefano Toldo Victoria Johnson Research Center and VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA Sofı´a Torres Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain Guillermo Velasco Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, and Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
Contributors
xv
Miaoying Wang State Key Laboratory of Plant Physiology and Biochemistry, College of Biological Sciences, China Agricultural University, Beijing, China Ines Witte Institute of Pharmacology, University Medical Center of the Johannes Gutenberg University Mainz, Germany Qiangyi Xu State Key Laboratory of Plant Physiology and Biochemistry, College of Biological Sciences, China Agricultural University, Beijing, China Jin Yang Education and Training Systems International, Inc., Chapel Hill, North Carolina, USA Ming Yuan State Key Laboratory of Plant Physiology and Biochemistry, College of Biological Sciences, China Agricultural University, Beijing, China Chunbin Zhang The Center for Molecular Medicine and Genetics, The Wayne State University School of Medicine, Detroit, Michigan, USA Kezhong Zhang The Center for Molecular Medicine and Genetics, and The Department of Immunology and Microbiology, The Wayne State University School of Medicine, Detroit, Michigan, USA Hong Zhao Department of Pathology, New York Medical College, Valhalla, New York, USA Ze Zheng The Center for Molecular Medicine and Genetics, The Wayne State University School of Medicine, Detroit, Michigan, USA, and Currently a graduate student in the program of Biological Science at the Wayne State University Ji Zhou Department of Medicine, Thrombosis and Atherosclerosis Research Institute (TaARI) and McMaster University, Hamilton, Ontario, Canada
PREFACE
The observation that the living cell contains a mechanism to sense and correct the accumulation of unfolded (or incorrectly folded) proteins in the endoplasmic reticulum was formidable in organizing thoughts about cellular integration. This mechanism both halts further protein synthesis and promotes the production of chaperone proteins that act to relieve this problem. If this problem cannot be corrected, the mechanism can initiate programmed cell death. Aspects of this unfolded protein response (UPR) are conserved from yeast to man, an observation that suggests a key role in the process of maintaining a living cell. The UPR presents a way of understanding cellular regulation, a mechanism for disease, and a therapeutic opportunity. The present volume provides descriptions of the occurrence of the UPR, the methods used to assess it, pharmacological tools, and other methodological approaches to analyze its impact on cellular regulation. The authors explain how these methods are able to provide important biological insights. Authors were selected based on research contributions in the area about which they have written and based on their ability to describe their methodological contributions in a clear and reproducible way. They have been encouraged to make use of graphics, comparisons to other methods, and to provide tricks and approaches not revealed in prior publications that make it possible to adapt methods to other systems. The editor expresses appreciation to the contributors for providing their contributions in a timely fashion, to the senior editors for guidance, and to the staff at Academic Press for their helpful inputs. P. MICHAEL CONN
xvii
This page intentionally left blank
METHODS IN ENZYMOLOGY
VOLUME I. Preparation and Assay of Enzymes Edited by SIDNEY P. COLOWICK AND NATHAN O. KAPLAN VOLUME II. Preparation and Assay of Enzymes Edited by SIDNEY P. COLOWICK AND NATHAN O. KAPLAN VOLUME III. Preparation and Assay of Substrates Edited by SIDNEY P. COLOWICK AND NATHAN O. KAPLAN VOLUME IV. Special Techniques for the Enzymologist Edited by SIDNEY P. COLOWICK AND NATHAN O. KAPLAN VOLUME V. Preparation and Assay of Enzymes Edited by SIDNEY P. COLOWICK AND NATHAN O. KAPLAN VOLUME VI. Preparation and Assay of Enzymes (Continued) Preparation and Assay of Substrates Special Techniques Edited by SIDNEY P. COLOWICK AND NATHAN O. KAPLAN VOLUME VII. Cumulative Subject Index Edited by SIDNEY P. COLOWICK AND NATHAN O. KAPLAN VOLUME VIII. Complex Carbohydrates Edited by ELIZABETH F. NEUFELD AND VICTOR GINSBURG VOLUME IX. Carbohydrate Metabolism Edited by WILLIS A. WOOD VOLUME X. Oxidation and Phosphorylation Edited by RONALD W. ESTABROOK AND MAYNARD E. PULLMAN VOLUME XI. Enzyme Structure Edited by C. H. W. HIRS VOLUME XII. Nucleic Acids (Parts A and B) Edited by LAWRENCE GROSSMAN AND KIVIE MOLDAVE VOLUME XIII. Citric Acid Cycle Edited by J. M. LOWENSTEIN VOLUME XIV. Lipids Edited by J. M. LOWENSTEIN VOLUME XV. Steroids and Terpenoids Edited by RAYMOND B. CLAYTON
xix
xx
Methods in Enzymology
VOLUME XVI. Fast Reactions Edited by KENNETH KUSTIN VOLUME XVII. Metabolism of Amino Acids and Amines (Parts A and B) Edited by HERBERT TABOR AND CELIA WHITE TABOR VOLUME XVIII. Vitamins and Coenzymes (Parts A, B, and C) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME XIX. Proteolytic Enzymes Edited by GERTRUDE E. PERLMANN AND LASZLO LORAND VOLUME XX. Nucleic Acids and Protein Synthesis (Part C) Edited by KIVIE MOLDAVE AND LAWRENCE GROSSMAN VOLUME XXI. Nucleic Acids (Part D) Edited by LAWRENCE GROSSMAN AND KIVIE MOLDAVE VOLUME XXII. Enzyme Purification and Related Techniques Edited by WILLIAM B. JAKOBY VOLUME XXIII. Photosynthesis (Part A) Edited by ANTHONY SAN PIETRO VOLUME XXIV. Photosynthesis and Nitrogen Fixation (Part B) Edited by ANTHONY SAN PIETRO VOLUME XXV. Enzyme Structure (Part B) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XXVI. Enzyme Structure (Part C) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XXVII. Enzyme Structure (Part D) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XXVIII. Complex Carbohydrates (Part B) Edited by VICTOR GINSBURG VOLUME XXIX. Nucleic Acids and Protein Synthesis (Part E) Edited by LAWRENCE GROSSMAN AND KIVIE MOLDAVE VOLUME XXX. Nucleic Acids and Protein Synthesis (Part F) Edited by KIVIE MOLDAVE AND LAWRENCE GROSSMAN VOLUME XXXI. Biomembranes (Part A) Edited by SIDNEY FLEISCHER AND LESTER PACKER VOLUME XXXII. Biomembranes (Part B) Edited by SIDNEY FLEISCHER AND LESTER PACKER VOLUME XXXIII. Cumulative Subject Index Volumes I-XXX Edited by MARTHA G. DENNIS AND EDWARD A. DENNIS VOLUME XXXIV. Affinity Techniques (Enzyme Purification: Part B) Edited by WILLIAM B. JAKOBY AND MEIR WILCHEK
Methods in Enzymology
VOLUME XXXV. Lipids (Part B) Edited by JOHN M. LOWENSTEIN VOLUME XXXVI. Hormone Action (Part A: Steroid Hormones) Edited by BERT W. O’MALLEY AND JOEL G. HARDMAN VOLUME XXXVII. Hormone Action (Part B: Peptide Hormones) Edited by BERT W. O’MALLEY AND JOEL G. HARDMAN VOLUME XXXVIII. Hormone Action (Part C: Cyclic Nucleotides) Edited by JOEL G. HARDMAN AND BERT W. O’MALLEY VOLUME XXXIX. Hormone Action (Part D: Isolated Cells, Tissues, and Organ Systems) Edited by JOEL G. HARDMAN AND BERT W. O’MALLEY VOLUME XL. Hormone Action (Part E: Nuclear Structure and Function) Edited by BERT W. O’MALLEY AND JOEL G. HARDMAN VOLUME XLI. Carbohydrate Metabolism (Part B) Edited by W. A. WOOD VOLUME XLII. Carbohydrate Metabolism (Part C) Edited by W. A. WOOD VOLUME XLIII. Antibiotics Edited by JOHN H. HASH VOLUME XLIV. Immobilized Enzymes Edited by KLAUS MOSBACH VOLUME XLV. Proteolytic Enzymes (Part B) Edited by LASZLO LORAND VOLUME XLVI. Affinity Labeling Edited by WILLIAM B. JAKOBY AND MEIR WILCHEK VOLUME XLVII. Enzyme Structure (Part E) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XLVIII. Enzyme Structure (Part F) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME XLIX. Enzyme Structure (Part G) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME L. Complex Carbohydrates (Part C) Edited by VICTOR GINSBURG VOLUME LI. Purine and Pyrimidine Nucleotide Metabolism Edited by PATRICIA A. HOFFEE AND MARY ELLEN JONES VOLUME LII. Biomembranes (Part C: Biological Oxidations) Edited by SIDNEY FLEISCHER AND LESTER PACKER
xxi
xxii
Methods in Enzymology
VOLUME LIII. Biomembranes (Part D: Biological Oxidations) Edited by SIDNEY FLEISCHER AND LESTER PACKER VOLUME LIV. Biomembranes (Part E: Biological Oxidations) Edited by SIDNEY FLEISCHER AND LESTER PACKER VOLUME LV. Biomembranes (Part F: Bioenergetics) Edited by SIDNEY FLEISCHER AND LESTER PACKER VOLUME LVI. Biomembranes (Part G: Bioenergetics) Edited by SIDNEY FLEISCHER AND LESTER PACKER VOLUME LVII. Bioluminescence and Chemiluminescence Edited by MARLENE A. DELUCA VOLUME LVIII. Cell Culture Edited by WILLIAM B. JAKOBY AND IRA PASTAN VOLUME LIX. Nucleic Acids and Protein Synthesis (Part G) Edited by KIVIE MOLDAVE AND LAWRENCE GROSSMAN VOLUME LX. Nucleic Acids and Protein Synthesis (Part H) Edited by KIVIE MOLDAVE AND LAWRENCE GROSSMAN VOLUME 61. Enzyme Structure (Part H) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME 62. Vitamins and Coenzymes (Part D) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME 63. Enzyme Kinetics and Mechanism (Part A: Initial Rate and Inhibitor Methods) Edited by DANIEL L. PURICH VOLUME 64. Enzyme Kinetics and Mechanism (Part B: Isotopic Probes and Complex Enzyme Systems) Edited by DANIEL L. PURICH VOLUME 65. Nucleic Acids (Part I) Edited by LAWRENCE GROSSMAN AND KIVIE MOLDAVE VOLUME 66. Vitamins and Coenzymes (Part E) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME 67. Vitamins and Coenzymes (Part F) Edited by DONALD B. MCCORMICK AND LEMUEL D. WRIGHT VOLUME 68. Recombinant DNA Edited by RAY WU VOLUME 69. Photosynthesis and Nitrogen Fixation (Part C) Edited by ANTHONY SAN PIETRO VOLUME 70. Immunochemical Techniques (Part A) Edited by HELEN VAN VUNAKIS AND JOHN J. LANGONE
Methods in Enzymology
xxiii
VOLUME 71. Lipids (Part C) Edited by JOHN M. LOWENSTEIN VOLUME 72. Lipids (Part D) Edited by JOHN M. LOWENSTEIN VOLUME 73. Immunochemical Techniques (Part B) Edited by JOHN J. LANGONE AND HELEN VAN VUNAKIS VOLUME 74. Immunochemical Techniques (Part C) Edited by JOHN J. LANGONE AND HELEN VAN VUNAKIS VOLUME 75. Cumulative Subject Index Volumes XXXI, XXXII, XXXIV–LX Edited by EDWARD A. DENNIS AND MARTHA G. DENNIS VOLUME 76. Hemoglobins Edited by ERALDO ANTONINI, LUIGI ROSSI-BERNARDI, AND EMILIA CHIANCONE VOLUME 77. Detoxication and Drug Metabolism Edited by WILLIAM B. JAKOBY VOLUME 78. Interferons (Part A) Edited by SIDNEY PESTKA VOLUME 79. Interferons (Part B) Edited by SIDNEY PESTKA VOLUME 80. Proteolytic Enzymes (Part C) Edited by LASZLO LORAND VOLUME 81. Biomembranes (Part H: Visual Pigments and Purple Membranes, I) Edited by LESTER PACKER VOLUME 82. Structural and Contractile Proteins (Part A: Extracellular Matrix) Edited by LEON W. CUNNINGHAM AND DIXIE W. FREDERIKSEN VOLUME 83. Complex Carbohydrates (Part D) Edited by VICTOR GINSBURG VOLUME 84. Immunochemical Techniques (Part D: Selected Immunoassays) Edited by JOHN J. LANGONE AND HELEN VAN VUNAKIS VOLUME 85. Structural and Contractile Proteins (Part B: The Contractile Apparatus and the Cytoskeleton) Edited by DIXIE W. FREDERIKSEN AND LEON W. CUNNINGHAM VOLUME 86. Prostaglandins and Arachidonate Metabolites Edited by WILLIAM E. M. LANDS AND WILLIAM L. SMITH VOLUME 87. Enzyme Kinetics and Mechanism (Part C: Intermediates, Stereo-chemistry, and Rate Studies) Edited by DANIEL L. PURICH VOLUME 88. Biomembranes (Part I: Visual Pigments and Purple Membranes, II) Edited by LESTER PACKER
xxiv
Methods in Enzymology
VOLUME 89. Carbohydrate Metabolism (Part D) Edited by WILLIS A. WOOD VOLUME 90. Carbohydrate Metabolism (Part E) Edited by WILLIS A. WOOD VOLUME 91. Enzyme Structure (Part I) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME 92. Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods) Edited by JOHN J. LANGONE AND HELEN VAN VUNAKIS VOLUME 93. Immunochemical Techniques (Part F: Conventional Antibodies, Fc Receptors, and Cytotoxicity) Edited by JOHN J. LANGONE AND HELEN VAN VUNAKIS VOLUME 94. Polyamines Edited by HERBERT TABOR AND CELIA WHITE TABOR VOLUME 95. Cumulative Subject Index Volumes 61–74, 76–80 Edited by EDWARD A. DENNIS AND MARTHA G. DENNIS VOLUME 96. Biomembranes [Part J: Membrane Biogenesis: Assembly and Targeting (General Methods; Eukaryotes)] Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 97. Biomembranes [Part K: Membrane Biogenesis: Assembly and Targeting (Prokaryotes, Mitochondria, and Chloroplasts)] Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 98. Biomembranes (Part L: Membrane Biogenesis: Processing and Recycling) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 99. Hormone Action (Part F: Protein Kinases) Edited by JACKIE D. CORBIN AND JOEL G. HARDMAN VOLUME 100. Recombinant DNA (Part B) Edited by RAY WU, LAWRENCE GROSSMAN, AND KIVIE MOLDAVE VOLUME 101. Recombinant DNA (Part C) Edited by RAY WU, LAWRENCE GROSSMAN, AND KIVIE MOLDAVE VOLUME 102. Hormone Action (Part G: Calmodulin and Calcium-Binding Proteins) Edited by ANTHONY R. MEANS AND BERT W. O’MALLEY VOLUME 103. Hormone Action (Part H: Neuroendocrine Peptides) Edited by P. MICHAEL CONN VOLUME 104. Enzyme Purification and Related Techniques (Part C) Edited by WILLIAM B. JAKOBY
Methods in Enzymology
VOLUME 105. Oxygen Radicals in Biological Systems Edited by LESTER PACKER VOLUME 106. Posttranslational Modifications (Part A) Edited by FINN WOLD AND KIVIE MOLDAVE VOLUME 107. Posttranslational Modifications (Part B) Edited by FINN WOLD AND KIVIE MOLDAVE VOLUME 108. Immunochemical Techniques (Part G: Separation and Characterization of Lymphoid Cells) Edited by GIOVANNI DI SABATO, JOHN J. LANGONE, AND HELEN VAN VUNAKIS VOLUME 109. Hormone Action (Part I: Peptide Hormones) Edited by LUTZ BIRNBAUMER AND BERT W. O’MALLEY VOLUME 110. Steroids and Isoprenoids (Part A) Edited by JOHN H. LAW AND HANS C. RILLING VOLUME 111. Steroids and Isoprenoids (Part B) Edited by JOHN H. LAW AND HANS C. RILLING VOLUME 112. Drug and Enzyme Targeting (Part A) Edited by KENNETH J. WIDDER AND RALPH GREEN VOLUME 113. Glutamate, Glutamine, Glutathione, and Related Compounds Edited by ALTON MEISTER VOLUME 114. Diffraction Methods for Biological Macromolecules (Part A) Edited by HAROLD W. WYCKOFF, C. H. W. HIRS, AND SERGE N. TIMASHEFF VOLUME 115. Diffraction Methods for Biological Macromolecules (Part B) Edited by HAROLD W. WYCKOFF, C. H. W. HIRS, AND SERGE N. TIMASHEFF VOLUME 116. Immunochemical Techniques (Part H: Effectors and Mediators of Lymphoid Cell Functions) Edited by GIOVANNI DI SABATO, JOHN J. LANGONE, AND HELEN VAN VUNAKIS VOLUME 117. Enzyme Structure (Part J) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME 118. Plant Molecular Biology Edited by ARTHUR WEISSBACH AND HERBERT WEISSBACH VOLUME 119. Interferons (Part C) Edited by SIDNEY PESTKA VOLUME 120. Cumulative Subject Index Volumes 81–94, 96–101 VOLUME 121. Immunochemical Techniques (Part I: Hybridoma Technology and Monoclonal Antibodies) Edited by JOHN J. LANGONE AND HELEN VAN VUNAKIS VOLUME 122. Vitamins and Coenzymes (Part G) Edited by FRANK CHYTIL AND DONALD B. MCCORMICK
xxv
xxvi
Methods in Enzymology
VOLUME 123. Vitamins and Coenzymes (Part H) Edited by FRANK CHYTIL AND DONALD B. MCCORMICK VOLUME 124. Hormone Action (Part J: Neuroendocrine Peptides) Edited by P. MICHAEL CONN VOLUME 125. Biomembranes (Part M: Transport in Bacteria, Mitochondria, and Chloroplasts: General Approaches and Transport Systems) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 126. Biomembranes (Part N: Transport in Bacteria, Mitochondria, and Chloroplasts: Protonmotive Force) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 127. Biomembranes (Part O: Protons and Water: Structure and Translocation) Edited by LESTER PACKER VOLUME 128. Plasma Lipoproteins (Part A: Preparation, Structure, and Molecular Biology) Edited by JERE P. SEGREST AND JOHN J. ALBERS VOLUME 129. Plasma Lipoproteins (Part B: Characterization, Cell Biology, and Metabolism) Edited by JOHN J. ALBERS AND JERE P. SEGREST VOLUME 130. Enzyme Structure (Part K) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME 131. Enzyme Structure (Part L) Edited by C. H. W. HIRS AND SERGE N. TIMASHEFF VOLUME 132. Immunochemical Techniques (Part J: Phagocytosis and Cell-Mediated Cytotoxicity) Edited by GIOVANNI DI SABATO AND JOHANNES EVERSE VOLUME 133. Bioluminescence and Chemiluminescence (Part B) Edited by MARLENE DELUCA AND WILLIAM D. MCELROY VOLUME 134. Structural and Contractile Proteins (Part C: The Contractile Apparatus and the Cytoskeleton) Edited by RICHARD B. VALLEE VOLUME 135. Immobilized Enzymes and Cells (Part B) Edited by KLAUS MOSBACH VOLUME 136. Immobilized Enzymes and Cells (Part C) Edited by KLAUS MOSBACH VOLUME 137. Immobilized Enzymes and Cells (Part D) Edited by KLAUS MOSBACH VOLUME 138. Complex Carbohydrates (Part E) Edited by VICTOR GINSBURG
Methods in Enzymology
xxvii
VOLUME 139. Cellular Regulators (Part A: Calcium- and Calmodulin-Binding Proteins) Edited by ANTHONY R. MEANS AND P. MICHAEL CONN VOLUME 140. Cumulative Subject Index Volumes 102–119, 121–134 VOLUME 141. Cellular Regulators (Part B: Calcium and Lipids) Edited by P. MICHAEL CONN AND ANTHONY R. MEANS VOLUME 142. Metabolism of Aromatic Amino Acids and Amines Edited by SEYMOUR KAUFMAN VOLUME 143. Sulfur and Sulfur Amino Acids Edited by WILLIAM B. JAKOBY AND OWEN GRIFFITH VOLUME 144. Structural and Contractile Proteins (Part D: Extracellular Matrix) Edited by LEON W. CUNNINGHAM VOLUME 145. Structural and Contractile Proteins (Part E: Extracellular Matrix) Edited by LEON W. CUNNINGHAM VOLUME 146. Peptide Growth Factors (Part A) Edited by DAVID BARNES AND DAVID A. SIRBASKU VOLUME 147. Peptide Growth Factors (Part B) Edited by DAVID BARNES AND DAVID A. SIRBASKU VOLUME 148. Plant Cell Membranes Edited by LESTER PACKER AND ROLAND DOUCE VOLUME 149. Drug and Enzyme Targeting (Part B) Edited by RALPH GREEN AND KENNETH J. WIDDER VOLUME 150. Immunochemical Techniques (Part K: In Vitro Models of B and T Cell Functions and Lymphoid Cell Receptors) Edited by GIOVANNI DI SABATO VOLUME 151. Molecular Genetics of Mammalian Cells Edited by MICHAEL M. GOTTESMAN VOLUME 152. Guide to Molecular Cloning Techniques Edited by SHELBY L. BERGER AND ALAN R. KIMMEL VOLUME 153. Recombinant DNA (Part D) Edited by RAY WU AND LAWRENCE GROSSMAN VOLUME 154. Recombinant DNA (Part E) Edited by RAY WU AND LAWRENCE GROSSMAN VOLUME 155. Recombinant DNA (Part F) Edited by RAY WU VOLUME 156. Biomembranes (Part P: ATP-Driven Pumps and Related Transport: The Na, K-Pump) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER
xxviii
Methods in Enzymology
VOLUME 157. Biomembranes (Part Q: ATP-Driven Pumps and Related Transport: Calcium, Proton, and Potassium Pumps) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 158. Metalloproteins (Part A) Edited by JAMES F. RIORDAN AND BERT L. VALLEE VOLUME 159. Initiation and Termination of Cyclic Nucleotide Action Edited by JACKIE D. CORBIN AND ROGER A. JOHNSON VOLUME 160. Biomass (Part A: Cellulose and Hemicellulose) Edited by WILLIS A. WOOD AND SCOTT T. KELLOGG VOLUME 161. Biomass (Part B: Lignin, Pectin, and Chitin) Edited by WILLIS A. WOOD AND SCOTT T. KELLOGG VOLUME 162. Immunochemical Techniques (Part L: Chemotaxis and Inflammation) Edited by GIOVANNI DI SABATO VOLUME 163. Immunochemical Techniques (Part M: Chemotaxis and Inflammation) Edited by GIOVANNI DI SABATO VOLUME 164. Ribosomes Edited by HARRY F. NOLLER, JR., AND KIVIE MOLDAVE VOLUME 165. Microbial Toxins: Tools for Enzymology Edited by SIDNEY HARSHMAN VOLUME 166. Branched-Chain Amino Acids Edited by ROBERT HARRIS AND JOHN R. SOKATCH VOLUME 167. Cyanobacteria Edited by LESTER PACKER AND ALEXANDER N. GLAZER VOLUME 168. Hormone Action (Part K: Neuroendocrine Peptides) Edited by P. MICHAEL CONN VOLUME 169. Platelets: Receptors, Adhesion, Secretion (Part A) Edited by JACEK HAWIGER VOLUME 170. Nucleosomes Edited by PAUL M. WASSARMAN AND ROGER D. KORNBERG VOLUME 171. Biomembranes (Part R: Transport Theory: Cells and Model Membranes) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 172. Biomembranes (Part S: Transport: Membrane Isolation and Characterization) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER
Methods in Enzymology
xxix
VOLUME 173. Biomembranes [Part T: Cellular and Subcellular Transport: Eukaryotic (Nonepithelial) Cells] Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 174. Biomembranes [Part U: Cellular and Subcellular Transport: Eukaryotic (Nonepithelial) Cells] Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 175. Cumulative Subject Index Volumes 135–139, 141–167 VOLUME 176. Nuclear Magnetic Resonance (Part A: Spectral Techniques and Dynamics) Edited by NORMAN J. OPPENHEIMER AND THOMAS L. JAMES VOLUME 177. Nuclear Magnetic Resonance (Part B: Structure and Mechanism) Edited by NORMAN J. OPPENHEIMER AND THOMAS L. JAMES VOLUME 178. Antibodies, Antigens, and Molecular Mimicry Edited by JOHN J. LANGONE VOLUME 179. Complex Carbohydrates (Part F) Edited by VICTOR GINSBURG VOLUME 180. RNA Processing (Part A: General Methods) Edited by JAMES E. DAHLBERG AND JOHN N. ABELSON VOLUME 181. RNA Processing (Part B: Specific Methods) Edited by JAMES E. DAHLBERG AND JOHN N. ABELSON VOLUME 182. Guide to Protein Purification Edited by MURRAY P. DEUTSCHER VOLUME 183. Molecular Evolution: Computer Analysis of Protein and Nucleic Acid Sequences Edited by RUSSELL F. DOOLITTLE VOLUME 184. Avidin-Biotin Technology Edited by MEIR WILCHEK AND EDWARD A. BAYER VOLUME 185. Gene Expression Technology Edited by DAVID V. GOEDDEL VOLUME 186. Oxygen Radicals in Biological Systems (Part B: Oxygen Radicals and Antioxidants) Edited by LESTER PACKER AND ALEXANDER N. GLAZER VOLUME 187. Arachidonate Related Lipid Mediators Edited by ROBERT C. MURPHY AND FRANK A. FITZPATRICK VOLUME 188. Hydrocarbons and Methylotrophy Edited by MARY E. LIDSTROM VOLUME 189. Retinoids (Part A: Molecular and Metabolic Aspects) Edited by LESTER PACKER
xxx
Methods in Enzymology
VOLUME 190. Retinoids (Part B: Cell Differentiation and Clinical Applications) Edited by LESTER PACKER VOLUME 191. Biomembranes (Part V: Cellular and Subcellular Transport: Epithelial Cells) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 192. Biomembranes (Part W: Cellular and Subcellular Transport: Epithelial Cells) Edited by SIDNEY FLEISCHER AND BECCA FLEISCHER VOLUME 193. Mass Spectrometry Edited by JAMES A. MCCLOSKEY VOLUME 194. Guide to Yeast Genetics and Molecular Biology Edited by CHRISTINE GUTHRIE AND GERALD R. FINK VOLUME 195. Adenylyl Cyclase, G Proteins, and Guanylyl Cyclase Edited by ROGER A. JOHNSON AND JACKIE D. CORBIN VOLUME 196. Molecular Motors and the Cytoskeleton Edited by RICHARD B. VALLEE VOLUME 197. Phospholipases Edited by EDWARD A. DENNIS VOLUME 198. Peptide Growth Factors (Part C) Edited by DAVID BARNES, J. P. MATHER, AND GORDON H. SATO VOLUME 199. Cumulative Subject Index Volumes 168–174, 176–194 VOLUME 200. Protein Phosphorylation (Part A: Protein Kinases: Assays, Purification, Antibodies, Functional Analysis, Cloning, and Expression) Edited by TONY HUNTER AND BARTHOLOMEW M. SEFTON VOLUME 201. Protein Phosphorylation (Part B: Analysis of Protein Phosphorylation, Protein Kinase Inhibitors, and Protein Phosphatases) Edited by TONY HUNTER AND BARTHOLOMEW M. SEFTON VOLUME 202. Molecular Design and Modeling: Concepts and Applications (Part A: Proteins, Peptides, and Enzymes) Edited by JOHN J. LANGONE VOLUME 203. Molecular Design and Modeling: Concepts and Applications (Part B: Antibodies and Antigens, Nucleic Acids, Polysaccharides, and Drugs) Edited by JOHN J. LANGONE VOLUME 204. Bacterial Genetic Systems Edited by JEFFREY H. MILLER VOLUME 205. Metallobiochemistry (Part B: Metallothionein and Related Molecules) Edited by JAMES F. RIORDAN AND BERT L. VALLEE
Methods in Enzymology
xxxi
VOLUME 206. Cytochrome P450 Edited by MICHAEL R. WATERMAN AND ERIC F. JOHNSON VOLUME 207. Ion Channels Edited by BERNARDO RUDY AND LINDA E. IVERSON VOLUME 208. Protein–DNA Interactions Edited by ROBERT T. SAUER VOLUME 209. Phospholipid Biosynthesis Edited by EDWARD A. DENNIS AND DENNIS E. VANCE VOLUME 210. Numerical Computer Methods Edited by LUDWIG BRAND AND MICHAEL L. JOHNSON VOLUME 211. DNA Structures (Part A: Synthesis and Physical Analysis of DNA) Edited by DAVID M. J. LILLEY AND JAMES E. DAHLBERG VOLUME 212. DNA Structures (Part B: Chemical and Electrophoretic Analysis of DNA) Edited by DAVID M. J. LILLEY AND JAMES E. DAHLBERG VOLUME 213. Carotenoids (Part A: Chemistry, Separation, Quantitation, and Antioxidation) Edited by LESTER PACKER VOLUME 214. Carotenoids (Part B: Metabolism, Genetics, and Biosynthesis) Edited by LESTER PACKER VOLUME 215. Platelets: Receptors, Adhesion, Secretion (Part B) Edited by JACEK J. HAWIGER VOLUME 216. Recombinant DNA (Part G) Edited by RAY WU VOLUME 217. Recombinant DNA (Part H) Edited by RAY WU VOLUME 218. Recombinant DNA (Part I) Edited by RAY WU VOLUME 219. Reconstitution of Intracellular Transport Edited by JAMES E. ROTHMAN VOLUME 220. Membrane Fusion Techniques (Part A) Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 221. Membrane Fusion Techniques (Part B) Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 222. Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation (Part A: Mammalian Blood Coagulation Factors and Inhibitors) Edited by LASZLO LORAND AND KENNETH G. MANN
xxxii
Methods in Enzymology
VOLUME 223. Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation (Part B: Complement Activation, Fibrinolysis, and Nonmammalian Blood Coagulation Factors) Edited by LASZLO LORAND AND KENNETH G. MANN VOLUME 224. Molecular Evolution: Producing the Biochemical Data Edited by ELIZABETH ANNE ZIMMER, THOMAS J. WHITE, REBECCA L. CANN, AND ALLAN C. WILSON VOLUME 225. Guide to Techniques in Mouse Development Edited by PAUL M. WASSARMAN AND MELVIN L. DEPAMPHILIS VOLUME 226. Metallobiochemistry (Part C: Spectroscopic and Physical Methods for Probing Metal Ion Environments in Metalloenzymes and Metalloproteins) Edited by JAMES F. RIORDAN AND BERT L. VALLEE VOLUME 227. Metallobiochemistry (Part D: Physical and Spectroscopic Methods for Probing Metal Ion Environments in Metalloproteins) Edited by JAMES F. RIORDAN AND BERT L. VALLEE VOLUME 228. Aqueous Two-Phase Systems Edited by HARRY WALTER AND GO¨TE JOHANSSON VOLUME 229. Cumulative Subject Index Volumes 195–198, 200–227 VOLUME 230. Guide to Techniques in Glycobiology Edited by WILLIAM J. LENNARZ AND GERALD W. HART VOLUME 231. Hemoglobins (Part B: Biochemical and Analytical Methods) Edited by JOHANNES EVERSE, KIM D. VANDEGRIFF, AND ROBERT M. WINSLOW VOLUME 232. Hemoglobins (Part C: Biophysical Methods) Edited by JOHANNES EVERSE, KIM D. VANDEGRIFF, AND ROBERT M. WINSLOW VOLUME 233. Oxygen Radicals in Biological Systems (Part C) Edited by LESTER PACKER VOLUME 234. Oxygen Radicals in Biological Systems (Part D) Edited by LESTER PACKER VOLUME 235. Bacterial Pathogenesis (Part A: Identification and Regulation of Virulence Factors) Edited by VIRGINIA L. CLARK AND PATRIK M. BAVOIL VOLUME 236. Bacterial Pathogenesis (Part B: Integration of Pathogenic Bacteria with Host Cells) Edited by VIRGINIA L. CLARK AND PATRIK M. BAVOIL VOLUME 237. Heterotrimeric G Proteins Edited by RAVI IYENGAR VOLUME 238. Heterotrimeric G-Protein Effectors Edited by RAVI IYENGAR
Methods in Enzymology
xxxiii
VOLUME 239. Nuclear Magnetic Resonance (Part C) Edited by THOMAS L. JAMES AND NORMAN J. OPPENHEIMER VOLUME 240. Numerical Computer Methods (Part B) Edited by MICHAEL L. JOHNSON AND LUDWIG BRAND VOLUME 241. Retroviral Proteases Edited by LAWRENCE C. KUO AND JULES A. SHAFER VOLUME 242. Neoglycoconjugates (Part A) Edited by Y. C. LEE AND REIKO T. LEE VOLUME 243. Inorganic Microbial Sulfur Metabolism Edited by HARRY D. PECK, JR., AND JEAN LEGALL VOLUME 244. Proteolytic Enzymes: Serine and Cysteine Peptidases Edited by ALAN J. BARRETT VOLUME 245. Extracellular Matrix Components Edited by E. RUOSLAHTI AND E. ENGVALL VOLUME 246. Biochemical Spectroscopy Edited by KENNETH SAUER VOLUME 247. Neoglycoconjugates (Part B: Biomedical Applications) Edited by Y. C. LEE AND REIKO T. LEE VOLUME 248. Proteolytic Enzymes: Aspartic and Metallo Peptidases Edited by ALAN J. BARRETT VOLUME 249. Enzyme Kinetics and Mechanism (Part D: Developments in Enzyme Dynamics) Edited by DANIEL L. PURICH VOLUME 250. Lipid Modifications of Proteins Edited by PATRICK J. CASEY AND JANICE E. BUSS VOLUME 251. Biothiols (Part A: Monothiols and Dithiols, Protein Thiols, and Thiyl Radicals) Edited by LESTER PACKER VOLUME 252. Biothiols (Part B: Glutathione and Thioredoxin; Thiols in Signal Transduction and Gene Regulation) Edited by LESTER PACKER VOLUME 253. Adhesion of Microbial Pathogens Edited by RON J. DOYLE AND ITZHAK OFEK VOLUME 254. Oncogene Techniques Edited by PETER K. VOGT AND INDER M. VERMA VOLUME 255. Small GTPases and Their Regulators (Part A: Ras Family) Edited by W. E. BALCH, CHANNING J. DER, AND ALAN HALL
xxxiv
Methods in Enzymology
VOLUME 256. Small GTPases and Their Regulators (Part B: Rho Family) Edited by W. E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 257. Small GTPases and Their Regulators (Part C: Proteins Involved in Transport) Edited by W. E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 258. Redox-Active Amino Acids in Biology Edited by JUDITH P. KLINMAN VOLUME 259. Energetics of Biological Macromolecules Edited by MICHAEL L. JOHNSON AND GARY K. ACKERS VOLUME 260. Mitochondrial Biogenesis and Genetics (Part A) Edited by GIUSEPPE M. ATTARDI AND ANNE CHOMYN VOLUME 261. Nuclear Magnetic Resonance and Nucleic Acids Edited by THOMAS L. JAMES VOLUME 262. DNA Replication Edited by JUDITH L. CAMPBELL VOLUME 263. Plasma Lipoproteins (Part C: Quantitation) Edited by WILLIAM A. BRADLEY, SANDRA H. GIANTURCO, AND JERE P. SEGREST VOLUME 264. Mitochondrial Biogenesis and Genetics (Part B) Edited by GIUSEPPE M. ATTARDI AND ANNE CHOMYN VOLUME 265. Cumulative Subject Index Volumes 228, 230–262 VOLUME 266. Computer Methods for Macromolecular Sequence Analysis Edited by RUSSELL F. DOOLITTLE VOLUME 267. Combinatorial Chemistry Edited by JOHN N. ABELSON VOLUME 268. Nitric Oxide (Part A: Sources and Detection of NO; NO Synthase) Edited by LESTER PACKER VOLUME 269. Nitric Oxide (Part B: Physiological and Pathological Processes) Edited by LESTER PACKER VOLUME 270. High Resolution Separation and Analysis of Biological Macromolecules (Part A: Fundamentals) Edited by BARRY L. KARGER AND WILLIAM S. HANCOCK VOLUME 271. High Resolution Separation and Analysis of Biological Macromolecules (Part B: Applications) Edited by BARRY L. KARGER AND WILLIAM S. HANCOCK VOLUME 272. Cytochrome P450 (Part B) Edited by ERIC F. JOHNSON AND MICHAEL R. WATERMAN VOLUME 273. RNA Polymerase and Associated Factors (Part A) Edited by SANKAR ADHYA
Methods in Enzymology
xxxv
VOLUME 274. RNA Polymerase and Associated Factors (Part B) Edited by SANKAR ADHYA VOLUME 275. Viral Polymerases and Related Proteins Edited by LAWRENCE C. KUO, DAVID B. OLSEN, AND STEVEN S. CARROLL VOLUME 276. Macromolecular Crystallography (Part A) Edited by CHARLES W. CARTER, JR., AND ROBERT M. SWEET VOLUME 277. Macromolecular Crystallography (Part B) Edited by CHARLES W. CARTER, JR., AND ROBERT M. SWEET VOLUME 278. Fluorescence Spectroscopy Edited by LUDWIG BRAND AND MICHAEL L. JOHNSON VOLUME 279. Vitamins and Coenzymes (Part I) Edited by DONALD B. MCCORMICK, JOHN W. SUTTIE, AND CONRAD WAGNER VOLUME 280. Vitamins and Coenzymes (Part J) Edited by DONALD B. MCCORMICK, JOHN W. SUTTIE, AND CONRAD WAGNER VOLUME 281. Vitamins and Coenzymes (Part K) Edited by DONALD B. MCCORMICK, JOHN W. SUTTIE, AND CONRAD WAGNER VOLUME 282. Vitamins and Coenzymes (Part L) Edited by DONALD B. MCCORMICK, JOHN W. SUTTIE, AND CONRAD WAGNER VOLUME 283. Cell Cycle Control Edited by WILLIAM G. DUNPHY VOLUME 284. Lipases (Part A: Biotechnology) Edited by BYRON RUBIN AND EDWARD A. DENNIS VOLUME 285. Cumulative Subject Index Volumes 263, 264, 266–284, 286–289 VOLUME 286. Lipases (Part B: Enzyme Characterization and Utilization) Edited by BYRON RUBIN AND EDWARD A. DENNIS VOLUME 287. Chemokines Edited by RICHARD HORUK VOLUME 288. Chemokine Receptors Edited by RICHARD HORUK VOLUME 289. Solid Phase Peptide Synthesis Edited by GREGG B. FIELDS VOLUME 290. Molecular Chaperones Edited by GEORGE H. LORIMER AND THOMAS BALDWIN VOLUME 291. Caged Compounds Edited by GERARD MARRIOTT VOLUME 292. ABC Transporters: Biochemical, Cellular, and Molecular Aspects Edited by SURESH V. AMBUDKAR AND MICHAEL M. GOTTESMAN
xxxvi
Methods in Enzymology
VOLUME 293. Ion Channels (Part B) Edited by P. MICHAEL CONN VOLUME 294. Ion Channels (Part C) Edited by P. MICHAEL CONN VOLUME 295. Energetics of Biological Macromolecules (Part B) Edited by GARY K. ACKERS AND MICHAEL L. JOHNSON VOLUME 296. Neurotransmitter Transporters Edited by SUSAN G. AMARA VOLUME 297. Photosynthesis: Molecular Biology of Energy Capture Edited by LEE MCINTOSH VOLUME 298. Molecular Motors and the Cytoskeleton (Part B) Edited by RICHARD B. VALLEE VOLUME 299. Oxidants and Antioxidants (Part A) Edited by LESTER PACKER VOLUME 300. Oxidants and Antioxidants (Part B) Edited by LESTER PACKER VOLUME 301. Nitric Oxide: Biological and Antioxidant Activities (Part C) Edited by LESTER PACKER VOLUME 302. Green Fluorescent Protein Edited by P. MICHAEL CONN VOLUME 303. cDNA Preparation and Display Edited by SHERMAN M. WEISSMAN VOLUME 304. Chromatin Edited by PAUL M. WASSARMAN AND ALAN P. WOLFFE VOLUME 305. Bioluminescence and Chemiluminescence (Part C) Edited by THOMAS O. BALDWIN AND MIRIAM M. ZIEGLER VOLUME 306. Expression of Recombinant Genes in Eukaryotic Systems Edited by JOSEPH C. GLORIOSO AND MARTIN C. SCHMIDT VOLUME 307. Confocal Microscopy Edited by P. MICHAEL CONN VOLUME 308. Enzyme Kinetics and Mechanism (Part E: Energetics of Enzyme Catalysis) Edited by DANIEL L. PURICH AND VERN L. SCHRAMM VOLUME 309. Amyloid, Prions, and Other Protein Aggregates Edited by RONALD WETZEL VOLUME 310. Biofilms Edited by RON J. DOYLE
Methods in Enzymology
xxxvii
VOLUME 311. Sphingolipid Metabolism and Cell Signaling (Part A) Edited by ALFRED H. MERRILL, JR., AND YUSUF A. HANNUN VOLUME 312. Sphingolipid Metabolism and Cell Signaling (Part B) Edited by ALFRED H. MERRILL, JR., AND YUSUF A. HANNUN VOLUME 313. Antisense Technology (Part A: General Methods, Methods of Delivery, and RNA Studies) Edited by M. IAN PHILLIPS VOLUME 314. Antisense Technology (Part B: Applications) Edited by M. IAN PHILLIPS VOLUME 315. Vertebrate Phototransduction and the Visual Cycle (Part A) Edited by KRZYSZTOF PALCZEWSKI VOLUME 316. Vertebrate Phototransduction and the Visual Cycle (Part B) Edited by KRZYSZTOF PALCZEWSKI VOLUME 317. RNA–Ligand Interactions (Part A: Structural Biology Methods) Edited by DANIEL W. CELANDER AND JOHN N. ABELSON VOLUME 318. RNA–Ligand Interactions (Part B: Molecular Biology Methods) Edited by DANIEL W. CELANDER AND JOHN N. ABELSON VOLUME 319. Singlet Oxygen, UV-A, and Ozone Edited by LESTER PACKER AND HELMUT SIES VOLUME 320. Cumulative Subject Index Volumes 290–319 VOLUME 321. Numerical Computer Methods (Part C) Edited by MICHAEL L. JOHNSON AND LUDWIG BRAND VOLUME 322. Apoptosis Edited by JOHN C. REED VOLUME 323. Energetics of Biological Macromolecules (Part C) Edited by MICHAEL L. JOHNSON AND GARY K. ACKERS VOLUME 324. Branched-Chain Amino Acids (Part B) Edited by ROBERT A. HARRIS AND JOHN R. SOKATCH VOLUME 325. Regulators and Effectors of Small GTPases (Part D: Rho Family) Edited by W. E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 326. Applications of Chimeric Genes and Hybrid Proteins (Part A: Gene Expression and Protein Purification) Edited by JEREMY THORNER, SCOTT D. EMR, AND JOHN N. ABELSON VOLUME 327. Applications of Chimeric Genes and Hybrid Proteins (Part B: Cell Biology and Physiology) Edited by JEREMY THORNER, SCOTT D. EMR, AND JOHN N. ABELSON
xxxviii
Methods in Enzymology
VOLUME 328. Applications of Chimeric Genes and Hybrid Proteins (Part C: Protein–Protein Interactions and Genomics) Edited by JEREMY THORNER, SCOTT D. EMR, AND JOHN N. ABELSON VOLUME 329. Regulators and Effectors of Small GTPases (Part E: GTPases Involved in Vesicular Traffic) Edited by W. E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 330. Hyperthermophilic Enzymes (Part A) Edited by MICHAEL W. W. ADAMS AND ROBERT M. KELLY VOLUME 331. Hyperthermophilic Enzymes (Part B) Edited by MICHAEL W. W. ADAMS AND ROBERT M. KELLY VOLUME 332. Regulators and Effectors of Small GTPases (Part F: Ras Family I) Edited by W. E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 333. Regulators and Effectors of Small GTPases (Part G: Ras Family II) Edited by W. E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 334. Hyperthermophilic Enzymes (Part C) Edited by MICHAEL W. W. ADAMS AND ROBERT M. KELLY VOLUME 335. Flavonoids and Other Polyphenols Edited by LESTER PACKER VOLUME 336. Microbial Growth in Biofilms (Part A: Developmental and Molecular Biological Aspects) Edited by RON J. DOYLE VOLUME 337. Microbial Growth in Biofilms (Part B: Special Environments and Physicochemical Aspects) Edited by RON J. DOYLE VOLUME 338. Nuclear Magnetic Resonance of Biological Macromolecules (Part A) Edited by THOMAS L. JAMES, VOLKER DO¨TSCH, AND ULI SCHMITZ VOLUME 339. Nuclear Magnetic Resonance of Biological Macromolecules (Part B) Edited by THOMAS L. JAMES, VOLKER DO¨TSCH, AND ULI SCHMITZ VOLUME 340. Drug–Nucleic Acid Interactions Edited by JONATHAN B. CHAIRES AND MICHAEL J. WARING VOLUME 341. Ribonucleases (Part A) Edited by ALLEN W. NICHOLSON VOLUME 342. Ribonucleases (Part B) Edited by ALLEN W. NICHOLSON VOLUME 343. G Protein Pathways (Part A: Receptors) Edited by RAVI IYENGAR AND JOHN D. HILDEBRANDT VOLUME 344. G Protein Pathways (Part B: G Proteins and Their Regulators) Edited by RAVI IYENGAR AND JOHN D. HILDEBRANDT
Methods in Enzymology
xxxix
VOLUME 345. G Protein Pathways (Part C: Effector Mechanisms) Edited by RAVI IYENGAR AND JOHN D. HILDEBRANDT VOLUME 346. Gene Therapy Methods Edited by M. IAN PHILLIPS VOLUME 347. Protein Sensors and Reactive Oxygen Species (Part A: Selenoproteins and Thioredoxin) Edited by HELMUT SIES AND LESTER PACKER VOLUME 348. Protein Sensors and Reactive Oxygen Species (Part B: Thiol Enzymes and Proteins) Edited by HELMUT SIES AND LESTER PACKER VOLUME 349. Superoxide Dismutase Edited by LESTER PACKER VOLUME 350. Guide to Yeast Genetics and Molecular and Cell Biology (Part B) Edited by CHRISTINE GUTHRIE AND GERALD R. FINK VOLUME 351. Guide to Yeast Genetics and Molecular and Cell Biology (Part C) Edited by CHRISTINE GUTHRIE AND GERALD R. FINK VOLUME 352. Redox Cell Biology and Genetics (Part A) Edited by CHANDAN K. SEN AND LESTER PACKER VOLUME 353. Redox Cell Biology and Genetics (Part B) Edited by CHANDAN K. SEN AND LESTER PACKER VOLUME 354. Enzyme Kinetics and Mechanisms (Part F: Detection and Characterization of Enzyme Reaction Intermediates) Edited by DANIEL L. PURICH VOLUME 355. Cumulative Subject Index Volumes 321–354 VOLUME 356. Laser Capture Microscopy and Microdissection Edited by P. MICHAEL CONN VOLUME 357. Cytochrome P450, Part C Edited by ERIC F. JOHNSON AND MICHAEL R. WATERMAN VOLUME 358. Bacterial Pathogenesis (Part C: Identification, Regulation, and Function of Virulence Factors) Edited by VIRGINIA L. CLARK AND PATRIK M. BAVOIL VOLUME 359. Nitric Oxide (Part D) Edited by ENRIQUE CADENAS AND LESTER PACKER VOLUME 360. Biophotonics (Part A) Edited by GERARD MARRIOTT AND IAN PARKER VOLUME 361. Biophotonics (Part B) Edited by GERARD MARRIOTT AND IAN PARKER
xl
Methods in Enzymology
VOLUME 362. Recognition of Carbohydrates in Biological Systems (Part A) Edited by YUAN C. LEE AND REIKO T. LEE VOLUME 363. Recognition of Carbohydrates in Biological Systems (Part B) Edited by YUAN C. LEE AND REIKO T. LEE VOLUME 364. Nuclear Receptors Edited by DAVID W. RUSSELL AND DAVID J. MANGELSDORF VOLUME 365. Differentiation of Embryonic Stem Cells Edited by PAUL M. WASSAUMAN AND GORDON M. KELLER VOLUME 366. Protein Phosphatases Edited by SUSANNE KLUMPP AND JOSEF KRIEGLSTEIN VOLUME 367. Liposomes (Part A) Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 368. Macromolecular Crystallography (Part C) Edited by CHARLES W. CARTER, JR., AND ROBERT M. SWEET VOLUME 369. Combinational Chemistry (Part B) Edited by GUILLERMO A. MORALES AND BARRY A. BUNIN VOLUME 370. RNA Polymerases and Associated Factors (Part C) Edited by SANKAR L. ADHYA AND SUSAN GARGES VOLUME 371. RNA Polymerases and Associated Factors (Part D) Edited by SANKAR L. ADHYA AND SUSAN GARGES VOLUME 372. Liposomes (Part B) Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 373. Liposomes (Part C) Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 374. Macromolecular Crystallography (Part D) Edited by CHARLES W. CARTER, JR., AND ROBERT W. SWEET VOLUME 375. Chromatin and Chromatin Remodeling Enzymes (Part A) Edited by C. DAVID ALLIS AND CARL WU VOLUME 376. Chromatin and Chromatin Remodeling Enzymes (Part B) Edited by C. DAVID ALLIS AND CARL WU VOLUME 377. Chromatin and Chromatin Remodeling Enzymes (Part C) Edited by C. DAVID ALLIS AND CARL WU VOLUME 378. Quinones and Quinone Enzymes (Part A) Edited by HELMUT SIES AND LESTER PACKER VOLUME 379. Energetics of Biological Macromolecules (Part D) Edited by JO M. HOLT, MICHAEL L. JOHNSON, AND GARY K. ACKERS VOLUME 380. Energetics of Biological Macromolecules (Part E) Edited by JO M. HOLT, MICHAEL L. JOHNSON, AND GARY K. ACKERS
Methods in Enzymology
VOLUME 381. Oxygen Sensing Edited by CHANDAN K. SEN AND GREGG L. SEMENZA VOLUME 382. Quinones and Quinone Enzymes (Part B) Edited by HELMUT SIES AND LESTER PACKER VOLUME 383. Numerical Computer Methods (Part D) Edited by LUDWIG BRAND AND MICHAEL L. JOHNSON VOLUME 384. Numerical Computer Methods (Part E) Edited by LUDWIG BRAND AND MICHAEL L. JOHNSON VOLUME 385. Imaging in Biological Research (Part A) Edited by P. MICHAEL CONN VOLUME 386. Imaging in Biological Research (Part B) Edited by P. MICHAEL CONN VOLUME 387. Liposomes (Part D) Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 388. Protein Engineering Edited by DAN E. ROBERTSON AND JOSEPH P. NOEL VOLUME 389. Regulators of G-Protein Signaling (Part A) Edited by DAVID P. SIDEROVSKI VOLUME 390. Regulators of G-Protein Signaling (Part B) Edited by DAVID P. SIDEROVSKI VOLUME 391. Liposomes (Part E) Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 392. RNA Interference Edited by ENGELKE ROSSI VOLUME 393. Circadian Rhythms Edited by MICHAEL W. YOUNG VOLUME 394. Nuclear Magnetic Resonance of Biological Macromolecules (Part C) Edited by THOMAS L. JAMES VOLUME 395. Producing the Biochemical Data (Part B) Edited by ELIZABETH A. ZIMMER AND ERIC H. ROALSON VOLUME 396. Nitric Oxide (Part E) Edited by LESTER PACKER AND ENRIQUE CADENAS VOLUME 397. Environmental Microbiology Edited by JARED R. LEADBETTER VOLUME 398. Ubiquitin and Protein Degradation (Part A) Edited by RAYMOND J. DESHAIES
xli
xlii
Methods in Enzymology
VOLUME 399. Ubiquitin and Protein Degradation (Part B) Edited by RAYMOND J. DESHAIES VOLUME 400. Phase II Conjugation Enzymes and Transport Systems Edited by HELMUT SIES AND LESTER PACKER VOLUME 401. Glutathione Transferases and Gamma Glutamyl Transpeptidases Edited by HELMUT SIES AND LESTER PACKER VOLUME 402. Biological Mass Spectrometry Edited by A. L. BURLINGAME VOLUME 403. GTPases Regulating Membrane Targeting and Fusion Edited by WILLIAM E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 404. GTPases Regulating Membrane Dynamics Edited by WILLIAM E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 405. Mass Spectrometry: Modified Proteins and Glycoconjugates Edited by A. L. BURLINGAME VOLUME 406. Regulators and Effectors of Small GTPases: Rho Family Edited by WILLIAM E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 407. Regulators and Effectors of Small GTPases: Ras Family Edited by WILLIAM E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 408. DNA Repair (Part A) Edited by JUDITH L. CAMPBELL AND PAUL MODRICH VOLUME 409. DNA Repair (Part B) Edited by JUDITH L. CAMPBELL AND PAUL MODRICH VOLUME 410. DNA Microarrays (Part A: Array Platforms and Web-Bench Protocols) Edited by ALAN KIMMEL AND BRIAN OLIVER VOLUME 411. DNA Microarrays (Part B: Databases and Statistics) Edited by ALAN KIMMEL AND BRIAN OLIVER VOLUME 412. Amyloid, Prions, and Other Protein Aggregates (Part B) Edited by INDU KHETERPAL AND RONALD WETZEL VOLUME 413. Amyloid, Prions, and Other Protein Aggregates (Part C) Edited by INDU KHETERPAL AND RONALD WETZEL VOLUME 414. Measuring Biological Responses with Automated Microscopy Edited by JAMES INGLESE VOLUME 415. Glycobiology Edited by MINORU FUKUDA VOLUME 416. Glycomics Edited by MINORU FUKUDA
Methods in Enzymology
VOLUME 417. Functional Glycomics Edited by MINORU FUKUDA VOLUME 418. Embryonic Stem Cells Edited by IRINA KLIMANSKAYA AND ROBERT LANZA VOLUME 419. Adult Stem Cells Edited by IRINA KLIMANSKAYA AND ROBERT LANZA VOLUME 420. Stem Cell Tools and Other Experimental Protocols Edited by IRINA KLIMANSKAYA AND ROBERT LANZA VOLUME 421. Advanced Bacterial Genetics: Use of Transposons and Phage for Genomic Engineering Edited by KELLY T. HUGHES VOLUME 422. Two-Component Signaling Systems, Part A Edited by MELVIN I. SIMON, BRIAN R. CRANE, AND ALEXANDRINE CRANE VOLUME 423. Two-Component Signaling Systems, Part B Edited by MELVIN I. SIMON, BRIAN R. CRANE, AND ALEXANDRINE CRANE VOLUME 424. RNA Editing Edited by JONATHA M. GOTT VOLUME 425. RNA Modification Edited by JONATHA M. GOTT VOLUME 426. Integrins Edited by DAVID CHERESH VOLUME 427. MicroRNA Methods Edited by JOHN J. ROSSI VOLUME 428. Osmosensing and Osmosignaling Edited by HELMUT SIES AND DIETER HAUSSINGER VOLUME 429. Translation Initiation: Extract Systems and Molecular Genetics Edited by JON LORSCH VOLUME 430. Translation Initiation: Reconstituted Systems and Biophysical Methods Edited by JON LORSCH VOLUME 431. Translation Initiation: Cell Biology, High-Throughput and Chemical-Based Approaches Edited by JON LORSCH VOLUME 432. Lipidomics and Bioactive Lipids: Mass-Spectrometry–Based Lipid Analysis Edited by H. ALEX BROWN
xliii
xliv
Methods in Enzymology
VOLUME 433. Lipidomics and Bioactive Lipids: Specialized Analytical Methods and Lipids in Disease Edited by H. ALEX BROWN VOLUME 434. Lipidomics and Bioactive Lipids: Lipids and Cell Signaling Edited by H. ALEX BROWN VOLUME 435. Oxygen Biology and Hypoxia Edited by HELMUT SIES AND BERNHARD BRU¨NE VOLUME 436. Globins and Other Nitric Oxide-Reactive Protiens (Part A) Edited by ROBERT K. POOLE VOLUME 437. Globins and Other Nitric Oxide-Reactive Protiens (Part B) Edited by ROBERT K. POOLE VOLUME 438. Small GTPases in Disease (Part A) Edited by WILLIAM E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 439. Small GTPases in Disease (Part B) Edited by WILLIAM E. BALCH, CHANNING J. DER, AND ALAN HALL VOLUME 440. Nitric Oxide, Part F Oxidative and Nitrosative Stress in Redox Regulation of Cell Signaling Edited by ENRIQUE CADENAS AND LESTER PACKER VOLUME 441. Nitric Oxide, Part G Oxidative and Nitrosative Stress in Redox Regulation of Cell Signaling Edited by ENRIQUE CADENAS AND LESTER PACKER VOLUME 442. Programmed Cell Death, General Principles for Studying Cell Death (Part A) Edited by ROYA KHOSRAVI-FAR, ZAHRA ZAKERI, RICHARD A. LOCKSHIN, AND MAURO PIACENTINI VOLUME 443. Angiogenesis: In Vitro Systems Edited by DAVID A. CHERESH VOLUME 444. Angiogenesis: In Vivo Systems (Part A) Edited by DAVID A. CHERESH VOLUME 445. Angiogenesis: In Vivo Systems (Part B) Edited by DAVID A. CHERESH VOLUME 446. Programmed Cell Death, The Biology and Therapeutic Implications of Cell Death (Part B) Edited by ROYA KHOSRAVI-FAR, ZAHRA ZAKERI, RICHARD A. LOCKSHIN, AND MAURO PIACENTINI VOLUME 447. RNA Turnover in Bacteria, Archaea and Organelles Edited by LYNNE E. MAQUAT AND CECILIA M. ARRAIANO
Methods in Enzymology
xlv
VOLUME 448. RNA Turnover in Eukaryotes: Nucleases, Pathways and Analysis of mRNA Decay Edited by LYNNE E. MAQUAT AND MEGERDITCH KILEDJIAN VOLUME 449. RNA Turnover in Eukaryotes: Analysis of Specialized and Quality Control RNA Decay Pathways Edited by LYNNE E. MAQUAT AND MEGERDITCH KILEDJIAN VOLUME 450. Fluorescence Spectroscopy Edited by LUDWIG BRAND AND MICHAEL L. JOHNSON VOLUME 451. Autophagy: Lower Eukaryotes and Non-Mammalian Systems (Part A) Edited by DANIEL J. KLIONSKY VOLUME 452. Autophagy in Mammalian Systems (Part B) Edited by DANIEL J. KLIONSKY VOLUME 453. Autophagy in Disease and Clinical Applications (Part C) Edited by DANIEL J. KLIONSKY VOLUME 454. Computer Methods (Part A) Edited by MICHAEL L. JOHNSON AND LUDWIG BRAND VOLUME 455. Biothermodynamics (Part A) Edited by MICHAEL L. JOHNSON, JO M. HOLT, AND GARY K. ACKERS (RETIRED) VOLUME 456. Mitochondrial Function, Part A: Mitochondrial Electron Transport Complexes and Reactive Oxygen Species Edited by WILLIAM S. ALLISON AND IMMO E. SCHEFFLER VOLUME 457. Mitochondrial Function, Part B: Mitochondrial Protein Kinases, Protein Phosphatases and Mitochondrial Diseases Edited by WILLIAM S. ALLISON AND ANNE N. MURPHY VOLUME 458. Complex Enzymes in Microbial Natural Product Biosynthesis, Part A: Overview Articles and Peptides Edited by DAVID A. HOPWOOD VOLUME 459. Complex Enzymes in Microbial Natural Product Biosynthesis, Part B: Polyketides, Aminocoumarins and Carbohydrates Edited by DAVID A. HOPWOOD VOLUME 460. Chemokines, Part A Edited by TRACY M. HANDEL AND DAMON J. HAMEL VOLUME 461. Chemokines, Part B Edited by TRACY M. HANDEL AND DAMON J. HAMEL VOLUME 462. Non-Natural Amino Acids Edited by TOM W. MUIR AND JOHN N. ABELSON VOLUME 463. Guide to Protein Purification, 2nd Edition Edited by RICHARD R. BURGESS AND MURRAY P. DEUTSCHER
xlvi
Methods in Enzymology
VOLUME 464. Liposomes, Part F Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 465. Liposomes, Part G Edited by NEJAT DU¨ZGU¨NES¸ VOLUME 466. Biothermodynamics, Part B Edited by MICHAEL L. JOHNSON, GARY K. ACKERS, AND JO M. HOLT VOLUME 467. Computer Methods Part B Edited by MICHAEL L. JOHNSON AND LUDWIG BRAND VOLUME 468. Biophysical, Chemical, and Functional Probes of RNA Structure, Interactions and Folding: Part A Edited by DANIEL HERSCHLAG VOLUME 469. Biophysical, Chemical, and Functional Probes of RNA Structure, Interactions and Folding: Part B Edited by DANIEL HERSCHLAG VOLUME 470. Guide to Yeast Genetics: Functional Genomics, Proteomics, and Other Systems Analysis, 2nd Edition Edited by GERALD FINK, JONATHAN WEISSMAN, AND CHRISTINE GUTHRIE VOLUME 471. Two-Component Signaling Systems, Part C Edited by MELVIN I. SIMON, BRIAN R. CRANE, AND ALEXANDRINE CRANE VOLUME 472. Single Molecule Tools, Part A: Fluorescence Based Approaches Edited by NILS G. WALTER VOLUME 473. Thiol Redox Transitions in Cell Signaling, Part A Chemistry and Biochemistry of Low Molecular Weight and Protein Thiols Edited by ENRIQUE CADENAS AND LESTER PACKER VOLUME 474. Thiol Redox Transitions in Cell Signaling, Part B Cellular Localization and Signaling Edited by ENRIQUE CADENAS AND LESTER PACKER VOLUME 475. Single Molecule Tools, Part B: Super-Resolution, Particle Tracking, Multiparameter, and Force Based Methods Edited by NILS G. WALTER VOLUME 476. Guide to Techniques in Mouse Development, Part A Mice, Embryos, and Cells, 2nd Edition Edited by PAUL M. WASSARMAN AND PHILIPPE M. SORIANO VOLUME 477. Guide to Techniques in Mouse Development, Part B Mouse Molecular Genetics, 2nd Edition Edited by PAUL M. WASSARMAN AND PHILIPPE M. SORIANO VOLUME 478. Glycomics Edited by MINORU FUKUDA
Methods in Enzymology
VOLUME 479. Functional Glycomics Edited by MINORU FUKUDA VOLUME 480. Glycobiology Edited by MINORU FUKUDA VOLUME 481. Cryo-EM, Part A: Sample Preparation and Data Collection Edited by GRANT J. JENSEN VOLUME 482. Cryo-EM, Part B: 3-D Reconstruction Edited by GRANT J. JENSEN VOLUME 483. Cryo-EM, Part C: Analyses, Interpretation, and Case Studies Edited by GRANT J. JENSEN VOLUME 484. Constitutive Activity in Receptors and Other Proteins, Part A Edited by P. MICHAEL CONN VOLUME 485. Constitutive Activity in Receptors and Other Proteins, Part B Edited by P. MICHAEL CONN VOLUME 486. Research on Nitrification and Related Processes, Part A Edited by MARTIN G. KLOTZ VOLUME 487. Computer Methods, Part C Edited by MICHAEL L. JOHNSON AND LUDWIG BRAND VOLUME 488. Biothermodynamics, Part C Edited by MICHAEL L. JOHNSON, JO M. HOLT AND GARY K. ACKERS VOLUME 489. The Unfolded Protein Response and Cellular Stress, Part A Edited by P. MICHAEL CONN
xlvii
This page intentionally left blank
S E C T I O N
O N E
UPR AND CELL STRESS IN NORMAL AND DISEASED CELLS
This page intentionally left blank
C H A P T E R
O N E
The Unfolded Protein Response in Mouse Cerebral Cortex Nirinjini Naidoo Contents 3 4 5 6 6 7 7 18 19 19
1. 2. 3. 4. 5. 6.
Introduction: The UPR Transduction of the UPR Signal by PERK, IRE1, and ATF6 UPR and Apoptosis The UPR in Health and Disease Induction of the UPR by Sleep Deprivation Experimental Protocols 6.1. Tissue procurement 7. Concluding Remarks Acknowledgments References
Abstract The unfolded protein response (UPR) is important for normal cellular homeostasis, development, and physiology. Endoplasmic reticulum stress and the UPR have also been implicated in a variety of diseases and pathologies. Thus the UPR is being studied in many model systems. We describe in this chapter methods for studying the UPR in a mouse model, specifically the cerebral cortex of mouse brain.
1. Introduction: The UPR The endoplasmic reticulum (ER) is a reticular membranous network that extends throughout the cytoplasm. In eukaryotic cells, it is the compartment within which all secretory and transmembrane proteins are folded in an energy-dependent manner. To ensure the proper folding of proteins, the ER utilizes a dedicated machinery of molecular chaperones and folding enzymes that associate directly with nascent polypeptides. These include the Center for Sleep and Circadian Neurobiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA Methods in Enzymology, Volume 489 ISSN 0076-6879, DOI: 10.1016/B978-0-12-385116-1.00001-7
#
2011 Elsevier Inc. All rights reserved.
3
4
Nirinjini Naidoo
molecular chaperone BiP/GRP78 (immunoglobulin-binding protein/glucose-regulated protein 78) and PDI (protein disulfide isomerase). Perturbations that alter ER homeostasis, therefore, disrupt folding and lead to the accumulation of unfolded proteins and protein aggregates, which are detrimental to cell survival. These perturbations include disturbances in calcium homeostasis, redox status, elevated secretory protein synthesis, and glucose or energy deprivation. As a consequence, the cell has evolved an adaptive coordinated response to limit accumulation of unfolded proteins in the ER. This signaling pathway is termed the ER stress response or the unfolded protein response (UPR) (for reviews, see Harding et al., 2002; Schroder and Kaufman, 2005a,b, 2006; Zhang and Kaufman, 2004). On a cellular level, the UPR triggers three kinds of protective cellular responses: (a) upregulation of ER-resident chaperones to assist in the refolding of misfolded proteins; (b) attenuation of protein translation which is mediated by the serine–threonine kinase PERK that serves to reduce protein load in the ER; and (c) degradation of misfolded proteins by the proteasome by a process called ER-associated degradation (ERAD). These three responses are protective measures to alleviate ER stress; however, prolonged stress leads to the activation of proapoptotic pathways (Szegezdi et al., 2006).
2. Transduction of the UPR Signal by PERK, IRE1, and ATF6 ER stress signals are transduced across the ER membrane by three proximal sensors of the UPR, inositol-requiring element-1 (IRE-1), PKRlike endoplasmic reticulum kinase (PERK), and activating transcription factor 6 (ATF6). All three of these sensors are maintained in an inactive state at the ER membrane by binding to BiP. Upon accumulation of unfolded proteins, bound BiP dissociates from ATF6, IRE1, and PERK to chaperone the misfolded proteins thereby permitting the activation of one or more of these transducers (Zhang and Kaufman, 2006). BiP, therefore, serves as the master regulator of the UPR. PERK signaling attenuates protein translation. PERK is a type I transmembrane serine–threonine kinase that appears to be present in most cells. Binding to BiP holds it in an inactive monomeric state. When this binding is disrupted, PERK is activated through homodimerization and autophosphorylation. Activated PERK phosphorylates translation initiation factor 2a (eIF2a), thereby reducing the rate of translation through the formation of a stalled 43S ternary complex. This results in a general decrease of most proteins. However, some selected proteins with internal ribosomal entry sites (IRES), such as ATF4 (activating transcription factor 4), GRP94, and
The Unfolded Protein Response in Mouse Cerebral Cortex
5
BiP, are translated more efficiently and hence their protein levels actually increase. PERK also activates two different regulators of redox homeostasis: Nrf2 (nuclear respiratory factor -2) and ATF4 (Cullinan et al., 2003). Signaling by both Nrf2 and ATF4 can modulate common targets, including the proapoptotic factor CHOP/GADD153 (C/EBP homologous protein/ growth arrest and DNA damage-inducible gene 153) (Cullinan and Diehl, 2004). In cells lacking Nrf2, CHOP expression levels are elevated compared to their wild-type controls, while Nrf2 overexpression ameliorates CHOP accumulation during the UPR (Cullinan and Diehl, 2004). In contrast, ATF4, a major downstream target of eIF2a phosphorylation, promotes CHOP expression (Harding et al., 2000). When ER stress is not mitigated, CHOP levels increase (Zinszner et al., 1998), which leads to activation of cell cycle arrest and apoptosis. IRE1 has both kinase and endoribonuclease activities. Once activated, the cytoplasmic domain of IRE1a gains endoribonuclease activity and cleaves 26 nucleotides from the mRNA encoding X-box-binding protein (XBP) 1, generating a spliced variant (XBP1s) that functions as a potent transcriptional transactivator of genes involved in ER expansion, protein maturation, folding and export from the ER, as well as export and degradation of misfolded proteins (Yoshida et al., 2001). Recent data indicate that the trigger for IRE1’s endoribonuclease activity is not phosphorylation per se, but rather a conformational change in the kinase domain induced by nucleotide binding, which is promoted by trans-autophosphorylation of the kinase activation loop (Ron and Walter, 2007). IRE1 may also degrade ER-targeted mRNAs, thus decreasing the production of new proteins in the organelle (Hollien and Weissman, 2006). ATF6 is a 90-kDa-bZIP protein that is activated by posttranslational modifications. ATF6 activation as part of the UPR leads to its translocation to the Golgi and cleavage by site-1 and -2 proteases (S1P and S2P). The 50-kDa cleaved ATF6a translocates to the cell nucleus, where it binds to the ER stress response element CCAAT(N)9CCACG (Yoshida et al., 1998) in genes encoding ER chaperone proteins such as BiP and GRP94. This results in increases in the level of these proteins and hence improved protein-folding activity in the ER (Yoshida et al., 1998).
3. UPR and Apoptosis Excessive and prolonged stress leads to apoptosis (Szegezdi et al., 2006). Apoptosis in response to ER stress is specific to metazoan cells (Schroder and Kaufman, 2005a). When cell protective changes mediated by the UPR fail to restore folding capacity, a combination of both the intrinsic and extrinsic apoptotic pathways are activated (Schroder and
6
Nirinjini Naidoo
Kaufman, 2005b). CHOP, together with Bcl-2 family members (Bak/Bax), caspase-12, and c-jun NH2 terminal kinase ( JNK) are components of the ER stress-mediated apoptotic pathway (Wu and Kaufman, 2006). Targets of CHOP include Bcl-2, GADD34, ERO1a, and TRB3 (Szegezdi et al., 2003). CHOP is known to repress Bcl-2 which is anti-apoptotic.
4. The UPR in Health and Disease The UPR pathway is important for normal cellular homeostasis, development, and physiology. ER stress and the UPR have also been implicated in a variety of diseases and pathologies including diabetes (Eizirik et al., 2008; Harding and Ron, 2002), cerebral ischemia (DeGracia and Montie, 2004), viral infections (He, 2006), cardiovascular disease (Vasa-Nicotera, 2004), cancer (Ma and Hendershot, 2004), inclusion body myositis (Vattemi et al., 2004), and neurodegenerative diseases (Lindholm et al., 2006; Rao et al., 2004).
5. Induction of the UPR by Sleep Deprivation We have shown that acute sleep loss or sleep deprivation leads to the induction of the UPR in mouse cerebral cortex (Naidoo et al., 2005) and Drosophila brain (Naidoo et al., 2007). In fact, several microarray studies indicate that BiP transcript is increased with sleep deprivation in all species examined, in Drosophila (Shaw et al., 2000), rat cerebral cortex (Cirelli et al., 2004), mouse cerebral cortex (Mackiewicz et al., 2007; Maret et al., 2007), and the telencephalon of the white crowned sparrow ( Jones et al., 2008). In mice, transcript and protein levels of BiP increase with 6, 9, and 12 h of sleep deprivation (Mackiewicz et al., 2007; Naidoo et al., 2005). Other UPR-specific transcripts that change with sleep deprivation in mouse cerebral cortex include DNA-J which is a cochaperone of BiP, XBP-1, calreticulin, caspase-9, ATF4, and ATF6. Immunoprecipitation studies indicate that BiP is dissociated from the kinase PERK with 6 h of sleep deprivation. There is phosphorylation of PERK and eIF2a indicative of inhibition of protein translation. Ribosome profiles from mice that have been subjected to 6 h of sleep deprivation indicate that there is a disaggregation of polysomes into monosomes in the sleep-deprived animals suggesting an attenuation of protein translation (Naidoo et al., 2005). Immunohistochemical studies also indicate that there is an increase in protein levels of ER chaperones GRP94, BiP/GRP78, and ERp72 during
The Unfolded Protein Response in Mouse Cerebral Cortex
7
sleep deprivation in both the dorsal and lateral cortex of mouse brain (Terao et al., 2003) again compatible with the induction of the UPR. The adaptive UPR response to sleep deprivation is attenuated in aged mice (22–24 months of age). Following 3, 6, 9, and 12 h of sleep deprivation, BiP levels did not increase in the cerebral cortex of aged mice in contrast to the robust increase in young animals (Naidoo et al., 2008). Instead, animals display upregulation of proapoptotic markers (Naidoo et al., 2008). GADD34 (growth arrest and DNA damage-inducible protein), a protein phosphatase 1 (PP1)-interacting protein, which causes PP1 to dephosphorylate eIF2a and relieves the translational block imposed by eIF2a phosphorylation (Brush et al., 2003; Szegezdi et al., 2006), was increased with both age and sleep deprivation. There was also a dramatic increase in the proapoptotic factor CHOP with age that was further increased in older animals with sleep loss. A role for CHOP in mediating apoptosis in response to ER stress is well established (Wang et al., 1996; Zinszner et al., 1998).
6. Experimental Protocols 6.1. Tissue procurement We examined molecular changes occurring with sleep deprivation in mouse cerebral cortex. We used C57BL/6J mice in all our studies. The protocol describing procurement and homogenization of cortical tissue follows: 1. Euthanize/sacrifice mice by cervical dislocation. 2. Remove the brain and dissect out the cerebral cortex of each mouse rapidly on ice using mouse brain atlas of Franklin and Paxinos (1996) as a guide. 3. Briefly, the first coronal cut will be performed approximately 1 mm rostral to the point where the optic nerves merge to form the optic chiasm and the second cut approximately 1 mm caudally to the optic chiasm (or just “behind” it). From the resulting slice, the left and right part of the cerebral cortex containing cingulate cortex (Cg1 and Cg2) primary and secondary motor areas (M1 and M2), as well as the somatosensory cortex (S1 and S2), will be separated from the subcortical structures along the corpus callosum. 4. Flash freeze the tissue in liquid nitrogen and store at –70 C until use. All animal protocols should be performed in accordance with National Institutes of Health guidelines and be approved by the Institutional Animal Care and Use Committee.
8
Nirinjini Naidoo
6.1.1. Tissue homogenization 1. Prepare lysis buffer for tissue homogenization. Lysis buffer 20 mM Tris–HCl pH 7.5 1 mM EGTA 1 mM EDTA 1% Triton X-100 10% glycerol Protease inhibitors (1 mM PMSF, 2 mg/ml pepstatin, and 4 mg/ml aprotinin). 2. Homogenize the cortical tissue in approximately 300 ml of cold lysis buffer on ice using a hand held or benchtop-motorized homogenizer equipped with a teflon pestle. 3. Centrifuge the lysate at 14,000 rpm for 10 min; save the supernatant on ice or at 4 C until the protein assay is done. 4. Determine protein concentration of the supernatant by the Pierce micro-BCA assay. 5. Store tissue homogenate in small aliquots (50 ml) at 70 C. 6.1.2. SDS-PAGE and westerns We use SDS-PAGE and westerns to determine the protein levels of BiP, activation of ATF6 by cleavage, activation of PERK by phosphorylation, phosphorylation of eIF2a, CHOP, and GADD34—the dilutions and source of antibodies used are listed in Table 1.1. 6.1.3. Determination of BiP/GRP78 BiP is the sentinel marker of the UPR. An increase in BiP expression usually indicates induction of the UPR. There are several commercial antibodies available to measure BiP protein levels. We have tried many of them and found that most work well. We prefer using the Stressgen (now Assay Designs) polyclonal BiP antibody for westerns. While we usually obtain just a single band at 78 kDa on our Western blots when testing a new batch of antibody or a new experiment, we usually run a sample of commercial hamster BiP/GRP78 (100–200 ng; Stressgen). All BiP antibodies tested are listed in Table 1.1. In our experiments, we examine the effect of different lengths of sleep deprivation on UPR induction in the mouse cerebral cortex. Individual sleep-deprived and matching control mouse cortex homogenates are run on SDS-PAGE gels in triplicate. We run several gels so that we can have both technical and biological replicates.
Table 1.1 UPR Antibodies, source, and description Antibody
Company
Immunogen
Host
Application Dilutions
GRP 78 (BiP) Santa Cruz aa 525–653 at the C-terminus of GRP 78 (H-129) Biotechnology GRP78 (BiP) Stressgen C-terminus of rat GRP78, sequence identical to that in mouse GADD 34 Santa Cruz C-terminus peptide of mouse GADD 34 (C-19) Biotechnology GADD 153 Santa Cruz Amino acids 1–168 representing full length mouse (CHOP) Biotechnology GADD153
Rabbit IHC
1:100
Rabbit Western
1:1000
Rabbit Western, IHC Rabbit Western, IHC
Caspase 12
Stressgen
Rabbit Western
1:200, 1:2000 1:500– 1:1000, 1:500 1:2000
P-eIF2a (Ser51) P-PERK
Rabbit Western
1:500
GADD 153 (CHOP) ATF6
Cell Signaling Technology Cell Signaling Technology Thermo Scientific Imgenex
Rabbit Western, IHC Mouse IHC
1:1000, 1:500 1:500
Mouse Western
1:500
eIF2a
Cell signaling
Rabbit Western
1:500
16 residue synthetic peptide corresponding to amino acids 2–17 of murine caspase-12 Synthetic phosphopeptide corresponding to residues surrounding Ser51 of eIF2a Phosphopeptide residues surrounding Thr980 of mouse PERK Corresponds to bacterially expressed mouse fusion CHOP Partial protein containing amino acids 1–273 of human ATF6 C-terminus sequence
10
Nirinjini Naidoo
6.1.4. PERK activation and phosphorylation of eIF2a PERK is maintained in an inactive state by binding to the lumenal domain of BiP/GRP78. Under conditions of ER stress, BiP/GRP78 dissociates to service the increasing load of ER client proteins; loss of BiP/GRP78 binding correlates with oligomerization, trans-autophosphorylation, and activation of downstream signaling by PERK (Bertolotti et al., 2000). Activated PERK phosphorylates eIF2a on serine 51, a modification that increases the affinity of eIF2 for eIF2B, a GDP–GTP exchange factor that charges the eIF2–GTP–tRNA-met ternary complex (Kimball et al., 2001). Functioning as a competitive inhibitor of eIF2B, phospho-eIF2a reduces the concentration of the active ternary complex, prevents assembly of the 43S preinitiation complex, and attenuates protein translation. Use of specific antibodies to the phosphorylated state of both PERK and eIF2a are useful to determine activation of PERK. 6.1.5. Activation of ATF6 The ER lumenal domain of ATF6 has two Golgi localization signals: GLS1 and GLS2. Binding to BiP/GRP78 masks the localization signals in the lumenal region of ATF6; dissociation of BiP allows ATF6 to be transported to the Golgi body. Further, the ER lumenal domain of ATF6 has disulfide bonds and ER stress-induced reduction plays an important role in both translocation of ATF6 to Golgi body and the subsequent recognition by the S1P and S2P (Nadanaka et al., 2007; Shen et al., 2002). Once cleaved by S1P and S2P, the 50-kDa ATF6a translocates to the cell nucleus. 6.1.6. Procedure 1. Prepare samples (20 mg protein) representing individual mice by adding 2 Laemmli buffer and boiling for 2–5 min. 2. Run on SDS-PAGE gels (Bio-Rad, 10% Tris–HCl) according to Laemmli (1970). 3. Transfer gels to nitrocellulose membranes (Bio-Rad) using either semidry or wet transfer. 4. Following transfer, place membranes in blocking solution, 5% milk in phosphate buffered saline, 0.05% Tween 20 (PBST), for 1 h at room temperature. 5. Incubate membrane with rabbit polyclonal antibody against BiP/GRP78 (Stressgen, 1:1000 in 5% milk and PBST) either at 4 C overnight or for 90 min at room temperature. 6. Wash the blots three times with PBST for 5–10 min each time. 7. Incubate with horseradish peroxidase-conjugated secondary antibody (anti-rabbit 1:3000, Sigma) made in 5%milk in PBST for 1 h at room temperature. 8. Wash the blots three times with PBST for 5–10 min each time.
11
The Unfolded Protein Response in Mouse Cerebral Cortex
9. Detect protein by enhanced chemiluminescence (ECL, Pierce Supersignal) using the AlphaInnotech Fluorochem 8900 ChemiImager (see Figs. 1.1 and 1.2). Alternatively, the membranes can be exposed to X-ray film until clear bands are observed after developing the film. 10. Quantify protein bands on the AlphaInnotech ChemiImagerTM using the Alphaease software. If X-ray film is being used, quantify bands using densitometry. We now also use the LI-COR Odyssey infrared imaging system (LI-COR, Inc., Lincoln, NE) for quantitative Western blotting.
CON
SD
BiP
P-Perk
P-eIF2a
eIF2a
Figure 1.1 Composite image showing representative Western blots for BiP, P-PERK, P-eIF2a, and eIF2a in the cerebral cortex of young mice that were sleep deprived (SD) for 6 h. Control (Con) mice were undisturbed during sleep.
Young
Aged
Control
SD
Figure 1.2 Western showing CHOP expression in young and aged control and sleep-deprived samples. CHOP levels are markedly higher in aged animals compared to young.
12
Nirinjini Naidoo
The Odyssey uses near-infrared fluorescence detection that allows the quantification of proteins over a much wider linear dynamic range than chemiluminescence can. There are several advantages of using the Odyssey over chemiluminescence. The signal is stable. The Odyssey has a two color detection system with two channels at 700 and 800 nm, respectively. Two antibodies can be simultaneously detected on the same membrane. Strong and weak bands are accurately detected on the same blot without the uncertainty and inconvenience of multiple exposures or time in the darkroom. The disadvantage of using the Odyssey includes having to purchase their patented “unknown” buffers which gets to be very expensive. The Odyssey buffer is used for blocking and diluting theTMprimary and secondary TM antibodies. The secondary antibodies are IRDye 800 and IRDye 680 made against the various host species. 6.1.7. Dissociation of BiP from PERK During the UPR, parallel with the increase of chaperone function is an attenuation of translation to decrease the protein-folding load. During ER stress, decrease in protein biosynthesis occurs when the eukaryotic translation initiation factor 2a is phosphorylated on serine 51 by PERK. PERK is an ER-resident type I transmembrane protein, whose N-terminal lumen domain is sensitive to the upstream ER stress signal and whose C-terminal cytoplasmic domain directly phosphorylates eIF2a (Harding et al., 1999). PERK is maintained in an inactive state by the binding of the ER chaperone BiP/GRP78 to its lumenal domain. Under conditions of ER stress, BiP/ GRP78 dissociates to service the increasing load of ER client proteins; loss of BiP/GRP78 binding correlates with oligomerization, trans-autophosphorylation, and activation of downstream signaling by PERK (Bertolotti et al., 2000). The association of BiP/GRP78 with PERK therefore indicates the state of the cell. We examined the effect of sleep deprivation on the degree to which BiP/GRP78 is associated with PERK. We used an antibody to PERK to co-immunoprecipitate BiP/GRP78 from cortical lysates of sleep deprived and control undisturbed animals using the protocol described below. The immunoprecipitated protein was resolved by 7.5% SDS-PAGE under reducing conditions and transferred to nitrocellulose membranes. Blots were incubated with GRP78 antibody (1:1000); signals were observed using horseradish peroxidase labeled secondary antibody. Protein bands were detected and analyzed by enhanced chemiluminescence (Pierce Supersignal) and quantitative imaging (AlphaInnotech Fluorochem 8900). Densitometry was performed using the Alphaease FC software. Alternatively, IR-conjugated secondary antibodies were used and protein bands were detected and quantified directly by infra red imaging on the Odyssey (LI-COR).
The Unfolded Protein Response in Mouse Cerebral Cortex
13
6.1.8. Immunoprecipitation protocol 1. Use about 100 mg of protein/experiment. 2. Preclear sample with about 10 ml of washed Protein-G Sepharose beads/1 h at 4 C; bead washing is described in step 3. 3. Before use, wash beads with lysis buffer containing protease inhibitor. Wash by adding 300 ml lysis buffer, suspend beads, spin down at 10,000 rpm for 1 min. Remove supernatant but do not allow beads to dry out. Repeat three times. 4. Add 25 ml lysis buffer to homogenates. 5. Add 2 ml of PERK antibody to each homogenate sample—incubate 4 C overnight, with end over end rotation. 6. Incubate 30 ml of washed beads (from step 3) with homogenate– antibody mixture for 1.5 h with end over end rotation. 7. Spin down beads at 10,000 rpm for 1 min. 8. Wash beads three times with 200 ml buffer. 9. Add 2 Laemmli buffer (50 ml), then boil for 2–5 min. 10. Spin down beads, 10,000 rpm for 1 min. 11. Remove supernatant for use in SDS gel electrophoresis. 12. Load 20 ml/well; run gel 13. Use appropriate antibody in western to detect interacting proteins
6.1.9. Immunohistochemistry While detection of the proteolytic processing of ATF6 by westerns works well it can sometimes be tricky to detect the cleavage products. It is advisable to carry out immunohistochemistry to look for nuclear localization of ATF6 as a marker of activation. We also use immunohistochemistry to detect localization of the UPR markers to specific neuronal populations within the mouse cerebral cortex and other brain areas. There is an image of ATF6 localization to the nucleus using immunostaining in Fig. 1.3. Using immunofluorescence and immunostaining with DAB (3,30 -diaminobenzidine), we have found that BiP localizes to the pyramidal neurons of layers I–VI of the medial prefrontal cortex, cingulate cortex, and piriform cortex (Fig. 1.4). We also found increased CHOP staining in these areas only in aged mice (Fig. 1.5). In contrast, BiP is reduced in these same cells in the aged animals. Aged mice also display more GADD34 staining in cortical neurons than do young mice; this is shown in Fig. 1.6. GADD34 is a downstream target of CHOP and is a good marker of a maladaptive response. The protocol below describes both immunofluorescence and immunostaining of free-floating brain sections.
14
Nirinjini Naidoo
25 mm
ATF6
Figure 1.3 Immunostaining of ATF6 in piriform cortical neurons. DAB-nickel was used to localize ATF6 in the nucleus of the neurons. 400 magnification. Scale bar, 25 mm.
Young
M1
Old
50 mm
Cg2
Pir
Figure 1.4 Decreased immunohistochemical labeling of BiP in with age. DAB labeled BiP in young and aged cingulate, M1 and piriform cortical neurons. 160 magnification. Scale bar, 50 mm.
15
The Unfolded Protein Response in Mouse Cerebral Cortex
Young
Cg1/M2
Old
100 mm
M1
Pir
Figure 1.5 Increased expression of CHOP with age. DAB labeled CHOP in young and aged cingulate, M1 and piriform neurons. 80 magnification. Scale bar, 100 mm (for all images).
6.1.10. General procedure 1. Procure brain tissue after pentobarbital anesthesia and transcardial perfusion with saline and 4% paraformaldehyde. 2. Incubate whole brains in 4% paraformaldehyde, then cryopreserve in 30% sucrose in PBS containing 0.05% sodium azide. 3. Slice the brain along the coronal axis in 20 or 40 mm sections from the medulla through the basal forebrain approximating murine coordinates 1.54–1.94 mm bregma (Franklin and Paxinos, 1996). 4. Store sections as 1:6 or 1:3 series in 0.1% sodium azide in PBS at 4 C before use. 5. Incubate sections with normal serum for 60–90 min to block nonspecific binding of immunoglobulin. Use the same species’ serum as the secondary antibody is made to.
16
Nirinjini Naidoo
2M
24 M
GADD34
GADD34
100 mm
Figure 1.6 GADD34 immunofluorescence in piriform cortex. The left panel shows GADD34 in young cerebral cortex and the right panel shows increased GADD34 immunofluorescence in aged mouse cortex. 200 magnification. Scale bar, 100 mm.
6. Incubate sections with primary antibody at appropriate dilution in blocking buffer for 1 h at room temperature or overnight at 4 C. We use MAP2 antibody (Abcam, 1:1000) as a neuronal marker. For BiP, we use GRP78 (H-129; Santa Cruz) antibody at 1:500, and CHOP is detected using the GADD153/CHOP antibody at 1:500 (sc575; Santa Cruz). 7. Rinse sections 3 10 min in PBS. 8. Incubate sections in secondary antibody diluted in PBS with 2% normal serum for 90 min at room temperature. For fluorescence use Alexa Fluor secondary antibodies diluted at 1:500. For DAB staining, use the appropriate biotinylated secondary antibody (see below). 9. Wash sections in PBS for 30 min in six 5 min intervals. 10. Mount sections on the slide and dry for 30 min in the dark. 11. Coverslip with slow-fade gold antifade reagent with DAPI. 6.1.11. DAB and DAB-nickel staining protocol DAB and DAB-Nickel (DAB-Ni) can be used for double staining of tissue sections. The DAB stain is very stable and immunostained sections can be kept for a long time without fading and loss of signal. Use of DAB results in a brown stain that is enhanced with nickel to produce a dark gray stain. Day 1 1. 2. 3. 4.
Wash sections in PBS for 3 5 min. Treat sections with 3% H2O2 in PBS for 30 min. Wash in PBS for 3 5 min. Incubate in blocking buffer (4% normal serum, 1% BSA, 0.4% Triton X-100 in PBS with 0.1% sodium azide at room temperature for 60–90 min).
The Unfolded Protein Response in Mouse Cerebral Cortex
17
5. Incubate sections in primary antibody diluted in blocking buffer at room temperature for overnight or 4 C for 48 h. Day 2 6. Wash sections in PBS for 6 5 min. 7. Incubate sections in biotinylated appropriate secondary antibody with 2% normal serum,0.5% BSA, 0.4% Triton X-100 in PBS at room temperature for 60 min. (Prepare the ABC reagent buffer. Let it sit at room temperature for at least 30 min before use. 1:1000 in PBS with 0.4% Triton X-100.) 8. Wash in PBS for 6 5 min. 9. Incubate in ABC reagent at room temperature for 60 min. 10. Wash in PBS for 3 5 min. 11. Wash in 0.175 M sodium acetate for 3 5 min. 12. Use DAB-Ni1 to visualize the reaction (from 5 to 20 min). 13. Wash in PBS for 6 5 min. For single labeling, go to step 14; for double labeling, go to step 15. 14. Dehydrate with progressive alcohol at 5–10 min each (70%, 95%, 100%, and 100%) and two times xylene for 10 min each. Mount with permount and coverslip. 15. For double labeling, repeat step 5 with the second primary antibody. Day 3 16. Repeat steps 6–14. (You should perform DAB-Ni staining first and it should be an antibody that localizes to the nucleus and then carry out the DAB staining for the cytosolic marker.)
6.1.12. Polysome analyses Actively translating ribosomes exist as polysomes; during a shutdown or attenuation of translation, a large fraction of the ribosomes is disassembled into monosomes (Doutheil et al., 1997; Gulow et al., 2002; Harding et al., 2000). We carried out polysome analyses to further assess whether protein synthesis was being inhibited after 6 h of sleep deprivation. The microsomal fraction of sleep deprived and control cortical lysates were separated by sucrose gradient centrifugation to yield the ribosomal profiles. The ribosomal profile of samples subjected to 6 h of sleep deprivation show a moderate increase in the monosome peak with a concomitant decrease in the polysomes peak when compared to controls, suggesting an attenuation of translation. For a more detailed description, see the chapter on Polysome Analysis in Methods in Molecular Biology by Sagliocco et al. (2006). 1
DAB-Ni: 2 mg DAB, 1 ml 5% Nickel in 0.175 M sodium acetate to 10 ml, add 8.3 ml 3% H2O2.
18
Nirinjini Naidoo
6.1.13. Polysome analysis protocol Cortex tissue from individual mice sleep deprived for 6 h and their matching controls was homogenized in 1 ml of polysome extraction buffer (15 mM Tris–HCl pH 7.4, 15 mM MgCl2, 0.3 M NaCl, 1% Triton X-100, 0.1 mg/ml cyclohexamide, 1 mM PMSF, 2 mg/ml pepstatin, and 4 mg/ml aprotinin). The lysates were cleared by centrifugation at 12,000g for 10 min, and then layered on top of a 4 mL 10–50% sucrose gradient prepared in extraction buffer. After a spin of 2 h at 40,000 rpm in a Sorvall AH650 rotor, 200 ml fractions were collected and the absorbance at 254 nm was read. 6.1.14. Assessment of changes in mRNA for BiP/Q-PCR of BiP In addition to assessing changes in protein levels and activation though phosphorylation, one can also determine transcript levels of the various UPR markers. We examined the alteration of BiP transcript levels using quantitative PCR. I outline below the protocol we used for BiP and provide information about the primer and probe sets used and that can be used for other UPR markers. The expression of the BiP gene in the cerebral cortex C57BL/6J mice during sleep and in sleep deprivation was established by quantitative RT-PCR using the TaqManÒ Gene Expression Assays and 7500 realtime PCR system (Applied Biosystems). Total RNA was isolated with Trizol (Invitrogen) and further cleaned using RNeasy purification kit (Qiagen). cDNA was synthesized using 0.5 mg total RNA and TaqManÒ Reverse Transcription Reagents (Applied Biosystems). The following sets of primers and probes for the relevant genes were used: Mm00517691_m1 (Hspa5/BiP) and Mm00545877_m1 (Apc). Each PCR reaction was repeated in triplicate. The relative transcript level was established by the “DD method” as described previously (Livak and Schmittgen, 2001). The Apc (adenomatosis poliposis coli) gene was used as an internal standard; this gene was identified as unchanged in its expression either during sleep or sleep deprivation in the cerebral cortex and hypothalamus of C57BL/6J mice (Mackiewicz et al., 2007).
7. Concluding Remarks This chapter described techniques and protocols for examining the UPR in whole mouse cerebral cortex. Currently, we know from immunohistochemistry that not all neuronal populations in the mouse brain respond to ER stress in a similar manner (Naidoo et al., 2009; unpublished observation). There are temporal and spatial differences. Use of laser capture microscopy and specific neuronal tags should soon allow one to examine
The Unfolded Protein Response in Mouse Cerebral Cortex
19
the UPR in very specific neuronal populations and discern why certain neurons respond the way they do. This would allow the development of neuron-specific therapeutics for the various diseases ER stress and the UPR are implicated in.
ACKNOWLEDGMENTS I am grateful to Dr. Marishka Brown for critical reading and discussions during the writing of this chapter; Drs. Jingxu Zhu and Yan Zhu for the images and Ms. Jennifer Montoya for assistance with the figures.
REFERENCES Bertolotti, A., et al. (2000). Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2, 326–332. Brush, M. H., et al. (2003). Growth arrest and DNA damage-inducible protein GADD34 targets protein phosphatase 1 alpha to the endoplasmic reticulum and promotes dephosphorylation of the alpha subunit of eukaryotic translation initiation factor 2. Mol. Cell. Biol. 23, 1292–1303. Cirelli, C., et al. (2004). Extensive and divergent effects of sleep and wakefulness on brain gene expression. Neuron 41, 35–43. Cullinan, S. B., and Diehl, J. A. (2004). PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J. Biol. Chem. 279, 20108–20117. Cullinan, S. B., et al. (2003). Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell. Biol. 23, 7198–7209. DeGracia, D. J., and Montie, H. L. (2004). Cerebral ischemia and the unfolded protein response. J. Neurochem. 91, 1–8. Doutheil, J., et al. (1997). Relation of neuronal endoplasmic reticulum calcium homeostasis to ribosomal aggregation and protein synthesis: Implications for stress-induced suppression of protein synthesis. Brain Res. 775, 43–51. Eizirik, D. L., et al. (2008). The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29, 42–61. Franklin, K. B. J., and Paxinos, G. (1996). The Mouse Brain in Sterotaxic Coordinates. Academic Press, San Diego. Gulow, K., et al. (2002). BiP is feed-back regulated by control of protein translation efficiency. J. Cell Sci. 115, 2443–2452. Harding, H. P., and Ron, D. (2002). Endoplasmic reticulum stress and the development of diabetes: A review. Diabetes 51(Suppl. 3), S455–S461. Harding, H. P., et al. (1999). Protein translation and folding are coupled by an endoplasmicreticulum-resident kinase. Nature 397, 271–274, [see comment][erratum appears in Nature 1999 Mar 4;398(6722):90]. Harding, H. P., et al. (2000). Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099–1108. Harding, H. P., et al. (2002). Transcriptional and translational control in the Mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 18, 575–599. He, B. (2006). Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ. 13, 393–403.
20
Nirinjini Naidoo
Hollien, J., and Weissman, J. S. (2006). Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response [see comment]. Science 313, 104–107. Jones, S., et al. (2008). Molecular correlates of sleep and wakefulness in the brain of the white-crowned sparrow. J. Neurochem. 105, 46–62. Kimball, S. R., et al. (2001). The double-stranded RNA-activated protein kinase PKR is dispensable for regulation of translation initiation in response to either calcium mobilization from the endoplasmic reticulum or essential amino acid starvation. Biochem. Biophys. Res. Commun. 280, 293–300. Laemmli, U. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685. Lindholm, D., et al. (2006). ER stress and neurodegenerative diseases. Cell Death Differ. 13, 385–392. Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408. Ma, Y., and Hendershot, L. M. (2004). The role of the unfolded protein response in tumour development: Friend or foe? Nat. Rev. Cancer 4, 966–977. Mackiewicz, M., et al. (2007). Macromolecule biosynthesis: A key function of sleep. Physiol. Genomics 31, 441–457. Maret, S., et al. (2007). Homer1a is a core brain molecular correlate of sleep loss. Proc. Natl. Acad. Sci. USA 104, 20090–20095. Nadanaka, S., et al. (2007). Role of disulfide bridges formed in the luminal domain of ATF6 in sensing endoplasmic reticulum stress. Mol. Cell. Biol. 27, 1027–1043. Naidoo, N., et al. (2005). Sleep deprivation induces the unfolded protein response in mouse cerebral cortex. J. Neurochem. 92, 1150–1157. Naidoo, N., et al. (2007). A role for the molecular chaperone protein BiP/GRP78 in Drosophila sleep homeostasis. Sleep 30, 557–565. Naidoo, N., et al. (2008). Aging impairs the unfolded protein response to sleep deprivation and leads to proapoptotic signaling. J. Neurosci. 28, 6539–6548. Naidoo, N., Galante, R., Zhang, L., Lian, J., Zhu, J., and Veasey, S. C. (2009). ER dyshomeostasis occurs in key sleep wake regions with aging. Soc. Neurosci. Abs. 376, 24. Rao, R. V., et al. (2004). Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 11, 372–380. Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529. Sagliocco, F., et al. (2006). Polysome Anlaysis. Methods Mol. Biol. 53, 297–311. Schroder, M., and Kaufman, R. J. (2005a). ER stress and the unfolded protein response. Mutat. Res. 569, 29–63. Schroder, M., and Kaufman, R. J. (2005b). The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739–789. Schroder, M., and Kaufman, R. J. (2006). Divergent roles of IRE1alpha and PERK in the unfolded protein response. Curr. Mol. Med. 6, 5–36. Shaw, P. J., et al. (2000). Correlates of sleep and waking in Drosophila melanogaster. Science 287, 1834–1837. Shen, J., et al. (2002). ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev. Cell 3, 99–111. Szegezdi, E., et al. (2003). Caspase-12 and ER-stress-mediated apoptosis: The story so far. Ann. NY Acad. Sci. 1010, 186–194. Szegezdi, E., et al. (2006). Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7, 880–885. Terao, A., et al. (2003). Differential increase in the expression of heat shock protein family members during sleep deprivation and during sleep. Neuroscience 116, 187–200.
The Unfolded Protein Response in Mouse Cerebral Cortex
21
Vasa-Nicotera, M. (2004). The new kid on the block: The unfolded protein response in the pathogenesis of atherosclerosis. Cell Death Differ. 11(Suppl. 1), S10–S11. Vattemi, G., et al. (2004). Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am. J. Pathol. 164, 1–7. Wang, X. Z., et al. (1996). Signals from the stressed endoplasmic reticulum induce C/EBPhomologous protein (CHOP/GADD153). Mol. Cell. Biol. 16, 4273–4280. Wu, J., and Kaufman, R. J. (2006). From acute ER stress to physiological roles of the unfolded protein response. Cell Death Differ. 13, 374–384. Yoshida, H., et al. (1998). Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J. Biol. Chem. 273, 33741–33749, [erratum appears in J. Biol. Chem. 1999 Jan 22;274(4):2592]. Yoshida, H., et al. (2001). XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107, 881–891. Zhang, K., and Kaufman, R. J. (2004). Signaling the unfolded protein response from the endoplasmic reticulum. J. Biol. Chem. 279, 25935–25938. Zhang, K., and Kaufman, R. J. (2006). The unfolded protein response: A stress signaling pathway critical for health and disease. Neurology 66, S102–S109. Zinszner, H., et al. (1998). CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 12, 982–995.
This page intentionally left blank
C H A P T E R
T W O
Immunohistochemical Detection of the Unfolded Protein Response in Atherosclerotic Plaques Sˇa´rka Lhota´k,* Ji Zhou,† and Richard C. Austin* Contents 24 24 25 27 27 29 29 30 33 33 40 42 44 44
1. 2. 3. 4.
Endoplasmic Reticulum and the Unfolded Protein Response Atherosclerosis UPR in the Atherosclerotic Lesion Mouse Models of Atherosclerosis 4.1. Lesion morphology 4.2. Lesion size 5. Methods 5.1. Sectioning the aortic root 5.2. Measuring lesion size in serial sections 5.3. Immunohistochemistry 5.4. Double immunofluorescence 5.5. Detection of apoptosis Acknowledgments References
Abstract It is well established that activation of the unfolded protein response (UPR) occurs during all stages of plaque development and progression. Mouse models of atherosclerosis have allowed the study of the UPR in the complex environment of lesions which are composed of different cell types, abundant extracellular matrix, as well as necrotic and apoptotic areas. For proper evaluation of the UPR, the processing, sectioning, and staining of lesions have to be performed in a consistent and reproducible manner. In this chapter, we describe in detail how to embed aortic roots in paraffin, cut serial sections through the aortic root, measure lesion size, and stain paraffin sections by immunohistochemistry, * Department of Medicine and Division of Nephrology, St. Joseph’s Hospital and McMaster University, Hamilton, Ontario, Canada { Department of Medicine, Thrombosis and Atherosclerosis Research Institute (TaARI) and McMaster University, Hamilton, Ontario, Canada Methods in Enzymology, Volume 489 ISSN 0076-6879, DOI: 10.1016/B978-0-12-385116-1.00002-9
#
2011 Elsevier Inc. All rights reserved.
23
24
Sˇa´rka Lhota´k et al.
immunofluorescence, and the terminal dUTP nick-end-labeling (TUNEL) technique, with special attention to the proteins involved in the UPR.
1. Endoplasmic Reticulum and the Unfolded Protein Response The endoplasmic reticulum (ER) is the site of synthesis, folding, and modification of proteins destined for secretion or the plasma membrane. ER lumenal-resident chaperones such as the 78-kDa glucose-regulated protein (GRP78), 94-kDa glucose-regulated protein (GRP94), protein disulfide isomerase (PDI), calnexin, and calreticulin assist in the folding process. The ER has a sophisticated mechanism of quality control to prevent misfolding of proteins termed the unfolded protein response (UPR). The UPR consists of three integrative pathways whose sensors (PKR-like ER kinase (PERK), inositol requiring kinase 1 (IRE1), and activating transcription factor 6 (ATF6)) reside in the ER membrane. Their activation leads to (i) the attenuation of general protein translation (through the PERK pathway) and (ii) the increased expression of specific ER chaperones, such as GRP78 and PDI (through the ATF6 and IRE1 pathways). In addition, components of the ERassociated degradation pathway are also activated so as to eliminate the accumulation of misfolded proteins. ER stress refers to the disruption of ER homeostasis (accumulation of misfolded proteins, release of ER calcium) leading to the activation of the UPR. Numerous agents and conditions have recently been identified that induce the UPR during the process of atherogenesis, including free cholesterol, peroxynitrite, homocysteine, and hypoxia (Austin, 2009). Under these conditions, the UPR is designed to alleviate ER stress, thereby restoring correct ER homeostasis. However, if the stress cannot be resolved, the cell is destined for ER stress-induced apoptosis via activation of caspase-12 and downstream caspases. For detailed review on the UPR and its role in apoptotic cell death, see Malhotra and Kaufman (2007).
2. Atherosclerosis Atherosclerosis refers to a disease of large and middle size arteries which is characterized by the formation of complex lesions within arterial walls (reviewed in Lusis, 2000). The first stage during atherogenesis consists of the “fatty streak” which is composed of foam cells. The formation of foam cells is initiated by the presence of modified LDL particles in the subendothelial space which leads to the recruitment of blood-borne monocytes to this site and their differentiation into macrophages. Macrophages ingest LDL particles, esterify the cholesterol, and store the lipid in vacuoles
Immunohistochemistry in Atherosclerotic Lesions
25
giving them their “foamy” appearance. Lesions progressively evolve by recruitment of smooth muscle cells from the media, deposition of extracellular matrix, and apoptosis of foam cells, thereby creating defined regions of cellular necrosis and calcification. Such plaques may become unstable and prone to rupture. Plaque rupture is the most devastating clinical complication of atherosclerosis leading to the formation of a thrombus and resulting in myocardial infarction or stroke.
3. UPR in the Atherosclerotic Lesion In the 1990s, increased plasma homocysteine was identified as a risk factor for cardiovascular disease (Boushey et al., 1995). To explain the mechanism behind this association, we as well as others identified a number of genes upregulated by homocysteine. Using mRNA differential display and cDNA analysis, we discovered in cultured endothelial cells that homocysteine induced the expression of GRP78 and the growth arrest and DNA damageinducible gene 153 (GADD153) (Outinen et al., 1998). Around that time, the unfolded protein pathways were being elucidated and these proteins were known to be induced by stress to the ER (Malhotra and Kaufman, 2007). To translate our findings to an in vivo model of atherosclerosis, we utilized a mouse model of hyperhomocysteinemia to assess the induction of the UPR in lesion resident cells (Zhou et al., 2001). In collaboration with Dr. Erling Falk and colleagues, we showed that increased plasma homocysteine levels in apoE/ mice supplemented with methionine led to increased lesion size (Zhou et al., 2001). Using immunohistochemistry, we found that the staining intensities for markers of ER stress, namely the ER chaperones and phosphoPERK, were increased in the lesions of hyperhomocysteinemic mice compared with controls (Zhou et al., 2004). Surprisingly, positive immunostaining for UPR markers was also observed in the aortic root lesions at all stages of lesion progression in control apoE/ mice (Zhou et al., 2005). The association between the UPR and atherosclerosis has now been clearly established (for review, see Austin, 2009; Marciniak and Ron, 2006). Currently, UPR-related research is focused in two main areas: ER stress and activation of the UPR in (i) atheroprone regions of the blood vessel (Civelek et al., 2009; Dickhout et al., 2005; Feaver et al., 2008; Sanson et al., 2009), as well as (ii) apoptotic cell death and plaque stability, which are crucial to the prevention of devastating clinical events. ER stress markers were found to be increased in unstable plaques in human carotid lesions (Dickhout et al., 2007; Myoishi et al., 2007). In both human and mouse lesions, the UPR is observed predominantly in macrophages and macrophage foam cells (Fig. 2.1). This is consistent with in vitro findings showing that cholesterol loading of macrophages causes UPR activation and
26
Sˇa´rka Lhota´k et al.
GRP78
p-PERK
A
I M
D
GADD153
B
C
E
F
A
I
A
M
Figure. 2.1 Endoplasmic reticulum stress in early and advanced lesions from apoE/ mice. Immunohistochemical staining for GRP78, phospho-PERK, and GADD153 is shown in early (A–C) and advanced (D–F) lesions. GRP78 was found in foam cells in the lesions and some cells in adventitia in both stages of the lesion progression (A, D). Phospho-PERK staining was also seen in the foam cells; however, only some of the cells were strongly expressing the protein (B, D), whereas others were devoid of the signal, most likely reflecting the temporary character of the protein phosphorylation. Few of the smooth muscle cells in the media were also positive (B). GADD153 strongly labeled nuclei in the foam cells in early lesions (C, arrows) and in the lumenal portion of the advanced lesion (F, arrows). I, intima; M, media; A, adventitia. Bar ¼ 50 mm.
subsequent apoptosis (Feng et al., 2003). Currently, macrophage apoptosis is under intense study given its direct relevance to plaque growth and stability (Han et al., 2006; Tabas et al., 2009, 2010; Tsukano et al., 2010). The complexity of atherosclerotic lesions and the interplay between its pathways and components dictate that research should be carried out using in vivo models. Immunohistochemistry is an excellent tool for studying the expression of various proteins in specific cells within the lesions. An example of the UPR-related immunostaining in early and advanced lesions from apoE/ mice is presented in Fig. 2.1. The ER chaperone GRP78 is detected in all macrophage foam cells in the early lesion (Fig. 2.1A) and on the lumenal side of the neointima in the advanced lesion (Fig. 2.1D). Only a few cells in the necrotic region of the neointima displayed any staining. Phospho-PERK staining was observed in the macrophage foam cells in both early and advanced lesions (Fig. 2.1B, E); however, the pattern of staining was different than that for GRP78. Some of the cells had intense staining while others were devoid of staining. We believe that this represents the transient activation of PERK in association with an increase in GRP78 expression. GADD153, one of the components of ER
Immunohistochemistry in Atherosclerotic Lesions
27
stress-induced apoptosis (Oyadomari and Mori, 2004), is strongly expressed in the nuclei (and less so in the cytoplasm) of foam cells in both early and advanced lesions (Fig. 2.1C, F).
4. Mouse Models of Atherosclerosis None of the in-bred strains of mice spontaneously develop atherosclerosis. Only small lesions consisting of foam cells can be induced by modified diets over long periods of time in some strains (Whitman, 2004). These are of limited use because the lesions do not progress to advanced and complicated lesions analogous to those seen in humans. A major advance in using mouse models to study atherosclerosis was triggered by the generation of apoE-deficient (apoE/) and LDL receptor-deficient (ldlr/) mice in 1992 and 1994, respectively (Ishibashi et al., 1994; Piedrahita et al., 1992; Plump et al., 1992). ApoE/ mice develop lesions spontaneously on chow diet, while ldlr/ mice require high cholesterol diet. In both models, lesions progress from simple fatty streaks composed of lipid laden macrophages to complex lesions with necrotic cores, extracellular lipid deposition, and fibrous cap formation, thus resembling the progression in human lesions. These mice have been crossed with other knockout or transgenic mice to study the role of various genes in lesion progression and stability. For designing an experiment using atheroprone mice, there are a number of helpful reviews summarizing the type of lesions, age, gender, diet, and genetic background (Daugherty, 2002; Daugherty and Rateri, 2005; Daugherty et al., 2009; Whitman, 2004).
4.1. Lesion morphology In all mouse models, lesions start in the atheroprone region of the aortic root. With time and increased hyperlipidemia, these lesions increase in size and complexity with new lesions forming in the aortic arch and the thoracic and abdominal aorta, predominantly around the ostia of large arteries. Early lesions are composed of macrophage foam cells. Morphologically, these are large cells filled with lipid droplets (Fig. 2.2A) and can be identified by immunostaining with a macrophage marker (Fig. 2.3). The morphology of advanced lesions is complex. The lumenal side is typically comprised of macrophage foam cells interspersed with smooth muscle cells forming the cap next to the endothelium. Below this layer, there are areas of apoptosis (dense fragmented nuclei) as well as acellular areas characterized by the lack of nuclei and extracellular matrix with cholesterol clefts (Fig. 2.2B). In early lesions, neutral lipids (cholesterol esters and triglycerides, stained with Oil Red O or Sudan IV) and free cholesterol (stained with filipin) can be
28
Sˇa´rka Lhota´k et al.
L
B
A
FC
L A M M
Figure. 2.2 Morphology of early and advanced lesions. Only a few foam cells are seen close to the valve leaflet in an early lesion (arrows, outline in green, A). Advanced lesion (outlined in green, B) consists of a cellular area on the lumenal side formed predominantly by foam cells (FC) and an acellular area devoid of nuclei (A). Cholesterol clefts (arrows) and apoptotic bodies (arrowheads) are embedded in extracellular matrix. L, lumen; M, media; FC, foam cells; A, acellular area; arrows, cholesterol clefts; arrowheads, apoptotic bodies. Bar ¼ 50 mm.
Mac-3 A
SMA B
vWF C
M
D
E
F
M
Figure. 2.3 Cellular composition of atherosclerotic lesions. Lesions are composed mostly of macrophage cells (stained here with the Mac-3 antibody, A, D) overlaid by a thin layer of endothelium (stained with von Wilebrandt factor (vWF), C, F). Smooth muscle cells are rarely seen in early lesions; staining is seen only in the media (M, B). In advanced lesions smooth muscle cells are present in the cap of the lesion (arrows, E), in addition to the media. SMA, smooth muscle actin. Bar ¼ 50 mm.
Immunohistochemistry in Atherosclerotic Lesions
29
identified in the macrophage foam cells. In advanced lesions, the lumenal side of the lesion stains for both neutral lipids and free cholesterol (not shown). However, the acellular necrotic core does not stain for neutral lipids. Thus, using neutral lipid staining on cryosections to highlight lesions for measurement (as is sometimes seen in literature) will underestimate lesion size.
4.2. Lesion size Several reviews describe how to assess and measure lesions (Daugherty and Rateri, 2005; Daugherty et al., 2009). In the early stages, lesions are only present in the aortic root. However, in more advanced cases of atherosclerosis where lesions are present throughout the aortic tree, lesions can be measured either on sections through the aortic root (paraffin or cryosections), as in early lesions, or in en face whole mount preparations of the aortic arch or the whole aortic tree. It was reported that lesion sizes in the aortic root, aortic arch, and the aortic tree correlate well in several different genetic models (Tangirala et al., 1995); therefore, one method can substitute for another. Due to a large variance between animals, it is recommended to use two methods that complement each other, such as serial sections through the aortic root and the en face preparation of the aortic tree. Both can be assessed from a single mouse. In en face preparations, lesions are stained with a neutral lipid stain (Oil Red O or Sudan IV) and the stained area is measured by an image analysis software and expressed as percentage of the total intimal area (Tangirala et al., 1995). For sectioning, the aortic root may be embedded in OCT and frozen for cryosectioning (detailed protocol in Baglione and Smith, 2006) or processed into paraffin for microtomy. Cryosections are preferred if lipid analysis is of importance, as in paraffin blocks, the lipid is extracted during tissue processing. Paraffin sectioning, however, allows for a more precise control of the angle of sectioning and easier collection of serial sections, in addition to easier storage of blocks and sections. Lipid analysis can still be performed in the corresponding en face whole mount preparation.
5. Methods We describe methods for embedding hearts with aortic roots in paraffin and serial sectioning the aortic root. Some of the serial sections are stained with H&E and used to measure lesion size (see Section 5.2). The rest may be used to study various components of the lesion such as extracellular matrix components or apoptosis, or for immunodetection of antigens of interest, such as cell type markers, markers of UPR activation, and others (see Section 5.3).
30
Sˇa´rka Lhota´k et al.
5.1. Sectioning the aortic root 5.1.1. Embedding the heart To obtain reproducible and comparable data, the lesions have to be sectioned perpendicular to the aortic root. If the aortic root is sectioned obliquely, the lesion size will be overestimated. Second, a starting point for measurements has to be anatomically defined. To aid in this, the following procedure is recommended. The heart is dissected from the mouse with 1–2 mm of the ascending aorta attached and fixed in formalin for 24 h. It is then cut transversally as described in Paigen et al. (1987), along the line A that connects the tips of the atria (Fig. 2.4). (It is helpful to do this under a dissecting microscope.) Line A is parallel to the aortic root (line B, Fig. 2.4B) and the correct angle ensures that the sections through the aortic root will be perpendicular to the aorta. The heart is then processed and embedded in paraffin, the cut face down, using deep molds (Ted Pella, Inc. #27195). Despite great care taken to cut the heart along the line A, this is not always achieved perfectly. However, it can be rectified during sectioning. We use a method that allows finding the perpendicular cut through the aortic root based on the landmarks observed in unstained sections during the sectioning process and correcting the angle by tilting the block. To allow this, the tissue must be embedded in deep molds, and for tilting at more extreme angles, a specimen holder like the one in Fig. 2.5 (e.g., Leica #7998) is useful.
A
B RA AA
LA
B A
A L R
Figure. 2.4 Preparing mouse heart for paraffin embedding. Formalin-fixed heart is positioned with the ascending aorta (AA) curving to the left. The heart should be cut along the line A connecting the tips of the atria (A). In B, the dorsal part of the heart was removed to expose the aortic valve (arrow) which lies in the plane of line B. AA, ascending aorta; L, left ventricle; R, right ventricle; LA, left atrium; RA, right atrium.
Immunohistochemistry in Atherosclerotic Lesions
A
31
B
Figure. 2.5 (A) Paraffin block and microtome clamp. Heart is embedded with the cut surface down in a deep mold creating a high paraffin block. A special microtome clamp is used that allows the block to be positioned at an angle inside the clamp. The whole assembly is cooled on ice during serial sectioning (B).
5.1.2. Orienting the block Sectioning is commenced at ambient temperature, moving quickly from inside toward the top of the heart with section thickness set at 8 mm. Occasionally an unstained section is collected for microscopic inspection (Fig. 2.6). When the mitral valves are observed (Fig. 2.6A), it is time to slow down and proceed carefully. From this point, every 10–12th unstained section is inspected under the microscope (Fig. 2.6B and C). At the first sign of the aortic valve leaflets (Fig. 2.6C, arrows), a decision has to be made regarding the orientation of the block. In Fig. 2.6C, two valve leaflets are visible (arrows), the third one, however, is missing (asterisk). Note also that the aortic wall in the sinus has a different morphology than cardiac muscle; layers of smooth muscle are seen in the aorta. The top side of the image (Fig. 2.6C) is still formed by cardiac muscle. Therefore, this side has to be brought closer to the knife and sectioned through until the third leaflet comes into view. (Note that in the microscope the image is inverted. We will be actually bringing the lower side of the block toward the knife. It is important to know which side in the image corresponds to which side of the section and the block.) The clamp assembly with the block may be tilted using knobs on the microtome. For larger angles, the block itself may be oriented in the clamp at an angle. After tilting, the block is sectioned through empty paraffin until the tissue is reached. Every other section (8 mm thick) is now captured and inspected under a microscope. The tissue will now be at the edge of the section (Fig. 2.6D, arrow). In Fig. 2.6, after tilting full angle with the microtome adjusting knobs, the third leaflet came into view (Fig. 2.6D). A little further, all three leaflets were visible, spaced evenly around the aorta (Fig. 2.6E). At this point, the serial sectioning begins.
32
Sˇa´rka Lhota´k et al.
A
B
C
D
E
R
L
Figure. 2.6 Finding the perpendicular cut through the aortic root. Upper panel: unstained sections as they present during the sectioning process. The area in the rectangle is shown in the lower panel, stained and enlarged, to better demonstrate landmark features: mitral valve, arrow (A); aortic valve leaflets, arrows, (C) a missing leaflet, asterisk (C). At this stage the block has been tilted and sectioned, new edge of the block, arrow (D). The third leaflet is coming into view, asterisk (D). All three leaflets are visible, spaced equally, double headed arrows (E). R, right ventricle; L, left ventricle.
5.1.3. Serial sectioning Serial sections are cut at 4 mm thickness, and for that, the block has to be cooled. To preserve the angle, the whole clamp assembly with the block is removed and placed with the cut face down on an ice tray (Fig. 2.5B). After reinserting in the microtome, serial sections are cut at 4 mm and floated in a warm water bath. After 10–15 sections, the block has to be cooled again. Sections are collected on numbered Plus slides (#12-55015, Fisher Scientific). The first 20 sections are collected and placed in the top portion of slides 1–20. For the section #21, we go back and place it in the middle portion of slide 1, section #22 on the slide 2, etc. Section #41 will be placed in the lower part of slide 1, and so on until section #60. Sections #61, 81, and 101 are placed on a new slide. Thus the three sections on each slide are 80 mm apart along the aortic root (4 mm section thickness times 20). Lesions can usually be seen in unstained slides. Sectioning and collecting sections continues until there are no more lesions present, often 100 sections or more for larger lesions. An example of serial sections through aortic root with early or advanced lesions is shown in Fig. 2.7.
33
Immunohistochemistry in Atherosclerotic Lesions
Section #: Microns
1 0
21 80
41 160
61 240
81 320
6.5
2.4
0
0
387.2
261.4
200.6
37.6
9 weeks
Area (×103 mm2) 27.7
23 weeks
Area (×103 mm2) 355.7
Figure. 2.7 Serial sections from early and advanced apoE/ mice on chow diet. Five sections spaced by 80 mm along the ascending aorta are presented for early lesions (upper panel) and advanced lesions (lower panel). The point of origin for measurement was defined at section #1. The lesion size for each image is shown (the measurement was performed at a higher magnification of the same section).
5.2. Measuring lesion size in serial sections The starting point for lesion measurements needs to be consistent and is usually set at the leaflet confluence (such as sections #1 in Fig. 2.7). Lesions should be measured in several sections along the aortic root and ascending aorta to account for the lateral length of the lesion as well as its thickness. It is suggested to serial section the aortic root and ascending aorta as far as lesions are observed and measure the lesion area on sections at 80 mm intervals. The mean lesion area in a given number of sections can then be used, or by plotting the lesion area versus distance from the leaflet origin and determining the area under the curve, the actual volume of the lesion is obtained (Fig. 2.8) (Daugherty and Rateri, 2005; Daugherty et al., 2009; Paigen et al., 1987; Purcell-Huynh et al., 1995). Various image analysis packages may be used to measure the areas of manually outlined lesions (Fig. 2.2). An example of sections selected for the measurement is presented in Fig. 2.7. Five sections each from two apoE/ mice on chow diet, one at 9 weeks of age (early lesions), the other at 23 weeks of age (advanced lesions), are shown. The sections are 80 mm apart along the aortic root. Lesion areas in each section are shown. In Fig. 2.8, these lesion areas were plotted against the distance from the origin.
5.3. Immunohistochemistry Immunohistochemistry on paraffin sections has proven to be a reliable tool for studying atherosclerotic lesions in mouse models. A general protocol for horseradish peroxidase substrate staining will be described. Particulars for
34
Sˇa´rka Lhota´k et al.
Lesion area in the aortic root 450,000 400,000 Lesion area (mm2)
350,000 300,000 250,000 200,000 150,000 100,000 50,000 0 0
100 200 300 Distance from the origin (mm) 23 weeks
400
9 weeks
Figure. 2.8 Lesion areas along the aortic root and ascending aorta. Lesion areas from Fig. 2.7 were plotted against the distance along the aortic root and ascending aorta. Area under the curve represents lesion volume.
some antibodies of interest are shown in Table 2.1, and suggestions for troubleshooting and optimizing new antibodies are included in Section 5.3.5. 5.3.1. Controls Every immunostaining experiment should be designed and performed with positive and negative controls in place. A positive control would include a tissue where the protein expression is expected. For UPR activation, a good positive control is the pancreas where ER chaperone expression is seen in the islets of Langerhans under normal physiological conditions (Harding et al., 2001; Iwawaki et al., 2004) (Fig. 2.9A–C). For a negative control, omitting the primary antibody is the simplest. For a more rigorous negative control, normal immunoglobulins of the species in which the primary antibody was raised, diluted to the same concentration as the primary antibody, are used. The most convincing negative control is using mouse tissue in which the protein of interest is genetically ablated (Fig. 2.10). 5.3.2. Materials and solutions
Various readymade immunohistochemistry kits may be used. We prefer using individual reagents which reduces cost and gives us flexibility to work with a range of antibodies from different species. Humidity chamber for staining
Table 2.1 Antibodies used for immunohistochemical evaluation of the UPR and apoptosis Blocking
Primary antibody Used at Dilution Antigen retrieval
Serum
Biotinylated secondary
Goat 5 Mouse 2
1:40 1:500
– –
Rabbit Goat
Rabbit anti-goat Goat anti-mouse*
Rabbit 5
1:40
Goat
Goat anti-rabbit
Stressgen #SPA-891 Stressgen #SPA-600 Cell signaling #3191þ Pharmingen #55322
Mouse Rabbit Rabbit Rat
2 Unknown Unknown 0.5
1:500 1:500 1:250 1:1000
HIER-Retrieve-all 2, Triton X – – – HIER-citric
Goat Goat Goat Rabbit
Mac-3
Pharmingen #550292
Rat
0.34
1:90
HIER-citric
Rabbit
Von Willebrand factor Smooth muscle actin Cleaved caspase-3 CD3
DakoCytomation A 0082
Rabbit 6
1:500
Protease
Goat
Goat anti-mouse* Goat anti-rabbit Goat anti-rabbit Rabbit anti-rat, mouse adsorbed Rabbit anti-rat, mouse adsorbed Goat anti-rabbit
Sigma A2547 Cell signaling #9661 DakoCytomation A 0452
Mouse Unknown 1:200 Rabbit Unknown 1:100 Rabbit 6 1:100
– HIER-citric HIER-citric
Goat Goat Goat
Goat anti-mouse* Goat anti-rabbit Goat anti-rabbit
Antigen
Source
Host
GRP78 KDEL GADD153
Santa Cruz sc-1050 KDEL Stressgen #SPA827 Santa Cruz sc-575
PDI Calreticulin Phospho-PERK Mac-3
mg/ml
* Alternatively, anti-mouse Dako EnVision #K4000 HRP conjugate may be used.
KDEL
PDI
A
B
Calreticulin C
I
I
I
p-PERK D
GRP78 E
Combined F
Figure. 2.9 Pancreas as a positive control for endoplasmic reticulum (ER) chaperone immunostaining. Various levels of staining for ER chaperones (GRP78 plus GRP94, KDEL, A; PDI, B; and calreticulin, C) were observed in endocrine cells within the islets of Langerhans (I). Occasionally, strong staining was also seen in an exocrine cell (arrowheads, A and C). Double immunofluorescence revealed that phospho-PERK and GRP78 staining were mutually exclusive in the islets (D–F). Cells with high levels of GRP78 exhibited a weak p-PERK staining (arrow) and vice versa (arrowhead). I, islet of Langerhans. Bar ¼ 50 mm. SR-B1 −/−ApoE −/−
SR-B1 +/+ ApoE −/− A
B
C
D
Figure. 2.10 Tissue from a gene-ablated mouse used as a negative control for immunohistochemistry. In tissues from the apoE/ mouse, scavenger receptor B1 (SR-B1) expression was observed in plasma membranes of hepatocytes (A) as well as cells in the adrenal gland (C). The staining was absent in the liver (B) and the adrenal gland (D) of the double knockout SR-B1//apoE/ mouse. Bar ¼ 50 mm.
37
Immunohistochemistry in Atherosclerotic Lesions
Biotinylated secondary antibodies: Anti-goat BA-5000, anti-mouse BA9200, anti-rabbit BA-1000, anti-rat, mouse adsorbed, BA-4001, Vector Laboratories. HRP-streptavidin, 20 concentrate, cat. # 50-242Z, Zymed, Invitrogen Nova Red (HRP substrate) cat. # SK-4800, Vector Laboratories Gill’s hematoxylin (Sigma–Aldrich) Permount (Fisher Scientific) Superfrost Plus slides (#12-550-15 Fisher Scientific) Rice steamer Tris buffer 20 Tris (hydroxymethyl) methylamine NaCl
121.1 g 170.0 g
Add distilled water Adjust pH to 7.6 with approximately 50–60 ml concentrated HCl Adjust final volume to 1000 ml with distilled water Tris buffer, working solution Dilute Tris buffer 20 with distilled water 5.3.3. General protocol Particulars for each antibody, such as antigen retrieval, blocking serum, and primary and secondary antibody information are listed in Table 2.1. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12.
Sections are dried at room temperature overnight. Sections are deparaffinized in three changes of xylene, 10 min each. Three changes of 100% ethanol, 1 min each Endogenous peroxidase block: 60 ml methanol þ 1 ml 30% H2O2 þ 4 drops of concentrated HCl, 10 min Wash in 70% ethanol, then distilled water three times Perform an antigen retrieval if required (Table 2.1 and Section 5.3.3.1). Rinse with Tris buffer. Move slides to the humidity chamber. Slides are now in horizontal position; avoid drying. Block with 5% normal serum (see Table 2.1). Flick off excess blocking serum; wipe a rectangular area around the tissue with Kleenex. This will keep the primary antibody from spreading over the slide and drying. Incubate with primary antibody diluted in the 5% normal serum, for 1–2 h, or overnight at 4 C. Wash with Tris buffer 2.
38
Sˇa´rka Lhota´k et al.
13. Incubate with biotinylated secondary antibody for 30 min.1 14. Wash with Tris buffer 2. 15. Incubate with streptavidin-peroxidase, diluted 1 drop in 2 ml of Tris buffer, for 10 min. 16. Wash with Tris buffer. 17. Wash with distilled water. 18. Prepare Nova Red solution according to manufacturer’s directions. 19. Incubate for 2–15 min, observing the reaction through microscope on the positive control or a section that is expected to be positive. 20. Wash with distilled water. 21. Counterstain with Gills hematoxylin No. 3, 30 s. 22. Wash with tap water. 23. Dehydrate in two changes of 100% ethanol and two changes of xylene. Use different xylenes and ethanols than for deparaffinizing. Avoid lower concentration of ethanol, go directly to 100% ethanol, and move quickly through ethanols and xylenes. Nova Red staining sometimes tends to disappear in ethanols. 24. Mount with Permount.
5.3.3.1. Antigen retrieval techniques Heat-induced epitope retrieval (HIER) Preheat appropriate buffer in a plastic slide container in rice steamer for 25 min Place slides in the preheated buffer, let steam for 30 min Remove the container from rice steamer, let cool down in the same solution for additional 30 min
Citric buffer, pH 6.0 Dissolve 2.3 g of citric acid in 1000 ml of distilled water. Adjust pH to 6.0 with 2 N NaOH ( 13 ml)
Retrieve-all Antigen Unmasking System 2: Basic pH 10, 1 (SIGNET) #SIG-31922, Covance Protease digestion Dissolve 0.025 g of protease (Streptomyces griseus, #P6911, Sigma) in 50 ml of PBS Treat slides for 5 min at room temperature Wash with PBS, then Tris buffer
1
Alternatively, for mouse primary antibodies, anti-mouse Dako EnVision #K4000 may be used diluted 1:3 in Tris buffer. Incubate for 30 min. It is an HRP conjugate, therefore, go directly to step 16.
Immunohistochemistry in Atherosclerotic Lesions
39
Triton X treatment 0.1% Triton X in PBS, incubate for 10 min 5.3.4. Helpful hints and pointers Helpful hints and pointers leading to convincing and visually appealing immunostaining
Never let slides dry during the procedure. Change xylenes often. We believe that the remains of undissolved paraffin inhibit the peroxidase reaction. After six racks of slides the last xylene should be replaced with a clean one. If a staining that used to give reliable results in the past stops working, a good rule of thumb is to replace xylenes. Use different set of alcohols and xylenes for deparaffinizing and for dehydrating before mounting with Permount. After each incubation, wash extensively with squeeze bottle pointed at the tissue and sweeping around it with considerable pressure. Expect to use 4 l of Tris buffer for staining 20 slides. Mouse monoclonal antibodies may produce mouse-on-mouse (MOM) background on mouse tissue conspicuous over blood vessels, calcified areas and elsewhere caused by the secondary antibody binding to mouse epitopes in the tissue. An alternative is to use anti-mouse Dako EnVision þ System-HRP Labelled Polymer #K4000 which reduces the problem. Another alternative is MOM kits supplied by various companies. 5.3.5. Designing an immunostaining protocol for a new antibody Before purchasing a new antibody, it is useful to conduct a literature search for immunohistochemical staining because not every antibody will work on formalin-fixed paraffin-embedded tissues. Manufacturers’ datasheets sometimes indicate applications tested though this information and pictures presented are not always convincing. A publication showing clear immunostaining will also provide information on antigen retrieval, concentration, type of tissue. Pilot experiments should be performed on a positive tissue (see Section 5.3.1) to test several primary antibody concentrations in the range of 1–10 mg/ml. If the antibody concentration is not known, a good rule of thumb is to use it 10 times more concentrated than recommended for Western blotting. The first run should include three sets of slides: without antigen retrieval, with protease digestion, and with HIER. In each set, a negative control and one or two primary antibody concentrations in the 1–10 mg/ml range are included. After assessing results from this run parameters may be fine-tuned. If the slide with no antigen retrieval shows staining where it was expected, antigen retrievals are not necessary and should be avoided. Though they may be necessary for some antibodies, with others they can induce
40
Sˇa´rka Lhota´k et al.
nonspecific staining. HIER is particularly problematic: nonspecific nuclear staining is often observed. After the appropriate antigen retrieval has been determined the staining can be further optimized. Background (haze over all cell types) may be reduced by diluting the primary antibody. Several dilutions should be tested.
5.4. Double immunofluorescence On paraffin-embedded tissues, peroxidase staining is preferable to immunofluorescence because it allows better orientation in the tissue. However, when colocalization of two antigens is needed, double immunofluorescence is the method of choice and can be performed on paraffin sections. For example, in Fig. 2.11, cytoplasmic staining of GRP78 and nuclear staining of GADD153 is shown in foam cells in an advanced lesion. 5.4.1. Controls The antibodies should first be optimized by the peroxidase protocol (see Section 5.3.3) to determine appropriate antigen retrievals and primary antibody concentrations. Both antibodies should work well on the same tissue using the same antigen retrieval. In addition, they should be raised in two different species.
GRP78
GADD153 B
A
Combined C
A FC
L
Figure. 2.11 Double immunofluorescence for GRP78 and GADD153 in advanced lesions. Nuclei in the foam cell-rich region were positive for GADD153 (green, A). Red cytoplasmic staining for GRP78 was observed in these cells (B), merged image (C). L, lumen; FC, foam cells; A, acellular area. Bar ¼ 50 mm.
Immunohistochemistry in Atherosclerotic Lesions
41
5.4.2. Materials Alexa fluorophores are stable dyes with high intensity of fluorescence available in various colors and conjugated to secondary antibodies (Invitrogen). The colors have to be selected based on the microscope available. Alexa Fluor 488 is excited by blue light and fluoresces green; excitation and emission are in the same ranges as fluorescein (FITC). All fluorescent microscopes are equipped with this filter. For orange or red color, Alexa Fluor 546 or 594 (corresponding to rhodamine or Texas Red) can be used, based on the filter available in the microscope.
Alexa Fluor secondaries raised in donkey (e.g., donkey anti-rabbit Alexa Fluor 488, donkey anti-goat Alexa 594, Invitrogen) Normal donkey serum Permafluor mountant (aqueous, Fisher) DAPI (40 ,6-diamidino-2-phenylindole), 10 mg/ml stock solution (D-9564, Sigma) 5.4.3. General protocol 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15.
Paraffin sections 4 mm thick are dried at room temperature overnight. Sections are deparaffinized in three changes of xylene, 10 min each. Three changes of 100% ethanol, 1 min each 70% ethanol, then distilled water, 3 Perform antigen retrieval if necessary (see Section 5.3.3.1 and Table 2.1). Wash with Tris buffer, 2. Block with 5% normal donkey serum in Tris, 10 min. In a humidity chamber, incubate with the cocktail of the two antibodies, diluted in 5% normal donkey serum, for 1 h at RT. Wash with Tris buffer, 2. Incubate with a mixture of secondary Alexa-conjugated antibodies, diluted 1/200 in Tris. Wash with Tris buffer. Wash with distilled water. Counterstain with DAPI (stock solution diluted 5000 in PBS), 5 min. Wash with distilled water. Mount with Permafluor.
5.4.4. Hints and pointers We do not find it necessary to protect slides from light during staining with Alexa Fluor conjugates. However, slides should be imaged and photographed the same day or within 24 h of staining because, with time, the signal diminishes and the background and autofluorescence increase. When presenting results, each color should be shown separately in addition to the merged image.
42
Sˇa´rka Lhota´k et al.
5.5. Detection of apoptosis Apoptosis is observed in more advanced lesions in mouse models. It is visible on H&E sections as dark condensed nuclei and apoptotic bodies (Fig. 2.2B). It can be detected by the terminal dUTP nick-end-labeling (TUNEL) nuclear staining or by immunostaining for cleaved caspase-3 (see Section 5.3 and Fig. 2.12D). TUNEL assay detects DNA fragmentation. It uses an enzyme, the terminal deoxynucleotidyl transferase (TdT), to insert labeled dUTP at the nicks in DNA. The thymus serves as a good positive control tissue due to abundance of apoptotic thymocytes (Fig. 2.12B–D). For a negative control, the TdT enzyme is omitted from the labeling mixture. In lesions, a false-positive TUNEL staining is sometimes detected in calcified areas. This can be avoided by pretreatment of sections with 3% citric acid for 1 h (Kockx et al., 1996). 5.5.1. TUNEL assay We use the TACSÒ 2 TdT In Situ Apoptosis detection kit (Trevigen). The individual components of the kit can be purchased separately. The dUTP is biotin labeled; therefore it can be used either for an HRP type of staining,
A
B
D
C
Figure. 2.12 Detection of apoptosis. TUNEL staining was detected over apoptotic bodies in advanced lesion from 23-week-old apoE/ mouse on chow diet (arrow, A). The thymus served as a positive control tissue. A number of thymocytes were stained (B), whereas no staining was observed in the control section where the TdT enzyme was omitted from the labeling mixture (C). Fluorescence was used to colocalize TUNEL staining with cleaved caspase-3 immunofluorescence in the thymus. Some of the thymocytes displayed both the red nuclear TUNEL staining and the green cytoplasmic cleaved caspase-3 staining (arrows, D) identifying them as apoptotic cells. Bar ¼ 50 mm.
43
Immunohistochemistry in Atherosclerotic Lesions
using streptavidin–HRP as in the immunostaining protocol (see Section 5.3.3), or for fluorescence, using a streptavidin-conjugated Alexa dye. For combined immunofluorescence and TUNEL, the TUNEL protocol is followed by blocking with a blocking serum and incubation with the antibody of interest (Fig. 2.12D). If antigen retrieval is required, it should be performed first. 5.5.1.1. Materials Cat# 4810-30-CK TACS 2 Core kit (includes 10 TdT labeling buffer, 10TdT Stop buffer, TdT dNTP Mix, TdT Enzyme) Individual components of the kit may be purchased separately Proteinase K Cat# 4810-30-01 5.5.1.2. TUNEL protocol 1. Sections are deparaffinized in three changes of xylene, 10 min each. 2. Three changes of 100% ethanol, 1 min each. 3. 70% ethanol, 3 distilled water. 4. PBS wash, 2 5 min 5. Move slides to the humidity chamber. Slides are now in horizontal position; avoid drying. 6. Incubate with proteinase K (1 ml pK þ 50 ml deionized water/slide), 30 min, 37 C. 7. Wash 2 with deionized water 2 min each. 8. Quench endogenous peroxidase: 45 ml methanol þ 5 ml 30% H2O2, in Koplin jar, 5 min 9. PBS wash, 1 min 10. Prepare 1 labeling buffer: 45 ml water þ 5 ml 10 labeling buffer 11. Prepare labeling mixture (/slide):
Labeling buffer TdTdNTP mix 50 Co2þ TdT enzyme
50 ml 1 ml 1 ml 1 ml
For negative control, omit the TdT enzyme. 12. 13. 14. 15. 16.
Incubate 1 h at 37 C. Nucleotides are biotin labeled. Prepare 1 stop buffer: 45 ml water þ 5 ml 10 stop buffer. Stop the reaction by incubating in stop buffer for 5 min. Wash 2 in PBS, 2 min each. Perform steps 14–24 of the immunostaining protocol (Section 5.3.3) or steps 10–15 of the immunofluorescence protocol (Section 5.4.3) using a streptavidin–Alexa conjugate, diluted 1/200 in PBS buffer.
44
Sˇa´rka Lhota´k et al.
ACKNOWLEDGMENTS We thank Dr. Bernardo Trigatti for providing us with tissues from the SR-B1 knockout mice. This work was supported in part by research grants to Richard Austin from the Heart and Stroke Foundation of Ontario (T-6146, NA-6393) and the Canadian Institutes of Health Research (MOP-74477). Financial support from St. Joseph’s Healthcare Hamilton is also acknowledged. Richard C. Austin is a Career Investigator of the Heart and Stroke Foundation of Ontario and holds the Amgen Canada Research Chair in the Division of Nephrology at St. Joseph’s Healthcare and McMaster University.
REFERENCES Austin, R. C. (2009). The unfolded protein response in health and disease. Antioxid. Redox Signal. 11, 2279–2287. Baglione, J., and Smith, J. D. (2006). Quantitative assay for mouse atherosclerosis in the aortic root. Methods Mol. Med. 129, 83–95. Boushey, C. J., Beresford, S. A., Omenn, G. S., and Motulsky, A. G. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049–1057. Civelek, M., Manduchi, E., Riley, R. J., Stoeckert, C. J., Jr., and Davies, P. F. (2009). Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. Circ. Res. 105, 453–461. Daugherty, A. (2002). Mouse models of atherosclerosis. Am. J. Med. Sci. 323, 3–10. Daugherty, A., and Rateri, D. L. (2005). Development of experimental designs for atherosclerosis studies in mice. Methods 36, 129–138. Daugherty, A., Lu, H., Howatt, D. A., and Rateri, D. L. (2009). Modes of defining atherosclerosis in mouse models: Relative merits and evolving standards. Methods Mol. Biol. 573, 1–15. Dickhout, J. G., Hossain, G. S., Pozza, L. M., Zhou, J., Lhotak, S., and Austin, R. C. (2005). Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: Implications in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25, 2623–2629. Dickhout, J. G., Colgan, S. M., Lhotak, S., and Austin, R. C. (2007). Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome: A balancing act between plaque stability and rupture. Circulation 116, 1214–1216. Feaver, R. E., Hastings, N. E., Pryor, A., and Blackman, B. R. (2008). GRP78 upregulation by atheroprone shear stress via p38-, alpha2beta1-dependent mechanism in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 1534–1541. Feng, B., Yao, P. M., Li, Y., Devlin, C. M., Zhang, D., Harding, H. P., Sweeney, M., Rong, J. X., Kuriakose, G., Fisher, E. A., Marks, A. R., Ron, D., et al. (2003). The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat. Cell Biol. 5, 781–792. Han, S., Liang, C. P., DeVries-Seimon, T., Ranalletta, M., Welch, C. L., CollinsFletcher, K., Accili, D., Tabas, I., and Tall, A. R. (2006). Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab. 3, 257–266. Harding, H. P., Zeng, H., Zhang, Y., Jungries, R., Chung, P., Plesken, H., Sabatini, D. D., and Ron, D. (2001). Diabetes mellitus and exocrine pancreatic dysfunction in perk-/mice reveals a role for translational control in secretory cell survival. Mol. Cell 7, 1153–1163.
Immunohistochemistry in Atherosclerotic Lesions
45
Ishibashi, S., Goldstein, J. L., Brown, M. S., Herz, J., and Burns, D. K. (1994). Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptornegative mice. J. Clin. Invest. 93, 1885–1893. Iwawaki, T., Akai, R., Kohno, K., and Miura, M. (2004). A transgenic mouse model for monitoring endoplasmic reticulum stress. Nat. Med. 10, 98–102. Kockx, M. M., Muhring, J., Bortier, H., De Meyer, G. R., and Jacob, W. (1996). Biotin- or digoxigenin-conjugated nucleotides bind to matrix vesicles in atherosclerotic plaques. Am. J. Pathol. 148, 1771–1777. Lusis, A. J. (2000). Atherosclerosis. Nature 407, 233–241. Malhotra, J. D., and Kaufman, R. J. (2007). The endoplasmic reticulum and the unfolded protein response. Semin. Cell Dev. Biol. 18, 716–731. Marciniak, S. J., and Ron, D. (2006). Endoplasmic reticulum stress signaling in disease. Physiol. Rev. 86, 1133–1149. Myoishi, M., Hao, H., Minamino, T., Watanabe, K., Nishihira, K., Hatakeyama, K., Asada, Y., Okada, K., Ishibashi-Ueda, H., Gabbiani, G., Bochaton-Piallat, M. L., Mochizuki, N., et al. (2007). Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 116, 1226–1233. Outinen, P. A., Sood, S. K., Liaw, P. C., Sarge, K. D., Maeda, N., Hirsh, J., Ribau, J., Podor, T. J., Weitz, J. I., and Austin, R. C. (1998). Characterization of the stressinducing effects of homocysteine. Biochem. J. 332(Pt. 1), 213–221. Oyadomari, S., and Mori, M. (2004). Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 11, 381–389. Paigen, B., Morrow, A., Holmes, P. A., Mitchell, D., and Williams, R. A. (1987). Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68, 231–240. Piedrahita, J. A., Zhang, S. H., Hagaman, J. R., Oliver, P. M., and Maeda, N. (1992). Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA 89, 4471–4475. Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setala, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., and Breslow, J. L. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343–353. Purcell-Huynh, D. A., Farese, R. V., Jr., Johnson, D. F., Flynn, L. M., Pierotti, V., Newland, D. L., Linton, M. F., Sanan, D. A., and Young, S. G. (1995). Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95, 2246–2257. Sanson, M., Auge, N., Vindis, C., Muller, C., Bando, Y., Thiers, J. C., Marachet, M. A., Zarkovic, K., Sawa, Y., Salvayre, R., and Negre-Salvayre, A. (2009). Oxidized lowdensity lipoproteins trigger endoplasmic reticulum stress in vascular cells: Prevention by oxygen-regulated protein 150 expression. Circ. Res. 104, 328–336. Tabas, I., Seimon, T., Timmins, J., Li, G., and Lim, W. (2009). Macrophage apoptosis in advanced atherosclerosis. Ann. NY Acad. Sci. 1173(Suppl. 1), E40–E45. Tabas, I., Tall, A., and Accili, D. (2010). The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ. Res. 106, 58–67. Tangirala, R. K., Rubin, E. M., and Palinski, W. (1995). Quantitation of atherosclerosis in murine models: Correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36, 2320–2328. Tsukano, H., Gotoh, T., Endo, M., Miyata, K., Tazume, H., Kadomatsu, T., Yano, M., Iwawaki, T., Kohno, K., Araki, K., Mizuta, H., and Oike, Y. (2010). The endoplasmic reticulum stress/EBP homologous protein pathway-mediated apoptosis in macrophages contributes to the instability of atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 30, 1925–1932.
46
Sˇa´rka Lhota´k et al.
Whitman, S. C. (2004). A practical approach to using mice in atherosclerosis research. Clin. Biochem. Rev. 25, 81–93. Zhou, J., Moller, J., Danielsen, C. C., Bentzon, J., Ravn, H. B., Austin, R. C., and Falk, E. (2001). Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21, 1470–1476. Zhou, J., Werstuck, G. H., Lhotak, S., de Koning, A. B., Sood, S. K., Hossain, G. S., Moller, J., Ritskes-Hoitinga, M., Falk, E., Dayal, S., Lentz, S. R., and Austin, R. C. (2004). Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. Circulation 110, 207–213. Zhou, J., Lhotak, S., Hilditch, B. A., and Austin, R. C. (2005). Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 111, 1814–1821.
C H A P T E R
T H R E E
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia Stefano Toldo,* Anna Severino,† Antonio Abbate,* and Alfonso Baldi‡ Contents 1. Introduction 2. Identification of PDI as Cardio-Protective Factor 2.1. Apoptosis detection in autoptic human heart samples after AMI 2.2. PDI is upregulated in ischemic cardiomyocytes 2.3. UPR regulation in hypoxic cardiomyocytes 2.4. Superoxide dismutase-1 is a target of the anti-apoptotic action of PDI 2.5. Protective effects of PDI overexpression during acute MI in the mouse model 2.6. UPR activation and PDI-altered redox state in diabetes 2.7. Detection of PDI-altered redox state in the diabetic heart 3. Conclusions References
48 50 51 52 53 54 55 57 58 62 62
Abstract Acute myocardial infarction (AMI) leads to activation of unfolded protein response (UPR) following endoplasmic reticulum (ER) stress. Failing in the restoration of the proper folding activity in the ER can lead to apoptosis and cell death. While it can be easy to detect transcripts and proteins expression alterations during a pathological state, it can be difficult to address the importance of changes in protein expression in the physiopathological context. We found protein disulfide isomerase (PDI) increased expression in human autoptic heart samples correlating with cell survival following AMI. PDI enzymatic activity resulted to be important to achieve cardiomyocyte protection from hypoxic stress, dependent on its ability to relieve ER stress preventing accumulation of * Victoria Johnson Research Center and VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA { Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy { Department of Biochemistry and Biophysics F. Cedrangolo, Second University of Naples, Italy Methods in Enzymology, Volume 489 ISSN 0076-6879, DOI: 10.1016/B978-0-12-385116-1.00003-0
#
2011 Elsevier Inc. All rights reserved.
47
48
Stefano Toldo et al.
nonfolded proteins in the ER, and to enhance superoxide dismutase 1 (SOD-1) activity. Furthermore, adenoviral-mediated PDI overexpression in an in vivo mouse model of AMI prevented adverse cardiac remodeling reducing cardiomyocyte apoptosis. Finally, we suggest a method to detect alterations in normal redox state in PDI (and eventually in the PDI family’s proteins) during pathologies in which ER stress is induced. Diabetes pathology correlates with increased risk of AMI and worse cardiac remodeling. We found an alteration in PDI redox state in the diabetic heart and suggest using this system for the detection of the redox state alteration to screen for therapies able to restore the proper redox state.
1. Introduction Ischemic cardiomyopathy (IC) refers to severe myocardial dysfunction resulting from occlusive coronary artery disease (CAD) (Burch and McDonald, 1971; Burch et al., 1970) and it represents the most frequent cause of cardiovascular mortality in Western countries. It is triggered by complete or partial occlusion of a major epicardial coronary artery, and it is associated with an imbalance between blood supply and demand, resulting in acute myocardial infarction (AMI). IC induces a significant impairment of left ventricular (LV) function. Despite treatment advances, complete reperfusion is not always achievable. This results in higher risk for pathologic cardiac enlargement, heart failure (HF), and death. Persistence of ischemia leads to irreversible cell death. Ischemic necrosis and myocardial apoptosis are both implicated in determining myocardiocyte loss in AMI (Cohn et al., 2000; Greenberg et al., 1984). Postinfarction LV remodeling consists of progressive chamber dilatation, wall thinning, and systolic/diastolic dysfunction (Fig. 3.1). This process involves cellular and molecular mechanisms, beginning days after AMI and persisting for weeks and months after the initial insult both at site of infarction (even after complete infarct healing) and in the surviving unaffected areas. Environmental changes and developmental processes can drastically change the workload of the endoplasmic reticulum (ER). To maintain ER homeostasis, a coordinated program known as the unfolded protein response (UPR) adjusts the folding capacity of the ER to meet demand and engages the destructive pathway if necessary (Hirsch et al., 2009). Hypoxic stress plays a pivotal role in the pathogenesis of heart disease, stroke, diabetes, and cancer (Okada et al., 2004; Thuerauf et al., 2006). Perturbations of ER homeostasis, such as prolonged hypoxic condition or metabolic stress, affect protein folding and cause ER stress (ERS). Diabetes is a group of heterogeneous disorders with the common elements of hyperglycemia and glucose intolerance, associated with more than
49
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
Adverse cardiac remodeling following AMI Acute MI
Hours Heart failure
Years Months
Days Weeks
Compensatory hypertrophy
Progressive dilatation
Figure 3.1 AMI is the most common cause of acute and chronic HF. The initial damage to the myocardium during AMI activates reparative processes that are initially beneficial but produce pathologic changes over time. In the first hours and days, cardiac cell death can determine the extent of remodeling. This process is activated as a result of the initial loss of functional myocardium and subsequent secondary changes in the surviving portions of the heart and is inevitably associated with an unfavorable clinical course. The greater is the damage to heart, the greater is the remodeling process, and the worse is the expected outcome for the patient.
doubled risk of heart disease and stroke (Haffner et al., 1998; Hayat et al., 2004). Diabetes may be associated with LV dysfunction independent of CAD, hypertension, or any other cause of heart disease (Hayat et al., 2004). Diabetic patients have an increased likelihood of developing HF following myocardial infarction (MI), and once established, outcome is worse than in nondiabetics (Hayat et al., 2004). Recent studies describe activation of the UPR in both diabetes mellitus and IC. Diabetes affects the ability of the UPR to restore the physiologic state by altering the function of its key components (Cai and Kang, 2001; Xu et al., 2009). Protein disulfide isomerase (PDI) is a member of the UPR necessary for the appropriate protein folding and prevention of misfolding during stress, as seen in myocardial ischemic injury (Schroder and Kaufman, 2005; Severino et al., 2007). In the liver of diabetic rodents, PDI has been reported to be in an altered redox state affecting PDI’s ability to function, leading to the accumulation of misfolded protein in the ER lumen (Nardai et al., 2005). PDI catalyzes the formation, reduction, and isomerization of disulfide bonds in the ER lumen, and as a polypeptide-binding protein, it can function as a molecular chaperone which assists the folding of polypeptides. Recently,
50
Stefano Toldo et al.
PDI has been described as a hypoxia-induced protein in some in vitro and in vivo models being enhanced at the mRNA level and protein level in human aortic and pulmonary artery endothelial cells (Graven et al., 2002; Myoishi et al., 2007; Tian et al., 2009). Upregulation of PDI specifically in endothelial cells contributes to their ability to tolerate hypoxia (Graven et al., 2002). Upregulation of PDI has been demonstrated also in neuroblastoma cells in response to hypoxia, where it is hypothesized to serve as protective role. Overexpression of PDI in these cells resulted in an increase of cell viability in response to hypoxia and protected hippocampal cells from apoptotic cell death in response to brain ischemia (Tanaka et al., 2000). All these results evidence a PDI protective role in degenerative diseases, brain ischemia, and in general in hypoxic systems, characterized by accumulation of unfolded or misfolded proteins and ER stress. In this chapter, we review (1) how apoptosis inversely correlates with PDI expression following ischemia in the heart of human patients and mouse heart; (2) how PDI expression modulates the extent of tissue injury; and (3) how changes in PDI redox state in vivo in the heart may affect its function in diabetes. Despite an increasing number of ways to detect markers of UPR activation and ER stress, the identification of key factors playing a role in human diseases remains difficult to be assessed. In this chapter, we describe our approach to determine protein expression, its redox state, and its functional consequences in a model of ischemic heart disease.
2. Identification of PDI as Cardio-Protective Factor In this section, we describe a direct approach to evaluate changes in gene expression in the ischemic heart and how to move on to identify and characterize the role and the importance of a specific protein in cell protection following AMI. Autoptic myocardial samples were collected from the proximal ischemic area and the remote zone to perform apoptotic cell death analysis and protein expression analysis. Previously, a gene expression analysis approach of the UPR proteins showed that in the ischemic heart, a cluster of ER stress-related genes was transcriptionally activated during the development of the disease (Azfer et al., 2006). This screening demonstrated elevated transcript levels of genes involved in UPR such as ER and cytoplasmic chaperones, oxidoreductases, PDI family, and ER-associated degradation system such as ubiquitin. PDI gene, as a member of the UPR regulon, was found to be upregulated in the viable myocardium. Using immunohistochemistry and the array technology we identified a correlation between PDI expression and apoptotic cell death following AMI.
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
51
2.1. Apoptosis detection in autoptic human heart samples after AMI Autopsy, in the examined subjects, was performed within 24 h after death (median 16 h). Gross examination of the hearts was performed to measure LV parameters and to define the infarct-related artery and the infarcted area. LV longitudinal and transverse diameters were measured at the atrioventricular section. The LV free wall thickness was measured at the median third of the posterior wall. Specimens were obtained at sites of MI and in regions of the left ventricle remote from the infarcted area by a patent coronary artery and were either snap frozen for RNA extraction or fixed in 10% paraformaldehyde for immunohistochemical analysis. The morphologic analysis of tissue structure, cellular and nuclear integrity, and inflammatory infiltrates was performed by light microscopy. In situ end-labeling of DNA fragmentation (TUNEL) have enabled an easy qualitative and quantitative evaluation of cell death in tissues (Haunstetter and Izumo, 1998; Narula et al., 1996; Olivetti et al., 1996, 1997). Several series of TUNEL-stained sections were subsequently used for the staining for caspase-3 or muscle-actin to better characterize which of the TUNEL positive cells was an apoptotic cardiomyocyte. Cardiomyocytes were defined as apoptotic if colocalization of TUNEL caspase-3 staining was evident. In the infarcted hearts, detection of apoptotic cardiomyocytes showed a significantly higher apoptotic rate in the peri-infarct versus remote areas. Interestingly, the apoptotic rate was higher both in the peri-infarct and remote areas and it significantly correlated with increasing cardiac weight and cardiac transverse diameter (Severino et al., 2007). Myocardial apoptosis peaks at 4–12 h in AMI and is persistently demonstrable up to 10 days (Abbate et al., 2002). In the context of MI, apoptosis represents the major form of death, being several times more common than necrosis (peak value of 43% of apoptotic cardiomyocytes at 4.5 h vs. peak value of 8% of necrotic cells at 24 h) (Kajstura et al., 1996). Several other studies, both experimental and observational, have confirmed such results (Abbate et al., 2002). Apoptosis is a fundamental physiologic and pathologic mechanism that allows elimination of normal but no-longer-useful cells during embryogenesis or of aged or damaged cells during life. A delicate balance between survival and death exists in cells undergoing physiologic and pathologic stress (such as hypoxia) and initiation of apoptosis during initial phases may not always be followed by its completion (Buja and Entman, 1998; Majno and Joris, 1995). Furthermore, balance between apoptosis and primary necrosis depends on available energetic levels, as completion of apoptosis needs adequate ATP cellular concentrations. Necrosis of cardiomyocytes is usually completed within 24–48 h following abrupt coronary occlusion and phagocytosis and removal of cellular debris by inflammatory cells starts at 24 h. Cardiomyocytes surviving through the acute phases undergo major
52
Stefano Toldo et al.
metabolic rearrangements in order to favor survival in the delicate balance between hibernation and apoptosis (Abbate et al., 2002). The term “hibernation” refers to a chronic condition of severe energy deprivation of the myocardium due to chronic or repetitive hypoperfusion associated to reversible contractile dysfunction (Braunwald and Kloner, 1982). Cardiomyocytes in the border zone have been described to have multiple overlapping phenotypes of oncosis, apoptosis, and autophagy (Arbustini et al., 2008; Dorn and Diwan, 2008, Kostin et al., 2003). Independent of the markers used to detect cardiomyocyte degeneration (TUNEL, annexin V, caspase-3 activation for apoptosis, or ubiquitin and LC3 staining for autophagy), the degree of this degeneration correlates with clinical signs of adverse cardiac remodeling and predicts outcome. Experimental induction of apoptosis is sufficient to cause dilated cardiomyopathy, HF, and death in the mouse (Wencker et al., 2003). However, therapies able to reduce cardiomyocyte apoptosis ameliorate postinfarction myocardial remodeling and cardiac function (Abbate et al., 2002, 2006; Dorn and Diwan, 2008; Nishida et al., 2008). The data collected from the autoptic heart samples confirmed that the apoptotic rate both in the peri-infarct and remote areas significantly correlated with increasing cardiac weight and cardiac transverse diameter (Severino et al., 2007).
2.2. PDI is upregulated in ischemic cardiomyocytes Impaired oxygen supplementation, inflammation, necrotic cell death, neurohormonal signaling, etc., contribute to altered gene and protein expression in the peri-infarct area (Abbate et al., 2009; Searles, 2002; Temsah et al., 1999, 2000). To evaluate the change in the transcriptome in the bordering zone, we performed a cardiovascular microarray on RNA extracted from the autoptic samples. The array for human cardiovascular specific genes was used to compare the RNA transcripts from two different pools: one from samples obtained in the peri-infarct region and one from the remote area. Five micrograms of pooled RNAs (from border and remote zones) were retrotranscribed using a-P32 dATP. The choice of pooling remote myocardium as comparison for the bordering zone was considered essential to have an internal (rather than external) control and to minimize the possibility of postmortem autolysis-related changes. Two independent RNA preparations were used to perform the experiment in duplicate. The PDI gene was upregulated threefold in the RNA extracted from the peri-infarct areas. Gene upregulation in the border zone was confirmed by semiquantitative reverse transcriptase polymerase chain reaction (qPCR) assay on the same pooled RNAs. Immunohistochemical analysis of PDI expression and the costaining for TUNEL was performed to confirm the upregulation of PDI at the protein level in the peri-infarct areas and to show a correlation between PDI expression and cell death. This analysis showed that most of the
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
53
cardiomyocytes overexpressing PDI were TUNEL negative. In the cases with intense PDI expression, the apoptotic rate was significantly lower compared with the samples having mild to moderate expression. Notably, subjects with intense PDI expression were less likely to be suffering from stage-C New York Heart Association functional class IV congestive HF and to have biventricular enlargement at postmortem examination.
2.3. UPR regulation in hypoxic cardiomyocytes BiP/GRP78, the major molecular chaperone of the ER, works as a sensor of unfolded proteins in the ER and regulates the activation of ER stress transducers. ER stress response leads to a transcriptional upregulation program, which is conducted by the three transducers PERK, ATF6, and IRE1. To test the effects of hypoxia on cardiomyocytes, we used the mouse HL-1 cell line. HL-1 cells are differentiated and proliferating atrial cardiomyocytes derived from mouse AT-1 cells (Yusuf et al., 2000). Hypoxia was induced with a gas mixture of 5% carbon dioxide and 95% gaseous nitrogen for 24 and 48 h (hypoxic groups). We used total RNA extracted from hypoxia-treated HL1 cells to analyze the expression levels of PDI as well as of PERK, ATF6, Bip, and IRE1 and the chaperone GRP94 by qRT-PCR. b-Actin, used as housekeeping gene to normalize the results, is not affected by hypoxic condition, as tested in many experiments conducted in our lab comparing the results with other housekeeping genes (data not shown). PDI, GRP94, and ATF6-a were significantly upregulated (p < 0.05) after exposure to hypoxia. ATF6 expression increased with duration of hypoxia while the expression of IRE1-a increased significantly (p < 0.05) only after 48-h exposure to hypoxia. The mRNA level of PERK did not significantly change, whereas the level of Bip-mRNA decreased under influence of hypoxia. PERK, a type-I ER transmembrane protein with a luminal domain, in normal conditions is bound by Bip/GRP78. Upon ER stress activation, Bip releases the luminal domain of PERK, allowing PERK to dimerize and become active, leading to general shut-off of the translation and upregulation of the genes involved in the recovery from ER stress (Raven and Koromilas, 2008). Our findings are consistent with the activity of these two proteins. The expression analysis of the PDI adjuvant enzyme Ero1 on the same mRNA samples showed that this protein is enhanced with the duration of hypoxia. These results provided independent confirmation for the observed upregulation of PDI during hypoxic condition. We have also repeated the qPCR experiments with cells transfected 24 h prior to hypoxia and overexpressing PDI. These data indicated that overexpression of PDI did not significantly change the expression of the tested genes, suggesting that the detected effects of PDI overexpression are direct. The co-upregulation of Ero1 supported the notion that the enzymatic activity of PDI protects cardiomyocytes after hypoxic stress. To test this hypothesis, we described as HL-1 cells
54
Stefano Toldo et al.
overexpressing PDI were protected by hypoxic stress. The forced expression of PDI carrying point mutations in one of the PDI’s active sites (PDIa C40S and PDIa’ C387S) abolished the protective role seen with the wild-type enzyme and actually increased the cell death compared to the controls. A similar set of experiments was performed infecting the cells with an adenoviral vector expressing the GFP and coding either for PDI–GFP/PDI– or for the PDI’s mutants (PDIa C40S–GFP/PDIa–, PDIa0 C387S–GFP/PDIa0 –, and the double mutant PDIaa0 C40S/C387S–GFP/PDIaa0 –) using the GFP vector (GFP/null) as control. The cells were infected with the adenoviruses 24 h before the hypoxic treatment (24 and 48 h). Cells were marked with propidium iodine and were analyzed by flow cytofluorimetry. Cytofluorimetric analysis showed a marked reduction of propidium iodine as the PDI– GFP positive cells compared to the GFP alone showed that the actually the population of cells overexpressing PDI had a less apoptotic rate than the others. Furthermore, all the PDI mutants increased the effects of hypoxia on cell survival (Fig. 3.2). These data indicates that PDI enzymatic activity is necessary to put into effect its anti-apoptotic action.
2.4. Superoxide dismutase-1 is a target of the anti-apoptotic action of PDI Impaired protein folding in the ER can be produced either by the reduction of the oxygen supply associated with the coronary occlusion or with the following oxidative stress associated with reperfusion. In fact, disulfide bond
Cell death %
80 70 60
* **
50
* **
40 30
* **
**
20 10
48 h
24 h
GFP/null GFP/aa⬘
48 h
24 h
Normoxia
Hypoxia GFP/PDI
GFP/PDIa
GFP/PDIa⬘
* p < 0.05 vs. GFP/null ** p < 0.05 vs. GFP/PDIa, – a⬘, – aa⬘
Figure 3.2 PDI overexpression limits cell death induced by hypoxia. Adenoviralmediated GFP-associated overexpression of PDI coupled with cytofluorimetry were used to assess the ratio of green fluorescent protein expressing cells with DNA damage. The infection with the wild-type gene reduces DNA damage, detected with propidium iodide, and cell death after 24 and 48 h of hypoxia. These results show that while PDI reduces propidium staining by 45% at 48 h and 60% at 24 h, the PDI mutants, a, a0 , and the double mutant, aa0 , increase the cell death also in normoxic condition.
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
55
formation requires oxygen and is compromised by the production of reactive oxygen species. Indeed, significant superoxide generation occurs in cardiomyocytes during both ischemia and reperfusion (King et al., 1998). Copper– zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD-1 is the principal superoxide scavenger system in the cytoplasm (Muller et al., 2007). Overexpression of SOD-1, which efficiently dismutases superoxide and prevents postischemic injury in the heart, during ischemia attenuates apoptosis and the inflammatory response (Wang et al., 1998). Recently, in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease in which mutations of SOD-1 (mSOD-1) are associated with familial type of the disease, it has been found an association between SOD-1 with PDI (Atkin et al., 2006). Although SOD-1 is very thermally stable, mSOD-1 aggregates are present in spinal cords of ALS patients and in transgenic mice overexpressing this mutant protein. The mechanism of mSOD-1-mediated toxicity is unclear, but it involves apoptotic signaling (Atkin et al., 2006; Pasinelli et al., 2004). Furthermore, neuronal cells transfected with wtSOD1 or mSOD1 and treated with the PDI inhibitor bacitracin showed an increased formation of aggregates suggesting that PDI prevents the formation of SOD1 inclusions in motor neurons (Atkin et al., 2006). Interestingly, it has been demonstrated that PDI is overexpressed in familial ALS, acting as a survival factor through physical interaction with SOD-1 (Buja and Entman, 1998). This interaction prevents SOD-1 aggregation and consequently neuronal degeneration. To obtain initial insights into protective mechanisms supported by PDI in our model, we investigated whether its anti-apoptotic effects were mediated by a direct action on the activity or the expression of SOD-1, determined by measuring the release of hydrogen peroxide (H2O2) and by Western blot analysis. The HL1 cells overexpressing PDI showed a significantly higher H2O2 release than HL1 cells transfected with the vector alone (Fig. 3.3A). However, this overexpression did not affect SOD-1 expression (Fig. 3.3B). Furthermore, hypoxia had no direct effects SOD-1 expression (Fig. 3.3C). Therefore, PDI in HL-1 cells was able to increase SOD-1 activity. Our finding of increased SOD activity is in line with the previous reports and suggests that increased expression of PDI might protect myocardial tissue from apoptosis mediated by superoxide, through increased SOD activity.
2.5. Protective effects of PDI overexpression during acute MI in the mouse model We tested the effects of PDI gene delivery in an in vivo mouse model of MI, by injecting the adenoviral vector expressing GFP/PDI into the hearts of adult male CD-1 mice before the infarction. The protocol for in vivo adenoviral-mediated gene transfer was set as follows: 48 h before the induction of the ischemic injury, four injections of adenoviral vectors
56
Stefano Toldo et al.
A
B
*
1400 H2O2 pM/mg of proteins
GFP null
GFP PDI
PDI b -Actin
1200
SOD-1
1000
C Hypoxia
800 600
–
+ 24 h
+ 48 h
PDI 400 b -Actin 200 SOD-1 Controls
PDI
*p < 0.05 vs. control Figure 3.3 PDI does not regulate SOD-1 expression but increases its activity. In HL-1 cell extracts driven by PDI overexpression, SOD-1 activity increases by 80% (A). This enhancement is not detected with a concomitant increase of SOD-1 expression but only with a boost in the dismutase activity (B). Hypoxic stress, while able to positively regulate PDI expression, does not affect SOD-1 expression (C).
were performed through a 32-gauge needle into the ventricular wall of adult CD-1 mice, two for each side flanking the left coronary artery. The volume of each injection was 2.5 ml and the approximate titer was 1010 PFU/ml. Hearts injected with transgene-null adenoviral vectors or hearts from sham-operated animal were used as a control. To induce MI, the left main coronary artery was ligated. Echocardiography was performed to assess cardiac function 7 days after MI, prior to sacrifice. Efficiency of the viral infection was assessed by Western blots and immunohistochemistry, by increased myocardial PDI expression and GFP detection in PDI/ GFP-injected mice. In vivo assessment of the remodeling pattern with transthoracic echocardiography confirmed a more favorable pattern in GFP/PDI-treated mice. Compared with sham-operated mice, GFP/nulltreated infarcted mice had significantly greater LV end diastolic and systolic diameter (LVEDD and LVESD). Compared with GFP/null animals, GFP/ PDI mice had significantly smaller LVEDD similar to that in sham-operated animals and a trend toward lower LVESD values. Infarct size assessment in the mid-ventricular section with Masson’s trichrome staining showed a significantly smaller infarct size in GFP/PDI-treated mice, determined as reduced circumferential extension and as transmural extension. The apoptotic rate in the peri-infarct region was also significantly reduced. PDI gene
57
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
AMI Myocardial damage
Oxidative stress
↑ SOD-1 activity
↑ Protein-folding activity
UPR activation
ER stress
UPR activation PDI upregulation
Figure 3.4 Role of PDI upregulation following acute myocardial infarction. Following AMI, cardiomyocyte’s fate in the border zone depends on their ability to counteract oxidative stress and endoplasmic reticulum overload-induced stress. Both this pathologic conditions induce activation of the UPR to relieve unfolded and misfolded protein accumulation in the ER lumen. PDI family members, including PDI, are upregulated to shrink the ER stress in response to UPR, acting directly as molecular chaperones to stabilize the proteins’ structure. PDI can also act on SOD-1 activity. This step is dependent on PDI catalytic activity and its enhanced expression. Both these actions on protein folding and SOD-1 activity can relieve ER stress and oxidative damage, reducing apoptosis and minimizing the effects of tissue injury on myocardial function.
transfer therapy was able to prevent both adverse cardiac remodeling and cardiomyocyte apoptosis. We hypothesize that this protective action is realized directly by PDI’s ability to relieve unfolded protein accumulation and indirectly by activation of SOD activity (Fig. 3.4).
2.6. UPR activation and PDI-altered redox state in diabetes We have, so far, described how PDI was identified as survival factor in ischemic cardiomyocytes. We now explore the concept that PDI-altered redox state may affect its function. A recent study in a mouse model of diabetes showed pathological and functional changes in the cardiomyocyte structure as well as increase cardiomyocytes apoptosis accompanied by ER stress activation (Cai and Kang, 2001). In these mice, the analysis of ER chaperones showed an increased expression of eIF2, GRP78, and GRP94 proteins and the activation of ATF6. Diabetes is a disease in which our knowledge of ER stress and UPR derives mainly from studies performed on pancreas, liver, vasculature, and specialized epithelial cells (i.e., ocular
58
Stefano Toldo et al.
epithelial cells). Nardai et al. (2005) showed that PDI redox state was altered during diabetes. We believe that understanding of PDI in AMI and diabetes is relevant to understand ER stress, UPR, and cell death responses. It is possible that PDI function is enhanced in diabetes considering the central role of the ER stress. However, it is possible that diabetes impairs PDI expression or function, in which case PDI dysfunction would represent an additional mechanism by which diabetes affects cardiovascular pathophysiology. As diabetes has been described to induce a pathologic state called diabetic cardiomyopathy (Hayat et al., 2004; Kannel et al., 1974; Rubler et al., 1972) in which ER stress plays a pivotal role, in this paragraph, we focus on the evaluation of PDI expression and redox state in the diabetic heart. Several pieces of evidence showed that the intracellular level of small molecules as FAD is lower in both diabetic animal models and diabetic patients (Banhegyi et al., 1998, Reddi, 1986) and that the activity of some FAD-containing enzymes, as Ero1, is significantly lower in experimental diabetes (Nardai et al., 2003). In streptozotocin-induced diabetic rats, despite of the oxidative changes of the extracellular space, the redox environment of liver microsomal vesicles was shifted to a more reduced state with an increase of total thiol content and an increase of protein-thiol/ disulfide ratio (Nardai et al., 2005). Interestingly, during diabetes, PDI has an almost complete shift to its most reduced form. Nardai et al. showed that in the liver of diabetic mice, a large fraction of PDI (and Erp57) is in a reduced form compared to healthy animals. The effect was selective on PDI because the redox state of other proteins, such as calnexin, Grp78, and Grp94 as well as the inactive PDI-homolog ERp28, was unchanged (Nardai et al., 2005). In an opposite way, Ero1 showed a more oxidized state. Further analysis assessed a significant decrease of the PDI enzymatic activity in diabetic samples compared to controls not accompanied by a decrease of the protein level.
2.7. Detection of PDI-altered redox state in the diabetic heart To define the redox state of PDI in the heart of diabetic mice, we used a biochemical assay to determine the differences in the redox status of PDI in heart samples of healthy and diabetic mice, to compare the quote of oxidized protein able to catalyze the disulfide bond formation. This assay can be used to study the effects of drug therapy on the restoration of the oxidized state of PDI. The assay takes advantage of the ability of methoxy-polyethylene glycol-maleimide (mPEG-mal), a polymer with a molecular mass of 5 kDa, to bind to the free thiol groups of a protein to induce a negative electrophoretic shift that is responsible for an apparent increase of molecular weight of almost 25 kDa for each mPEG-mal molecule linked. The pegylation reaction is performed using the method published by Appenzeller-Herzog
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
59
and Ellgaard (2008) with some modifications to be adapted for tissue protein analysis using an immunological-based analysis. Hearts of diabetic mice were harvested after 4 weeks from the injection of streptozotocin (130 mg/kg). In this model, glucose levels were permanently elevated from day 3 to the end of the chosen time point. The snap-frozen hearts were powdered using a mortar and a pestle. The samples were prepared as follow for biochemical modifications to discriminate between different redox states of the sulfhydryl groups of PDI. A control tissue sample was prepared to disclose any nonspecific signal in the Western blot analysis. Ten milligrams of powdered tissue was homogenized in 200 ml of extraction buffer (80 mM Tris–HCl, pH 7.3, 200 mM PMSF) containing DTT (10 mM) for 5 min at 37 C. This sample was prepared to assess the maximum reduction state of the proteins and was used to avoid false-positive signals. The DTT-treated control tissue sample did not undergo the pegylation reaction to maintain the highest electrophoretic mobility. However, all the other samples were pegylated to produce samples with lower electrophoretic mobility. Ten milligrams of the test samples from diabetic and control mice underwent chemical alkylation with N-ethylmaleimide (NEM) to block the sulfhydryl groups of the free-reduced cysteines. NEM is a cell membrane permeable molecule. Briefly, the tissue powdered in liquid nitrogen was incubated in 100 ml of ice-cold extraction buffer supplemented with 20 mM NEM and 30% DMSO (v/v). Samples were vortexed for 5 s and then centrifuged 1 min at 20,000g at 4 C followed by resuspension in the same buffer and 10 min incubation on ice. These steps and the use of high concentration of DMSO help the rapid diffusion of NEM in the powdered tissue. After 1 min centrifugation at 20,000g at 4 C, the tissue was then placed in 200 ml of fresh extraction buffer and homogenized passing the sample 10 times through a 25-gauge needle syringe. After addition of SDS (final concentration 0.1%), the samples were denatured for 10 min at 97 C, centrifuged 1 min at 25 C, and the supernatant was collected for the following biochemical treatments. One hundred microliters of NEM-alkylated samples were reduced for 15 min by addition of Tris(2-carboxyethyl) phosphine hydrochloride (TCEP, final concentration 10 mM) to reduce the oxidize cysteines and were incubated for 1 h with mPEG-mal (15 mM). This sequence of reactions allowed the alkylation of the sulfhydryl groups gained in covalent bounds, producing a molecule with higher molecular weight compared to the native protein. Excess mPEG-mal was removed by using methanol/chloroform protein precipitation. One sample volume of methanol was added to the lysate, followed by vortexing. After the addition of 0.25 sample volumes of chloroform and vortexing the mixture was centrifuged for 5 min at 20,000g at room temperature for phase separation. The lower phase was discarded, and the proteins in the interphase were resuspended adding 0.75
60
Stefano Toldo et al.
sample volumes of methanol and vortexing followed by centrifugation for 2 min at 20,000g (all sample volumes compared with the original sample). The supernatant was carefully aspirated, and the pellet dried for 15 min at room temperature. The samples were resuspended in nonreducing Laemmli buffer 1 for Western blot analysis. Samples underwent SDS-PAGE analysis in 8% acrylamide gels to allow better separation of the bands. We recommend analyzing 1/10 of the sample resuspended in Laemmli buffer. The proteins were transferred onto nitrocellulose membranes, incubated with a rabbit anti-mouse polyclonal antibody raised against PDI (DL-11, Sigma-Aldrich) and a mouse anti-mouse b-actin (clone C-2, Sigma-Aldrich), following enhanced-chemiluminescence (ECL) analysis and autoradiography (Fig. 3.5). For the detection of the most oxidized form (with the lower electrophoretic mobility), we recommend to use a more sensitive ECL, because of the low ratio of PDI
Pegylation of cysteines H
H
S
S
S
PDI
PDI Alkilation of reduced + groups/reduction
R
R
S
S
Alkilation of reduced + groups/reduction
PDI
H
H
S
S
PDI + mPEG-mal
mPEG-mal +
R
R
mPEG-mal
S
S
S
PDI
S
WB
WB
mal-PEGm S
PDI
Figure 3.5 Relationship between the sequence of reactions in the cysteines pegylation protocol and Western blot hybridization based on the thiols redox state. In the figure are reported the two sets of reactions developed to induce pegylation of the cysteines gained in disulphide bonds in the two active sites of PDI and the expected result after Western blot analysis. On the left and the right sides are represented the alkylation reactions in the active sites in the case of a reduced (left) or oxidized (right) catalytic site. In reduced catalytic site (left side), the first alkylation produces sulfur-bound N-ethylmaleimide, while the following reactions are ineffective. The product is a PDI bound to a low molecular weight molecule, without any effect on its electrophoretic properties. When the active sites are oxidized (right side), the cysteines are protected by the N-ethylmaleimide alkylation. The reduction with TCEP and the following reaction with mPEG-mal produce a high molecular weight PDI, with decreased electrophoretic mobility.
61
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
completely pegylated. The protein bands were compared by densitometric analysis (Scion Image, Scion Image Corporation) and the results were adjusted to the b-actin quantity in the samples. In Fig. 3.6 are reported the resulting bands after the Western blot analysis. In the diabetic hearts, after 4 weeks from the streptozotocin treatment, PDI expression is unaffected compared to the healthy hearts, but the quantity of oxidized PDI is lower. Compared to the previous published techniques (AppenzellerHerzog and Ellgaard, 2008, Nardai et al., 2005), this method offers both vantages and limitations. We are able to detect easily the quote of the most reduced and most oxidized PDI in the tissue with a good resolution between the bands. However, it is hard to analyze the semioxidized variants of this protein due to the presence of many bands close to each other. This is
A
Control
STZ
Oxidized PDI
Total PDI
b-Actin
Total PDI
C Change compared to the control (%)
Change compared to the control (%)
B 400 350 300 250 200 150 100 50
Controls
STZ
Oxidized PDI p < 0.05 160 140 120 100 80 60 40 20 Controls
STZ
Figure 3.6 Diabetes induces reduction of PDI active sites. PDI expression analysis was performed on total protein extracted from the heart tissue of healthy and diabetic mice to detect differences in the amount of oxidized form of the protein. The detection was performed with Western blot analysis (A). The densitometric analysis revealed that while total PDI expression is unaffected during diabetes (B), the portion of the oxidized protein is markedly reduced by 60% (C).
62
Stefano Toldo et al.
an approach to detect how in vivo a pathological condition affecting the ER is able to modify the redox state of PDI’s catalytic sites as well as of other PDI family members. Furthermore, it is a powerful tool to analyze the ability of therapeutic drugs to restore the catalytic activity of PDI in vivo.
3. Conclusions PDI upregulation following hypoxia is part of the survival response due to the oxygen deprivation to maintain the correct protein folding in the cells. Following AMI, overexpression of PDI correlates with less cell death and its forced overexpression induces a better cardiac remodeling due to reduced cardiomyocytes apoptosis. The mechanism of myocardial protection can be determined in part by the PDI ability to reduce the protein overload and the ER stress induced by hypoxia, and in part to the ability of PDI to induce SOD-1 activity in cardiomyocytes. Both these actions are able to reduce the apoptotic cell death preventing ER-dependent apoptosis and the oxidative damage enhanced by reactive oxygen species. The worse outcome seen in both diabetic patients with AMI and animal model of AMI can be due to a preexisting condition disabling the protective pathway activated following ischemic damage. PDI ability to create new disulphide bonds is dependent on the oxidation of its active sites. To oxidize two reduced cysteines, PDI has to be oxidized. The finding that during diabetes, PDI is found mostly reduced in different organs (Nardai et al., 2005) and in the heart can partially explain the induction of UPR and ER stress correlated with reduced protein secretion, protein accumulation in the ER, and increased ER-dependent apoptosis. This shift to a more reduced form of PDI could be responsible for reduced protection of cardiomyocyte following AMI. The possibility to detect PDI-altered redox state can help to characterize pathological condition associated with many diseases, including diabetes, diabetic cardiomyopathy, and ischemic heart disease, and can help to find therapeutic approach able to restore the correct redox state.
REFERENCES Abbate, A., Biondi-Zoccai, G. G., and Baldi, A. (2002). Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J. Cell. Physiol. 193, 145–153. Abbate, A., Bussani, R., Amin, M. S., Vetrovec, G. W., and Baldi, A. (2006). Acute myocardial infarction and heart failure: Role of apoptosis. Int. J. Biochem. Cell Biol. 38, 1834–1840.
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
63
Abbate, A., Biondi-Zoccai, G. G., Van Tassell, B. W., and Baldi, A. (2009). Cellular preservation therapy in acute myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 296, H563–H565. Appenzeller-Herzog, C., and Ellgaard, L. (2008). In vivo reduction–oxidation state of protein disulfide isomerase: The two active sites independently occur in the reduced and oxidized forms. Antioxid. Redox Signal. 10, 55–64. Arbustini, E., Brega, A., and Narula, J. (2008). Ultrastructural definition of apoptosis in heart failure. Heart Fail. Rev. 13, 121–135. Atkin, J. D., Farg, M. A., Turner, B. J., Tomas, D., Lysaght, J. A., Nunan, J., Rembach, A., Nagley, P., Beart, P. M., Cheema, S. S., and Horne, M. K. (2006). Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J. Biol. Chem. 281, 30152–30165. Azfer, A., Niu, J., Rogers, L. M., Adamski, F. M., and Kolattukudy, P. E. (2006). Activation of endoplasmic reticulum stress response during the development of ischemic heart disease. Am. J. Physiol. Heart Circ. Physiol. 291, H1411–H1420. Epub 2006 Apr 14. Banhegyi, G., Marcolongo, P., Puskiis, F., Fulceri, R., Mandl, J., and Benedetti, A. (1998). Dehydroascorbate and ascorbate transport in rat liver microsomal vesicles. J. Biol. Chem. 273, 2758–2762. Braunwald, E., and Kloner, R. A. (1982). The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 66, 1146–1149. Buja, L. M., and Entman, M. L. (1998). Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 98, 1355–1357. Burch, G. E., and McDonald, C. D. (1971). Prolonged bed rest in the treatment of ischemic cardiomyopathy. Chest 60, 424–430. Burch, G. E., Criles, T. D., and Colcolough, H. L. (1970). Ischemic cardiomyopathy. Am. Heart J. 79, 291–292. Cai, L., and Kang, Y. J. (2001). Oxidative stress and diabetic cardiomyopathy: A brief review. Cardiovasc. Toxicol. 1, 181–193. Cohn, J. N., Ferrari, R., and Sharpe, N. (2000). Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 35, 569–582. Dorn, G. W., and Diwan, A. (2008). The rationale for cardiomyocyte resuscitation in myocardial salvage. J. Mol. Med. 86, 1085–1095. Graven, K., Molvar, C., Roncarati, J. S., Klahn, B. D., Lowrey, S., and Farber, H. W. (2002). Identification of protein disulfide isomerase as an endothelial hypoxic stress protein. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L996–L1003. Greenberg, H., McMaster, P., and Dwyer, E. M., Jr. (1984). Left ventricular dysfunction after acute myocardial infarction: Results of a prospective multicenter study. J. Am. Coll. Cardiol. 5, 867–874. Haffner, S. M., Lehto, S., Ro¨nnemaa, T., Pyo¨ra¨la¨, K., and Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234. Haunstetter, A., and Izumo, S. (1998). Apoptosis: Basic mechanisms and implications for cardiovascular disease. Circ. Res. 82, 1111–1129. Hayat, S. A., Patel, B., Khattar, R. S., and Malik, R. A. (2004). Diabetic cardiomyopathy: Mechanisms, diagnosis and treatment. Clin. Sci. 107, 539–557. Hirsch, C., Gauss, R., Horn, S. C., Neuber, O., and Sommer, T. (2009). The ubiquitylation machinery of the endoplasmic reticulum. Nature 458, 453–460. Kajstura, J., Cheng, W., Reiss, K., Clark, W. A., Sonnenblick, E. H., Krajewski, S., Reed, J. C., Olivetti, G., and Anversa, P. (1996). Apoptotic and necrotic myocyte cell
64
Stefano Toldo et al.
deaths are independent contributing variables of infarct size in rats. Lab. Invest. 74, 86–107. Kannel, W. B., Hjortland, M., and Castelli, W. P. (1974). Role of diabetes in congestive heart failure: The Framingham study. Am. J. Cardiol. 34, 29–34. King, H., Aubert, R. E., and Herman, W. H. (1998). Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diab. Care 21, 1414–1431. Kostin, S., Pool, L., Elsa¨sser, A., Hein, S., Drexler, H. C., Arnon, E., Hayakawa, Y., Zimmermann, R., Bauer, E., Klo¨vekorn, W. P., and Schaper, J. (2003). Myocytes die by multiple mechanisms in failing human hearts. Circ. Res. 92, 715–724. Majno, G., and Joris, I. (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146, 3–15. Muller, F. L., Lustgarten, M. S., Jang, Y., Richardson, A. Van, and Remmen, H. (2007). Trends in oxidative aging theories. Free Radic. Biol. Med. 43, 477–503. Myoishi, M., Hao, H., Minamino, T., Watanabe, K., Nishihira, K., Hatakeyama, K., Asada, Y., Okada, K., Ishibashi-Ueda, H., Gabbiani, G., Bochaton-Piallat, M. L., Mochizuki, N., et al. (2007). Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 116, 1226–1233. Nardai, G., Korcsmaros, T., Papp, E., and Csertnely, P. (2003). Reduction of the endoplasmic reticulum accompanies the oxidative damage of diabetes mellitus. Biofactors 17, 259–267. Nardai, G., Stadler, K., Papp, E., Korcsma´ros, T., Jakus, J., and Csermely, P. (2005). Diabetic changes in the redox status of the microsomal protein folding machinery. Biochem. Biophys. Res. Commun. 334, 787–795. Narula, J., Haider, N., Virmani, R., DiSalvo, T. G., Kolodgie, F. D., Hajjar, R. J., Schmidt, U., Semigran, M. J., Dec, G. W., and Khaw, B. A. (1996). Apoptosis in myocytes in end-stage heart failure. N. Engl. J. Med. 335, 1182–1189. Nishida, K., Yamaguchi, O., and Otsu, K. (2008). Crosstalk between autophagy and apoptosis in heart disease. Circ. Res. 103, 343–351. Okada, K., Minamino, T., Tsukamoto, Y., Liao, Y., Tsukamoto, O., Takashima, S., Hirata, A., Fujita, M., Nagamachi, Y., Nakatani, T., Yutani, C., Ozawa, K., et al. (2004). Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction. Circulation 110, 705–712. Olivetti, G., Quaini, F., Sala, R., Lagrasta, C., Corradi, D., Bonacina, E., Gambert, S. R., Cigola, E., and Anversa, P. (1996). Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J. Mol. Cell. Cardiol. 28, 2005–2016. Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., Cheng, W., Nitahara, J. A., Quaini, E., Di Loreto, C., Beltrami, C. A., Krajewski, S., Reed, J. C., and Anversa, P. (1997). Apoptosis in the failing human heart. N. Engl. J. Med. 336, 1131–1141. Pasinelli, P., Belford, M. E., Lennon, N., Bacskai, B. J., Hyman, B. T., Trotti, D., and Brown, R. H., Jr. (2004). Amyotrophic lateral sclerasis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43, 19–30. Raven, J. F., and Koromilas, A. E. (2008). PERK and PKR: Old kinases learn new tricks. Cell Cycle 7, 1146–1150. Reddi, A. S. (1986). Riboflavin nutritional status and flavoprotein enzymes in streptozotocin diabetic rats. Biochim. Biophys. Acta 882, 71–76. Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W., and Grishman, A. (1972). New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595–602. Schroder, M., and Kaufman, R. J. (2005). The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739.
The Role of PDI as a Survival Factor in Cardiomyocyte Ischemia
65
Searles, C. D. (2002). The nitric oxide pathway and oxidative stress in heart failure. Congest. Heart Fail. 8(142–147), 155. Severino, A., Campioni, M., Straino, S., Salloum, F. N., Schmidt, N., Herbrand, U., Frede, S., Toietta, G., Di Rocco, G., Bussani, R., Silvestri, F., Piro, M., et al. (2007). Identification of protein disulfide isomerase as a cardiomyocyte survival factor in ischemic cardiomyopathy. J. Am. Coll. Cardiol. 50, 1029–1037. Tanaka, S., Uehara, T., and Nomura, Y. (2000). Up-regulation of protein disulfide isomerase in response to hypoxia/brain ischemia and its protective effect against apoptotic cell death. J. Biol. Chem. 275, 10388–10393. Temsah, R. M., Netticadan, T., Chapman, D., Takeda, S., Mochizuki, S., and Dhalla, N. S. (1999). Alterations in sarcoplasmic reticulum function and gene expression in ischemic– reperfused rat heart. Am. J. Physiol. 277, H584–H594. Temsah, R. M., Dyck, C., Netticadan, T., Chapman, D., Elimban, V., and Dhalla, N. S. (2000). Effect of beta-adrenoceptor blockers on sarcoplasmic reticular function and gene expression in the ischemic–reperfused heart. J. Pharmacol. Exp. Ther. 293, 15–23. Thuerauf, D. J., Marcinko, M., Gude, N., Rubio, M., Sussman, M. A., and Glembotski, C. C. (2006). Activation of the unfolded protein response in infarcted mouse heart and hypoxic cultured cardiac myocytes. Circ. Res. 99, 275–282. Tian, F., Zhou, X., Wikstro¨m, J., Karlsson, H., Sjo¨land, H., Gan, L. M., Bore´n, J., and Akyu¨rek, L. M. (2009). Protein disulfide isomerase increases in myocardial endothelial cells in mice exposed to chronic hypoxia: A stimulatory role in angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 297, 1078–1086. Wang, P., Chen, H., Qin, H., Sankarapandi, S., Becher, M. W., Wong, P. C., and Zweier, J. L. (1998). Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc. Natl. Acad. Sci. USA 95, 4556–4560. Wencker, D., Chandra, M., Nguyen, K., Miao, W., Garantziotis, S., Factor, S. M., Shirani, J., Armstrong, R. C., and Kitsis, R. N. (2003). A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 111, 1497–1504. Xu, J., Wang, G., Wang, Y., Liu, Q., Xu, W., Tan, Y., and Cai, L. (2009). Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: Metallothionein protection. J. Cell. Mol. Med. 13, 1499–1512. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., and Dagenais, G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 20(342), 145–153.
This page intentionally left blank
C H A P T E R
F O U R
Measurement of the Increase in Endoplasmic Reticulum Stress-Related Proteins and Genes in Adipose Tissue of Obese, Insulin-Resistant Individuals Guenther Boden* and Salim Merali† Contents 1. Introduction 2. Study Subjects and Fat Biopsies 2.1. Subjects 2.2. Fat biopsies 3. Proteomic Analysis 3.1. Required materials 3.2. Protein extraction protocol for two-dimensional electrophoresis 3.3. First dimension of 2DE 3.4. Second dimension of 2DE 3.5. Fluorescent staining with SYPROÒ Ruby 3.6. 2DE image analysis 3.7. In-gel digestion 3.8. Extraction of peptides 3.9. Preparation of MALDI matrix 3.10. Sample plate preparation and MALDI-TOF/TOF analysis 3.11. Results of proteomic analysis 4. Western Blot Analysis 4.1. Required materials 4.2. Expression analysis 4.3. Results of Western blot analysis
68 69 69 70 70 70 70 71 72 73 73 74 75 75 75 76 79 79 79 79
* Department of Medicine and the Clinical Research Center, Temple University School of Medicine, Philadelphia, PA, USA { Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA, USA Methods in Enzymology, Volume 489 ISSN 0076-6879, DOI: 10.1016/B978-0-12-385116-1.00004-2
#
2011 Elsevier Inc. All rights reserved.
67
68
Guenther Boden and Salim Merali
5. RT-PCR Analysis 5.1. Results of RT-PCR analysis Acknowledgments References
80 81 81 82
Abstract Here, we provide a detailed description of proteomic, Western blot and RT-PCR analyses performed to examine fat biopsy samples from lean insulin-sensitive and obese insulin-resistant nondiabetic individuals for evidence of endoplasmic reticulum (ER) stress. Subcutaneous fat biopsies were obtained from the upper thighs of six lean and six obese nondiabetic subjects. Fat homogenates were used for proteomic (two-dimensional gel (2DE) and MALDI-TOF/TOF), Western blot, and RT-PCR analysis. Proteomic analysis revealed 19 differentially upregulated proteins in fat of obese subjects. Three of these proteins were the ER stress-related unfolded protein response (UPR) proteins calreticulin, protein disulfide-isomerase A3, and glutathione-S-transferase P; Western blotting revealed upregulation of several other UPR stress-related proteins, including calnexin, a membranebound chaperone, and phospho c-jun NH2-terminal kinase ( JNK)-1, a downstream effector protein of ER stress; RT-PCR analysis revealed upregulation of the spliced form of X-box-binding protein-1s, a potent transcription factor and part of the proximal ER stress sensor inositol-requiring enzyme-1 pathway. These findings demonstrate of UPR activation in subcutaneous adipose tissue of obese human subjects. As JNK can inhibit insulin action and activate proinflammatory pathways, ER stress activation of JNK may be a link between obesity, insulin resistance, and inflammation.
1. Introduction Obesity is closely associated with insulin resistance and with a state of low-grade inflammation characterized by elevation of inflammatory cytokines in blood and tissues (Bray, 2004). Insulin resistance and inflammation contribute to the development of several disorders including type 2 diabetes, hypertension, atherogenic dyslipidemia, and abnormalities in blood coagulation and fibrinolysis, all of which are independent risk factors for atherosclerotic vascular disease such as heart attacks, strokes, and peripheral arterial disease (Bray, 2004). Therefore, it has become important to understand why and how obesity is so tightly linked with insulin resistance and inflammation. On one hand, free fatty acids (FFA) have been established as important links between obesity, insulin resistance, and inflammation. Most obese people have elevated plasma FFA levels (Reaven et al., 1988) and elevated plasma FFA levels have been shown to cause insulin resistance and
ER Stress Proteins and Genes in Human Fat
69
inflammation (Boden et al., 1994, 2001, 2005; Itani et al., 2002; Santomauro et al., 1999; Yu et al., 2002). On the other hand, not all of these insulin resistant subjects have elevated plasma FFA levels which means that there must be other causes for obesity-related insulin resistance and inflammation. One of these appears to be endoplasmic reticulum (ER) stress (Ozcan et al., 2004). This raises the question as to why there is ER stress in obesity and how obesity-associated ER stress can cause insulin resistance and inflammation. Excessive macronutrient intake is the main cause for obesity and several recent studies in rodents have implicated ER stress as an early sign of nutrient excess and a cause for the development of insulin resistance and inflammation. For instance, in mice fed high fat diets for 3 months, the chronic excessive macronutrient intake caused obesity and ER stress in adipose tissue and liver, whereas overexpression or administration of ER stress reducing chaperone proteins reduced ER stress, insulin resistance, and inflammation (Schroder and Kaufman, 2005). ER stress can lead to the development of insulin resistance and inflammation. Proposed mechanisms include ER stress-induced phosphorylation and activation of C-jun Nterminal kinase ( JNK), and activation and nuclear translocation of nuclear factor kB (NFkB), which is a key promoter of inflammation (Zhang and Kaufman, 2008). In addition, ER stress is a major source for the production of reactive oxygen species (ROS) which can produce insulin resistance and inflammation (Schroder and Kaufman, 2005; Zhang and Kaufman, 2008). Thus, it has been proposed that the ER may be a proximal site that senses nutritional excess and translates that into signals producing insulin resistance and inflammatory responses (Zhang and Kaufman, 2008). Until very recently, however, all the evidence linking ER stress with obesity, insulin resistance, and inflammation were based on in vitro and animal data. We have recently shown, however, that there is ER stress in fat of obese people (Boden et al., 2008). In this chapter, details of this study are described.
2. Study Subjects and Fat Biopsies 2.1. Subjects Six lean and six obese healthy volunteers were studied. None of the participants had a family history of diabetes or other endocrine disorders or were taking medications. Their body weights were stable for at least 2 months before the biopsies. Compared with the nonobese volunteers, the obese volunteers were heavier (93.4 vs. 77.4 kg; P < 0.03) and had more body fat 40.7 vs. 19.9 kg; P < 0.004) but had the same fat-free mass (57.6 vs. 57.6 kg) and were insulin resistant (1/homeostasis model assessment 0.44 vs. 0.29; P < 0.05). Informed written consent was obtained from all subjects after explanation of the nature, purpose, and potential risks of these
70
Guenther Boden and Salim Merali
studies. The study protocol was approved by the Institutional Review Board of Temple University Hospital.
2.2. Fat biopsies The subjects were admitted to the Temple University Hospital Clinical Research Center on the day before the studies. At 8 a.m. on the day after admission, a venous blood sample was obtained and an open fat biopsy was performed by a surgeon. Fat biopsies were obtained from the lateral aspect of the upper thigh (15 cm above the patella) under local anesthesia, as described (Boden et al.,1994). The excised fat was dropped immediately into isopentane and kept at its freezing point (160 C) by liquid nitrogen. The frozen fat was stored at 80 C until analyzed.
3. Proteomic Analysis 3.1. Required materials
SYPROÒ Ruby (Invitrogen, Carlsbad, California) Milli-Q System (Millipore, Billerica, MA)
The following is from GE Healthcare, Piscataway, NJ:
IPGphor horizontal electrophoresis apparatus IPGphor strip holders, IEF sample applicator strip Immobiline DryPlate 4–7 and/or 3–10 IPG buffers (pH range 4–7 and/or 3–10) IPG cover fluid DeStreak reagent
The following is from Sigma–Aldrich, St. Louis, MO:
CHAPS Urea Thiourea DTT Iodoacetamide
3.2. Protein extraction protocol for two-dimensional electrophoresis 1. Place the amount of tissue sample to be processed in a precooled (–20 C), clean mortar.
ER Stress Proteins and Genes in Human Fat
71
2. Freeze the tissue sample thoroughly by adding a small volume (2–5 mL) of liquid nitrogen. 3. Allow most of the liquid nitrogen to evaporate, leaving 1–2 mL. 4. Grind the tissue with a precooled (–20 C) pestle until a fine powder is obtained. 5. Transfer the powder into a 1.5-mL tube and measure the wet weight. Add 0.5 mL of extraction buffer: 7 M urea,1 2 M thiourea, 4% CHAPS, 43 mM DTT,2 60 mM Tris/HCl (pH 8.8), and 0.1% SDS; additives: 1 protease inhibitor cocktail2 and 0.2 mM EDTA. 6. Sonicate sample with five pulses of 10 s each. Add 2 mM MgCl2 and Benzonase (50 U per 100 ml of sample solution) mix and incubate at room temperature (RT) for 15 min with vortexing every 5 min.3 7. Spin solution at max speed (21,000g) for 30 min at RT. Discard the pellet. 8. Mix protein extract (supernatant) with 20 C cold acetone/0.1% DTT at 1:3 (v/v) ratio and store the mixture at 20 C overnight. 9. Spin at 21,000g for 30 min at 4 C, discard the supernatant and resuspend the pellet with 1.2 mL 80% (20 C) cold acetone/0.2% DTT2 and spin (21,000g/4 C) for 5 min and discard the supernatant. Repeat wash.4 10. Air dry the pellet till no acetone is remaining and redissolved in DeStreak rehydration solution or two-dimensional electrophoresis (2DE) sample buffer: 7 M urea, 2 M thiourea, 4% CHAPS, 1.2% DeStreak, and 0.01% bromophenol blue. Shaking for 3 h at RT to solubilize. 11. Determine the protein concentration using 2D Quant Kit as per manufacturer’s instructions (Amersham).
3.3. First dimension of 2DE 12. Mix sample to the final volume with DeStreak rehydration buffer supplemented with the corresponding immobilized pH gradient (IPG) buffer. 13. Rehydrate the IPG strips overnight at 22 C in rehydration buffer: 7 M urea, 2 M thiourea, 4% CHAPS, 5% glycerol, 15% 2-propanol, 1.2% DeStreak reagent2, 0.5% IPG buffer 7–112, and 0.2% methylcellulose mixed with an appropriate sample volume.5 1 2 3 4 5
Deionize urea stirring it during 10 min with w/v 0.6% mixed-ion exchanger (e.g., Amberlite MB-1). These reagents should be added fresh. In order to prevent carbamylation modifications, avoid incubation at 37 C. Since benzonase is a protein it may appear on the 2D map. To increase protein recovery, sample can be incubated at 20 C/1 h during the first wash prior spin. Rehydration and sample volumes depend on pH range, separation distance, and detection method.
72
Guenther Boden and Salim Merali
14. Use Ethan IPGphor system (GE Health system) to perform isoelectric focusing (IEF). Program the settings to temperature of 20 C and use the following settings. Step T ( C) Start volt (V) IEF protocol (7 cm) 1 20 0 2 20 250 3 20 1500 4 20 3000
End volt (V)
Duration (h) Total (Vh)
250 1500 3000 8000
0.5 1 1 3
11,000
3.4. Second dimension of 2DE 1. Dissolve 100 mg of DTT in 10 mL of equilibration buffer 6 M urea, 30% (w/v) glycerol, and 2% (w/v) SDS in 0.05 M Tris–HCl buffer (pH 8.8). Take out the focused IPG gel strips from the freezer and place them into individual test tubes. Add 10 mL of equilibration buffer I and 50 mL of the bromophenol blue (0.25%, w/v) solution. Seal the test tubes with Parafilm, rock them 15 min on a shaker, and then pour off equilibration buffer I. 2. Dissolve 400 mg of iodoacetamide in 10 mL of equilibration buffer. Add equilibration buffer II and 50 mL of bromophenol blue solution to the test tube as above and equilibrate for another 15 min on a rocker. 3. After the second equilibration, rinse the IPG gel strip with deionized water for a second and place it on a piece of filter paper at one edge for a few minutes to drain off excess equilibration buffer. 4. Place IPG gel strip on top of the vertical SDS gel. 5. Fill the electrophoresis chamber with electrode buffer and turn on the SDS gel cassettes in a vertical position to facilitate the application of the first dimension IPG strips. 6. Equilibrate the IPG gel strips as described above for first dimension and immerse them in electrode buffer for a few seconds. 7. Place the IPG gel strip on top of an SDS gel. Carefully press the IPG strip with a spatula onto the surface of the SDS gel to achieve complete contact. Repeat this procedure for the remaining IPG strips. 8. Insert the gel cassettes in the electrophoresis apparatus and start electrophoresis.6 9. Run the SDS–PAGE gels in Bio-Rad Mini-PROTEANÒ 3 System (Hercules, CA) at 200 V for 45 min. 6
Remove the IPG gel strips from the surface of the vertical SDS gel once the proteins have migrated out of the IPG gel strip.
ER Stress Proteins and Genes in Human Fat
73
10. Terminate the run when the bromophenol blue tracking dye has migrated off the lower end of the gel. 11. Open the cassettes carefully with a spatula. Peel the gel off the glass plate carefully, lifting it by the lower edge, and place it in a tray containing fixing solution or transfer buffer, respectively. Then continue with fixing, protein staining, or blotting.
3.5. Fluorescent staining with SYPROÒ Ruby 1. After electrophoresis, place the gel into a clean container with 100 mL of fixing solution (50% methanol, 7% acetic acid) and agitate on an orbital shaker for 30 min. Repeat once more with fresh fixing solution. Pour off the used fixing solution.7 After fixing, perform three washes in ultrapure water for 10 min each, before proceeding to the staining step. 2. Add 60 mL of SYPROÒ Ruby gel stain. Agitate on an orbital shaker overnight. 3. Transfer the gel to a clean container and wash in 100 mL of wash solution (10% methanol, 7% acetic acid) for 30 min. The transfer step helps minimize background staining irregularities and stain speckles on the gel. Before imaging rinse the gel in ultrapure water a minimum of two times for 5 min to prevent possible corrosive damage to the imager. 4. SYPROÒ Ruby protein gel stain has two excitation maxima, one at 280 nm and one at 450 nm, and has an emission maximum near 610 nm. Proteins stained with the dye can be visualized using a 300 nm UV transilluminator, a blue-light transilluminator, or a laser scanner. The stain has exceptional photostability allowing long exposure times for maximum sensitivity.
3.6. 2DE image analysis 1. Perform 2DE analysis by PDQuest software (Bio-Rad), version 8.0. 2. Enumerate and analyze each gel from obese and lean fat samples for spot detection, background subtraction, and protein spot volume quantification. 3. Make manual corrections to validate the matches automatically generated by the software. 4. Normalize spot volume values in each gel by dividing the raw quantity of each spot by the total volume of all spots included in the same gel. 5. Determine SD for each protein spot and the average spot volume values. 7
For IEF gels, place the gel into a clean container with 100 mL of IEF fix solution and agitate on an orbital shaker for 3 h.
74
Guenther Boden and Salim Merali
6. Perform Student’s t-test on the match spots in order to determine the spots that were differentially expressed. 7. Choose spots that show a statistically significant difference with a confidence level of 0.05. 8. To test for inter gel reproducibility, perform 2DE analysis in triplicate using one representative sample.
3.7. In-gel digestion 1. Wearing gloves and sleeve protectors, wipe down ALL surfaces in the hood with methanol/water-moistened lint-free cloth, including the outside of all the tubes (make sure to not wipe off the labeling), the outside and inside of the Speed Vac and centrifuge, tube racks, bottles, etc. Wipe razor blades with methanol-soaked lint-free cloth. 2. Prepare the following solutions: 25 mM NH4HCO3 (100 mg/50 mL) 25 mM NH4HCO3 in 50% ACN 50% ACN/5% formic acid (may substitute TFA or acetic acid) 12.5 ng/mL trypsin (Promega) in 25 mM NH4HCO3 (freshly diluted) 3. Dice each gel slice into small pieces (1 mm2) and place into 0.65-mL siliconized tubes (PGC Scientific). 4. Add 100 mL (or enough to cover) of 25 mM NH4HCO3/50% ACN and vortex for 10 min. 5. Using gel loading pipet tip, extract the supernatant and discard. 6. Repeat steps 3 and 4 once or twice. 7. Speed Vac the gel pieces to complete dryness ( 20 min). 8. Prepare fresh solutions: 10 mM DTT in 25 mM NH4HCO3 (1.5 mg/mL) 55 mM iodoacetamide in 25 mM NH4HCO3 (10 mg/mL) 9. Add 25 mL (or enough to cover) 10 mM DTT in 25 mM NH4HCO3 to dried gels. Vortex and spin briefly. Allow reaction to proceed at 56 C for 1 h. 10. Remove supernatant, add 25 mL 55 mM iodoacetamide to the gel pieces. Vortex and spin briefly. Allow reaction to proceed in the dark for 45 min at RT. 11. Remove supernatant (discard). Wash gels with 100 mL NH4HCO3, vortex 10 min, spin. 12. Remove supernatant (discard). Dehydrate gels with 100 mL (or enough to cover) of 25 mM NH4HCO3 in 50% ACN, vortex 5 min, spin. Repeat one time. 13. Speed Vac the gel pieces to complete dryness (20 min). Proceed with trypsin digest.
ER Stress Proteins and Genes in Human Fat
75
14. Add trypsin solution (step 2) to just barely cover the gel pieces. Estimate the gel volume and add about 3 volume of trypsin solution. This volume will vary from sample to sample, but on average 5–25 mL is sufficient. 15. Rehydrate the gel pieces on ice or at 4 C for 10 min Spin. Add 25 mM NH4HCO3 as needed to cover the gel pieces. 16. Spin briefly and incubate at 37 C for 4 h—overnight.
3.8. Extraction of peptides 1. Transfer the digest solution (aqueous extraction) into a clean 0.65-mL siliconized tube. 2. To the gel pieces, add 30 mL (enough to cover) of 50% ACN/5% formic acid, vortex 20–30 min, spin, sonicate 5 min. Repeat. 3. Vortex the extracted digests, spin and Speed Vac to reduce volume to 10 mL. 4. Either proceed with C18 ZipTip (Millipore) cleanup or analyze with LC–MS. Add 2–5 mL of 5% formic acid. When analyzing low levels of protein, concentrate the peptides by eluting from ZipTips using 3 mL of elution solution, into a clean 0.65-mL siliconized tube. 5. Use 1 mL of the unseparated digests for analysis by Matrix Assisted Laser Desorption Ionization/Time of Flight (MALDI/TOF).
3.9. Preparation of MALDI matrix 1. Dissolve the contents of a 10-mg tube of a-cyano-4-hydroxycinammic acid in 1 mL of the 50% acetonitrile in 0.05% triflouroacetic acid solution. For best performance, once in solution, the matrix should be stored in the dark and used within 1 week. 2. Some residual crystals may be visible in the matrix solution. The acetonitrile concentration can be adjusted to suit individual preferences. A mixture of 70% ACN and 30% of the 0.1% TFA solution can also be used.
3.10. Sample plate preparation and MALDI-TOF/TOF analysis 1. Transfer 10 mL of the matrix solution to a small tube. 2. Add 1 mL of the standard/sample to the tube containing the matrix and vortex. 3. Apply 1.0 mL from the mixture to wells of an AnchorChipTM sample target plate used for the Bruker Auto-flex MALDI-TOF/TOF. 4. Once the liquid has evaporated (2 h), the target is ready for analysis.
76
Guenther Boden and Salim Merali
5. Obtain peptide mass fingerprints using the reflective and positive ion mode of Autoflex MALDI TOF/TOF mass spectrometer (Bruker, Daltonics Inc., Billerica, MA) 6. Use FlexAnalysisTM software with signal-to-noise ratio of 2:1 to collect mass spectra from 100 to 400 laser shots. 7. Generate mono-isotopic peaks by mass peak value calculation. 8. Use two trypsin auto-digestion peptides with M þ H values 842.509 and 2211.104 as internal standards. 9. Indentify protein by matching the calibrated peptide mass values within NCBInr protein databases using an in-house version of Mascot Server 2.2 imbedded in Bruker’s Biotool software. 10. Select Homo sapiens species for taxonomy. 11. Use the following match variances: mass tolerance of 40 ppm, one missed trypsin cleavage, fixed modification of carbamidomethyl cysteine, and variable modification of methionine oxidation.
3.11. Results of proteomic analysis Gels with isoelectric focusing ranges of PI 4–7 and 6–10 produced a total of 900 protein spots in each gel (Fig. 4.1). The comparison of all spots visualized yielded 24 spots that were significantly different in lean versus obese volunteers. Three of these spots represented multiple isoforms of vimentin. Three vimentin isoforms were considered as one protein (24 2 ¼ 22). Two other spots could not be identified (22 2 ¼ 20). Of 20 remaining differentially expressed proteins, 10 were upregulated and 1 (a-enolase) was downregulated in obese versus lean volunteers (Table 4.1). The differentially expressed proteins were grouped into the following categories: (1) UPR and stress (seven proteins), (2) energy and FFA metabolism (five proteins), (3) structural proteins (four proteins), and (4) protein transport and signaling (four proteins). UPR and stress. Levels of expression of the following UPR proteins were overexpressed in 2DEs in adipose tissue from obese volunteers: CRT, a protein chaperone, increased from undetectable to 1019 236 arbitrary units; PDI, a protein foldase, increased approximately threefold; and glutathione-S-transferase P, an antioxidant protein belonging to a UPR-upregulated pathway increased 1.8-fold. Several cytosolic small heat-shock proteins (HSPs) (20 and 27 kDa HSP) and one mitochondrial HSP (60 kDa HSP) were also overexpressed in the adipose tissue of obese volunteers, suggesting the presence of cytosolic and mitochondrial stress in addition to ER stress (Table 4.1).
77
ER Stress Proteins and Genes in Human Fat
Lean
Obese PDI PDI Calreticulin
Lean
Obese
14 9 12 7 8
7
19
19
8 9 12
3 2
3
4
2
18 5
18
4 11
5
11
15
16
13
16 13
15 17 1
6
1
20
14
20
17
6 10
10
pI 4
7 pI 4
7
Lean
Obese
21
21
23
23 24
24
22
pI 6
22
10 pI 6
10
Figure 4.1 Expression of the UPR proteins CRT and PDI in adipose tissue of one lean and one obese subject (upper panels). Differentially expressed proteins in fat homogenates from one lean and one obese subject. Proteins were separated by isoelectric focusing and molecular weight (2DE) as described in Section 3. The subproteom from each sample was assessed using PI ranges of 4–7 (middle panels) and 6–10 (lower panels). The proteins were stained with SPYROÒ Ruby and images compared by PD Quest software. The numbers correspond to the spot numbers in Table 4.1. The arrows indicate upregulated proteins in the fat of obese subjects (from Boden et al., 2008 with permission).
Table 4.1 Proteins differentially expressed in 2DGs
Spot no.
Protein identification
UPR and stress 3 CRT 23 PDI 20 20 kDa HSPb-6 21 27 kDa HSPb-1 25 HSPb-5 16 60 kDa HSP 19 Glutathione-S-transferase P Energy and FFA metabolism 12 ATP synthase subunit-b 15 Perilipin 22 Aldehyde dehydrogenase 24 a-Enolase 26 Carbonic anhydrase-1 Structural proteins 1 Myosin light-chain polypeptide-6 2 Tropomyosin b-chain 4 Tropomyosin a4-chain 7–9 Vimentin Protein transport and signaling 6 g-Synuclein 11 pGDP dissociation inhibitor-1 5 14-3-3 protein-g 10 Galectin-1 Data are means S.D.
Swiss protein accession no.
Mouse score
Peptides matched
Normalized spot volumes SD (lean; n ¼ 6)
Normalized spot volumes SD (lean; n ¼ 6)
P27797 P30101 014558 P04792 P02511 P10809 P09211
66 61 76 78 74 69 107
7 6 5 8 9 6 8
0 421 328 2534 1157 4242 1438 4162 558 600 558 2231 698
1019 1170 7530 8140 8967 1868 3936
P06576 060240 P05091 P06733 P00915
138 57 87 65 198
11 6 9 7 11
2413 801 1602 381 1341 161 803 214 2463 774
5499 1251 3960 1019 4088 799 293 74 4846 523
0.01 0.007 0.001 0.018 0.012
P60660
60
6
1792 528
3837 284
0.002
P07951 P67936 P08670
58 94 204
6 8 19
1141 443 770 355 3136 1418
4072 531 3429 779 11,005 3353
0.03 0.002 0.007
076070 P52565
66 75
4 5
488 465 2163 612
1714 670 3168 286
0.034 0.049
P61981 P09382
78 113
6 10
875 525 9030 1387
3619 1005 25,049 4175
0.005 0.001
236 63 248 1643 2918 56 390
P
< 0.001 < 0.01 0.001 0.001 0.049 < 0.001 0.013
ER Stress Proteins and Genes in Human Fat
79
4. Western Blot Analysis 4.1. Required materials
Blotting chamber (Bio-Rad) Protein disulfide isomerase A3 (Santa Cruz, CA, SC-20132) Calreticulin (Santa Cruz, CA, SC-11398) Calnexin (Santa Cruz, CA, SC-11397) Mouse anti-rabbit horseradish peroxidase-conjugated secondary antibody (Biomeda, Foster City, CA)
4.2. Expression analysis 1. Separate the proteins (30–80 mg) from the same adipose tissue lysates as used for the 2DEs by 10–14% gradient SDS-PAGE. 2. Transfer the separated proteins to a nitrocellulose membrane in a semidry blotting chamber according to the manufacturer’s protocol. 3. Block the blots with 5% milk in Tris-buffered saline solution (pH 7.6) containing 0.05% Tween-20. 4. Probe with the following rabbit anti-human antibodies from Santa Cruz Biotechnology (Santa Cruz, CA) at a concentration of 0.4 mg/mL: protein disulfide isomerase A3 (PDI), calreticulin (CRT), and calnexin (CNX). 5. Use a rabbit antiserum that detects phosphor c-jun NH2-terminal kinase ( JNK)-1, -2, and -3 (Cell Signaling Technology, Danvers, MA) and a rabbit antiserum that detects total JNK. 6. Incubate the blots with primary antibody overnight at 4 C at with gentle shaking and then incubate with a mouse anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:10,000) (Biomeda) for 1 h at RT. 7. Expose the blots using a chemiluminescent detection method (Enhanced ECL Detection System; GE Healthcare BioSciences).
4.3. Results of Western blot analysis Western blotting confirmed upregulation of CRT and PDI and revealed upregulation of CNX ( 1.8-fold), a membrane bound chaperone and phospho-JNK-1 2.0-fold, a downstream effector protein of the UPR. Phospho-JNK 2/3, however, was unchanged (Fig. 4.2).
80
p-JNK-1
cnx b -actin
0.8
JNK-1
0.8
P < 0.05 P = 0.024
0.6
0.4
0.4 0.2
Calreticulin/b -actin
0.0 1.5
0.0 p-JNK-2,3
crt b -actin
P < 0.005
ns
0.8
1.0
0.4
0.5 0.0 2.0
PDI/b -actin
1.2
JNK-2,3
1.5
Lean
PDI b -actin
Obese
0.0
Phospho-JNK-2,3/JNK-2,3
Calnexin/b -actin
1.0
Phospho-JNK-1/JNK-1
Guenther Boden and Salim Merali
P = 0.05
1.0 0.5 0.0
Lean
Obese
Figure 4.2 Protein abundance (by Western blots) of CNX/b-actin, CRT/b-actin, PDI, phospho-JNK-1/JNK-1, and phospho-JNK-2,3/JNK-2,3 in subcutaneous adipose tissue from four lean (insufficient fat was available for Western analysis from two of six lean subjects) and six obese nondiabetic subjects. Inserts show representative Western blots (from Boden et al., 2008 with permission).
5. RT-PCR Analysis Total RNAs were isolated from frozen adipose tissues, and real-time RT-PCR was performed with a SYBR Green One-Step qRT-PCR kit (Invitrogen) and a Light-Cycler (Roche, Indianapolis, IN). Primers for X-box-binding protein (XBP)-1s (NM-005080) were sense: TTGAGAACCAGGAGTTAAG and antisense CCTGCACCTGCTGCGGACT.
81
ER Stress Proteins and Genes in Human Fat
XBP-1
0.8
12 mRNA/18S rRNA arbitrary units
TNF-a P = 0.03 0.6
8 P = 0.024
0.4
4
0.2
0
0.0 IL-6
IL-1b 0.8
0.8
0.6
0.6
0.4
0.4
02
02
0.0
Lean
Obese
Lean
Obese
0.0
Figure 4.3 Messenger RNA (mRNA) corrected for 18S ribosomal RNA (18S rRNA) of sXBP-1, tumor necrosis factor-a, interleukin-1b, and interleukin-6 in six lean and six obese nondiabetic subjects (from Boden et al., 2008 with permission).
5.1. Results of RT-PCR analysis Upregulation of the spliced form of XPP-1s, a part of the IRE-1/XBP-1 proximal ER stress sensor, and of tumor necrosis factor-a, a proinflammatory cytokine, were documented with RT-PCR, whereas there were no differences in interleukin-1b and -6 mRNA in adipose tissue of lean and obese subjects (Fig. 4.3).
ACKNOWLEDGMENTS This work was supported by National Institutes of Health grants R01-DK58895, a grant from the American Diabetes Association (1-10-CT-06), a grant from the Department of Health, Commonwealth of Pennsylvania, and a grant from the Groff Foundation (all to G. B.) and R01-A1064017 (to S. M.).
82
Guenther Boden and Salim Merali
REFERENCES Boden, G., Chen, X., Ruiz, J., and Rossetti, L. (1994). Mechanisms of fatty acid induced inhibition of glucose uptake. J. Clin. Invest. 93, 2438–2446. Boden, G., Lebed, B., Schatz, M., Homko, C., and Lemieux, S. (2001). Effects of acute changes on plasma FFA on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50, 1612–1617. Boden, G., She, P., Mozzoli, M., Gumireddy, K., Reddy, P., Xiang, X., Luo, Z., and Ruderman, N. (2005). Free fatty acids produce insulin resistance and activate the proinflammatory NFkB pathway in rat liver. Diabetes 54, 3458–3465. Boden, G., Duan, X., Homko, C., Molina, E. J., Song, W., Perez, O., Cheung, P., and Merali, S. (2008). Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese insulin-resistant individuals. Diabetes 57, 2438–2444. Bray, G. A. (2004). Medical consequences of obesity. J. Clin. Endocrinol. Metab. 89, 2583–2589. Itani, S. I., Ruderman, N. B., Schmieder, F., and Boden, G. (2002). Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-a. Diabetes 51, 2005–2011. Ozcan, U., Cao, Q., Yilmaz, E., et al. (2004). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457–461. Reaven, G. M., Hollenbeck, C., Jeng, C.-Y., Wu, M. S., and Chen, Y. D. (1988). Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with NIDDM. Diabetes 37, 1020–1024. Santomauro, A. T., Boden, G., Silva, M., Rocha, D. M., Santos, R. F., Ursich, M. J., Strassmann, P. G., and Wajchenberg, B. L. (1999). Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48, 1836–1841. Schroder, M., and Kaufman, R. J. (2005). The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739–789. Yu, C., Chen, Y., Cline, G. W., et al. (2002). Mechanism by which fatty acids inhibit activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230–50236. Zhang, K., and Kaufman, R. J. (2008). From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455–462.
C H A P T E R
F I V E
Measurement of the Unfolded Protein Response (UPR) in Monocytes Toma´s P. Carroll, Catherine M. Greene, and Noel G. McElvaney Contents 84 84 85 86
1. Introduction 1.1. ER stress and the unfolded protein response 1.2. The monocyte 2. Investigating UPR Activation in the Monocyte 2.1. Isolation, culture, and treatment of peripheral blood monocytes 2.2. Enzyme-linked immunosorbent assay 2.3. RNA isolation, cDNA synthesis, and RT-PCR 2.4. Detection of UPR markers by immunoblotting 2.5. Immunofluorescence Acknowledgments References
86 88 89 91 92 93 93
Abstract In mammalian cells, the primary function of the endoplasmic reticulum (ER) is to synthesize and assemble membrane and secreted proteins. As the main site of protein folding and posttranslational modification in the cell, the ER operates a highly conserved quality control system to ensure only correctly assembled proteins exit the ER and misfolded and unfolded proteins are retained for disposal. Any disruption in the equilibrium of the ER engages a multifaceted intracellular signaling pathway termed the unfolded protein response (UPR) to restore normal conditions in the cell. A variety of pathological conditions can induce activation of the UPR, including neurodegenerative disorders such as Parkinson’s disease, metabolic disorders such as atherosclerosis, and conformational disorders such as cystic fibrosis. Conformational disorders are characterized by mutations that modify the final structure of a protein and any cells that express abnormal protein risk functional impairment. The monocyte is an important and long-lived immune cell and acts as a key immunological orchestrator, dictating the intensity and duration of the host immune response. Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland Methods in Enzymology, Volume 489 ISSN 0076-6879, DOI: 10.1016/B978-0-12-385116-1.00005-4
#
2011 Elsevier Inc. All rights reserved.
83
84
Toma´s P. Carroll et al.
Monocytes expressing misfolded or unfolded protein may exhibit UPR activation and this can compromise the host immune system. Here, we describe in detail methods and protocols for the examination of UPR activation in peripheral blood monocytes. This guide should provide new investigators to the field with a broad understanding of the tools required to investigate the UPR in the monocyte.
1. Introduction 1.1. ER stress and the unfolded protein response Newly synthesized secreted and transmembrane proteins are transported into the lumen of the endoplasmic reticulum (ER) where they are folded and correctly assembled. The homeostasis of this organelle is vital to continued normal cell function and survival. Perturbations that disrupt ER homeostasis, such as fluctuations in calcium storage or increased demand for protein folding arising from elevated production of secretory proteins, compromise ER protein folding capacity resulting in the accumulation of unfolded or misfolded protein within the lumen of the ER. An imbalance between the load of unfolded proteins entering the ER and the ability of the ER to process this load is termed ER stress, and can be detrimental to cell survival. ER stress can also be induced by a range of pathophysiological conditions, including stroke, ischemia, diabetes, obesity, viral infection, and mutations that impair protein folding (Kaufman, 1999). To maintain homeostasis, the ER has evolved highly specific signaling pathways collectively referred to as the unfolded protein response (UPR), which strives to adapt for survival or induce apoptosis. In the event of ER stress, this protective pathway causes the translational attenuation of general protein synthesis, induces a transcriptional program of ER-resident chaperones, and coordinates the degradation of misfolded proteins through ERassociated degradation (ERAD) (Mori, 2000). Three proximal ER-resident transmembrane sensors, protein kinase RNA (PKR)-like ER kinase (PERK), inositol-requiring kinase 1 (IRE1), and activating transcription factor 6 (ATF6) form a tripartite management system that orchestrates the mammalian UPR (Ron and Walter, 2007). The luminal domain of these three molecules is sequestered by the ER chaperone glucose-regulated protein 78 (GRP78), however, upon misfolded protein accumulation, GRP78 dissociates from PERK, IRE1, and ATF6, leading to their activation (Malhotra and Kaufman, 2007). The most immediate step in the UPR is translational attenuation to prevent further accumulation of unfolded proteins in stressed cells. This is mediated by PERK, through phosphorylation of eukaryotic initiation factor 2 (eIF2) at Serine 51 on its alpha subunit (eIF2a) (Harding et al., 1999).
Measuring UPR Activation in the Monocyte
85
While reducing the rate of protein synthesis and the protein load in the ER, eIF2a phosphorylation paradoxically promotes the translation of ATF4 mRNA, a basic leucine zipper (bZIP) transcription factor. ATF4 induces a pro-survival program of genes essential for amino acid import, glutathione biosynthesis, and resistance to oxidative stress (Harding et al., 2003). The next step in the UPR employs IRE1 and ATF6, which regulate chaperone induction, expansion of the ER in response to increased client protein load, and ERAD (Mori, 2000). Upon UPR engagement, IRE1 is activated and its endoribonuclease activity causes removal of a 26-nucleotide intron from X-box-binding protein 1 (XBP-1) mRNA (Tirasophon et al., 1998). The spliced XBP-1 mRNA is translated into a potent bZIP transcription factor which translocates to the nucleus and acts as a key regulator of ER folding capacity. Concurrently, another bZIP transcription factor ATF6 is released from GRP78 and transported to the Golgi where it undergoes sequential cleavage by site-1 protease (S1P) and site-2 protease (S2P). Cleaved ATF6 cooperates with spliced XBP-1 to induce the expression of ER chaperones, ER quality control genes, folding enzymes, and ERAD (Yoshida et al., 1998, 2001). ERAD ensures the removal of terminally misfolded proteins from the ER lumen to the cytoplasm for ultimate degradation by the ubiquitin–proteasome system (Travers et al., 2000).
1.2. The monocyte The human immune system has been historically divided into innate immunity and acquired or adaptive immunity. Monocytes and their multitude of differentiated offspring fulfill important regulatory and effector roles in both arms of the immune system (Medzhitov and Janeway, 2000). Peripheral blood monocytes in the circulation migrate through blood vessel walls into various organs and differentiate into more specialized macrophages. Monocytes and their macrophage progeny act as immunological orchestrators and serve three major functions, antigen presentation, phagocytosis, and immunomodulation (Dale et al., 2008). Upon activation, monocytes and macrophages produce large amounts of cytokines and chemokines that recruit other immune cells such as neutrophils to sites of infection and inflammation. The first reports of ER stress and UPR activation in immune cells were in professional antibody-secreting plasma cells (Calfon et al., 2002). This developmental ER stress is a natural consequence of the transition from B cell to plasma cell, which produces huge amounts of antibodies and requires a massive expansion in ER folding capacity (Iwakoshi et al., 2003). However, there is emerging evidence that UPR activation in monocytes and macrophages may play a role in the pathogenesis of a number of diseases. In mouse models of atherosclerosis, macrophages overloaded with free cholesterol were shown to exhibit UPR activation (Li et al., 2005), and
86
Toma´s P. Carroll et al.
monocytes from Type II diabetes patients showed elevated expression of GRP78 (Komura et al., 2010). Monocytes from cystic fibrosis (CF) patients were shown to be intrinsically abnormal in their cytokine responses (Zaman et al., 2004), but this can be reversed by inhibitors designed to prevent DF508 CFTR (CF transmembrane conductance regulator) degradation by ERAD and increase the secretion of CFTR (Vij et al., 2006). In addition, work from this group has demonstrated intracellular accumulation of Z alpha-1 antitrypsin (AAT) in the ER of monocytes, and this causes sustained activation of the UPR with subsequent effects on immune function (Carroll et al., 2010). As the tissue macrophage can present a challenge in terms of isolation with unreliable sampling techniques or lengthy differentiation protocols from monocytes that risk cell activation, the monocyte is a useful tool for investigating immune system derangement in a variety of disorders.
2. Investigating UPR Activation in the Monocyte 2.1. Isolation, culture, and treatment of peripheral blood monocytes In this section, we will provide details for isolating monocytes from freshly drawn whole blood from human donors. It must be noted that studying the behavior and function of human monocytes is a difficult undertaking. Monocytes constantly observe their surroundings and swiftly react to changes, as is their nature. The isolation, purification, and culture of these cells in vitro can affect their phenotype, and care must be taken not to stimulate the cells. The faster the isolation process the less chance of cell activation, and all buffers to be used should be prewarmed to 37 C. We use Lymphoprep (Axis-Shield) to perform density gradient separation but Ficoll-Paque can also be used (Yeo et al., 2009). 2.1.1. Required materials
Lymphoprep (Axis-Shield) 1 saline (0.9% NaCl) Hanks balanced salt solution (Biosciences) EasySep Human CD14 positive selection kit (Stemcell Technologies) and EasySep magnet (Stemcell Technologies). The kit is designed to isolate CD14 positive cells from fresh or previously frozen peripheral blood mononuclear cells by positive selection. 5 mL polystyrene round bottom Falcon tube (BD Biosciences, product)
Measuring UPR Activation in the Monocyte
87
RPMI 1640 (Biosciences) supplemented with 10% FCS, 2% glutamine and penicillin/streptomycin (necessary for culturing monocytes) Thapsigargin (Molecular Probes) and tunicamycin (Sigma) for chemically inducing UPR activation. Thapsigargin depletes calcium stores in the ER by inhibiting Ca2þ ATPase, while tunicamycin inhibits N-linked glycosylation of newly synthesized proteins. 2.1.2. Monocyte isolation Mononuclear cells are isolated from venous peripheral blood obtained from donors by density gradient separation. The blood must be collected in tubes containing an anticoagulant (EDTA or heparin). Once drawn, blood is immediately placed in 50-mL tube and mixed with an equal volume of 0.9% NaCl (1 saline). The diluted blood is then layered over Lymphoprep in a fresh 50-mL tube. For example, if 15 mL blood is obtained, mix with 15 mL 1 saline and then slowly and carefully layer over 15 mL Lymphoprep. Alternatively, Lymphoprep can be under-layered below the diluted blood using a long pipette. It is essential to avoid mixing of blood and Lymphoprep before centrifugation. Centrifuge the Lymphoprep and blood at 800g for 10 min at room temperature, with the centrifuge brake switched off. After centrifugation, the mononuclear cells (which include monocytes and lymphocytes) form a distinct band at the blood/Lymphoprep interface. Carefully remove this band using a Pasteur pipette and place in a fresh tube. Add an equal volume of 1 saline or HBSS to reduce the density of the solution and pellet these cells by gentle centrifugation (300 g, 10 min). Resuspend cells in 1 mL EasySep recommended medium (1 mM EDTA, 2% fetal calf serum (FCS) in PBS Dulbecco) and transfer this 1 mL cell suspension to a 5-mL Falcon tube. It is useful to count the number of mononuclear cells isolated at this step. Monocytes should typically represent 10% of this total mononuclear fraction. From this point, we follow the EasySep CD14 kit protocol exactly as described in order to isolate monocytes from the mononuclear cell population. In our experience, the most critical step in the Lymphoprep protocol is to ensure the centrifuge brake is switched off as this will ensure a tight band of mononuclear cells forms at the interface between serum and Lymphoprep. Another critical step is the careful layering of diluted blood over Lymphoprep to ensure no mixing occurs between the layers. Leaving the centrifuge brake on or inefficient layering technique will result in a diffuse mononuclear band at the interface, and a poor monocyte yield. Once monocytes are successfully isolated and counted they can be used in a variety of applications. For example, if performing stimulation experiments, monocytes can be cultured in RPMI containing 10% (v/v) FCS and 1% penicillin/streptomycin at 37 C in a 5% CO2 atmosphere for up to 24 h. However, it is essential that monocytes are cultured in polypropylene tubes,
88
Toma´s P. Carroll et al.
and not polystyrene tubes, as polystyrene promotes significant adherence and probable activation of monocytes.
2.2. Enzyme-linked immunosorbent assay In addition to its role in maintaining ER homeostasis, it has become apparent that ER stress-induced UPR activation can influence the expression of a subset of inflammatory genes. The spliced form of XBP-1 has been shown to control the production of IL-6 in the mouse B cell (Iwakoshi et al., 2003). XBP-1 was also shown to regulate the production of IFN-b in mouse macrophages subjected to ER stress (Smith et al., 2008). Another study in a mouse model of atherosclerosis demonstrated that accumulation of free cholesterol in macrophages caused UPR activation and the secretion of significant amounts of TNF-a and IL-6 (Li et al., 2005). Thus, the underestimated technique of enzyme-linked immunosorbent assay (ELISA) is a reliable method of investigating an aberrant immune response in monocytes, often a consequence of UPR activation. This quantitative method is highly reproducible, relatively cheap, and easy to perform. However, due to the large quantities of chemokines and cytokines secreted by monocytes, dilution of supernatants is often required and as little as 2 mL of supernatant can be sufficient in some cases, for example, when assaying IL-8. Another application for ELISA is in the investigation of impaired secretion of specific proteins. For example, we have used this technique to show impaired secretion of AAT from monocytes isolated from AATdeficient individuals (Carroll et al., 2010). 2.2.1. Required materials for IL-8 ELISA
Monocyte supernatants Immulon 2HB 96 well high-binding microtitre plates (Thermo Electron Corporation) Voller’s coating buffer (100 mM bicarbonate/carbonate buffer, pH 9.6) Wash buffer (0.05% Tween in PBS, pH 7.4) Blocking buffer (1% BSA, 0.05% Tween in PBS, pH 7.4) Recombinant human IL-8 (R&D Systems) Monoclonal antibody to human IL-8 (MAB208, R&D Systems) Biotinylated antibody to human IL-8 (BAF208, R&D Systems) Streptavidin–horseradish peroxidase (HRP) (Biolegend) ABTS substrate (Invitrogen)
2.2.2. ELISA to measure IL-8 Supernatants are recovered and protein concentrations determined by ELISA with specific antibodies to the secreted protein of interest, in this example, the chemokine IL-8. The day before, a high-binding 96-well
Measuring UPR Activation in the Monocyte
89
plate is coated with 100 mL per well of capture antibody (MAB208, 1/500 dilution) diluted in Voller’s buffer—this is a key point. If PBS is used as a diluent for the coating antibody, as stated in the manufacturer’s datasheet, the ELISA will not work. The plate is sealed and incubated overnight at 4 C. Next day, each well is aspirated and filled with wash buffer and repeated for a total of three washes using a multichannel pipette. Complete removal of the liquid at each step is achieved by inverting the plate and blotting on clean tissue paper. Plate is blocked by the addition of 200 mL of blocking buffer and incubated for 1 h at room temperature. Repeat aspiration and wash steps as before for three washes. Plates are filled with 100 mL per well of monocyte supernatant (diluted). Serial dilutions of recombinant human IL-8 in serum-free RPMI medium are performed to construct a standard curve (31.25–2000 pg/mL) and the plate is incubated for 2 h at room temperature. Plate is washed three times as before, 100 mL of the detection antibody (BAF208, 1/2500 dilution) is added to each well, and plate is incubated for a further 2 h. Next, plate is washed three times, 100 mL streptavidin–HRP is added (1/2500 dilution) and incubated for 30 min at room temperature. Another three washes are performed, and the plate is incubated with 100 mL ABTS for 5–30 min in a dark box or cupboard protected from direct light. It is useful to check the plate periodically for the development of a green color, and once a significant color is observed, measure the absorbance of each well at 405 nm on a Victor2 microplate reader (Wallac). Prepare a standard curve from the data produced from the serial dilutions with concentration on the X axis versus absorbance on the Y axis (linear). Interpolate the concentration of the sample from this standard curve using Prism 4.0 statistical analysis software (GraphPad). As an ancillary step to ELISA, cytokine arrays can be employed to measure multiple proteins in the monocyte supernatants (RayBiotech, Inc.). This technique, although expensive, allows the semiquantitative measurement of over 100 cytokines, chemokines, proteases, antiproteases, and growth factors from a single sample. Any potential leads can then be confirmed by ELISA or quantitative RT-PCR.
2.3. RNA isolation, cDNA synthesis, and RT-PCR There are inherent difficulties involved in measuring the activation of the major UPR orchestrators. The phosphorylation of PERK and IRE1 and the proteolytic cleavage of ATF6 are hallmarks of their activation. However, these proteins are expressed at very low levels and detection is hindered by a lack of high-quality commercial antibodies. As surrogate markers of activation, a number of UPR genes downstream of these proximal sensors have been identified, and can be easily measured by realtime PCR. For example, ATF4 is selectively activated by PERK-induced phosphorylation of eIF2a, and while IRE1 activation is difficult to
90
Toma´s P. Carroll et al.
reproducibly and consistently measure, the processing of unspliced XBP-1 mRNA into mature spliced XBP-1 (sXBP-1) mRNA is a convenient, widely used indicator of IRE1 activation (Marciniak et al., 2004). The expression of several other UPR-responsive genes can be easily measured in this way, including calreticulin, calnexin, CHOP, ERdj5, p97/VCP, GRP78, and GRP94. 2.3.1. Required materials
TRI reagent (Sigma) QuantiTect reverse-transcription cDNA synthesis kit (Qiagen) SYBR Green I Master mix (Roche) for real-time quantitative RT-PCR GoTaq Green Master mix (Promega) for conventional RT-PCR Oligonucleotide primers (Eurofins MWG Operon)
2.3.2. Real-time PCR For analysis of UPR markers, 500 mL TRI reagent is added to the isolated monocytes (in a fume hood) and RNA is recovered according to the manufacturer’s instructions. We prefer to resuspend RNA in 0.1% diethylpyrocarbonate (DEPC)-treated water, as DEPC is an efficient, nonspecific inhibitor of RNases. Store the isolated RNA at 80 C and avoid repeated freeze–thaw cycles. Quantify RNA concentration on a spectrophotometer prior to each separate cDNA synthesis. Equal quantities of RNA are then reverse transcribed into cDNA using the Quantitect Reverse Transcription kit. The resulting cDNA is used as the template for quantitative real-time PCR. Oligonucleotide primers are synthesized specific to each target UPR gene and quantitative PCRs performed containing 2 mL template cDNA, 10 mL 2 SYBR Green I master mix, 10 pmol of forward and reverse primers, and nuclease-free water to give a final volume of 20 mL. Amplification is performed on the Roche LightCycler 480 PCR system with the expression of target genes relative to the housekeeping gene b-actin determined using the 2 DDCT method (Livak and Schmittgen, 2001) (Fig. 5.1). 2.3.3. Analysis of XBP-1 mRNA cleavage XBP-1 mRNA splicing is analyzed in our laboratory using a conventional semiquantitative RT-PCR assay developed by Harding et al. (Calfon et al., 2002). RNA is isolated using TRI reagent and cDNA synthesized as described. The resulting cDNA is template in a reaction with GoTaq master mix and specific XBP-1 forward and reverse primers. The primers used to amplify XBP-1 cDNA: forward 50 -AAACAGAGTAGCAGCTCAGACTGC-30 ; reverse 50 -TCCTTCTGGGTAGACCTCTGGGA-30 . PCR products are resolved on a 2.5% agarose gel with unspliced XBP-1 yielding a product of 480 bp, while spliced XBP-1 is 454 bp. Agarose gel
91
Measuring UPR Activation in the Monocyte
40 Relative mRNA
CRT
30
sXBP-1 GRP78
20 10 0 0
100 Thapsigargin (nM)
300
Figure 5.1 Quantitative RT-PCR analysis of calreticulin (CRT), sXBP-1, and GRP78 mRNA induction in peripheral blood monocytes after treatment with thapsigargin for 4 h.
electrophoresis may need to be performed for up to 2 h to detect an appreciable difference between spliced and unspliced XBP-1.
2.4. Detection of UPR markers by immunoblotting As previously described, the phosphorylation of PERK and IRE1 and the proteolytic cleavage of ATF6 are difficult to detect. However, the activation of a number of other downstream UPR proteins such as ATF4, CHOP, GRP78, and p97/VCP can be detected by Western blotting. 2.4.1. Immunoblotting method Monocytes are isolated as described, pelleted by gentle centrifugation (400g, 5 min) and cells resuspended in 1 mL hypotonic buffer (10 mM Hepes (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM PMSF, and 0.5 mM DTT) (Sigma). Cells are lysed for 30 min on ice before centrifugation at 14,000g for 10 min at 4 C. The supernatant is then recovered for immunoblotting and stored at 80 C until required. Protein concentration in the monocyte lysate is determined by the method of Bradford (1976). Whole cell lysates are separated by electrophoresis on SDS-polyacrylamide gel and transferred to a PVDF membrane (Sigma). The percent polyacrylamide used will depend on the size of the UPR protein being investigated. PVDF membranes can be cut to investigate the levels of multiple proteins if there is sufficient difference in the size of the proteins being examined, and this can eliminate the need to strip and reprobe membranes. Nonspecific binding is blocked with 5% bovine serum albumin (Sigma) in PBS containing 0.1% Tween-20 (Sigma). Immunoreactive proteins are detected by incubating the membrane with specific antibodies to UPR proteins of interest, for example, the excellent anti-KDEL antibody
92
Toma´s P. Carroll et al.
which detects GRP78 and GRP94 (Stressgen), and comparing with appropriate loading controls such as GAPDH or b-actin.
2.5. Immunofluorescence Immunofluorescence is a powerful tool that can be used to demonstrate the accumulation of misfolded protein within the ER. For example, we have used this technique to show intracellular accumulation of AAT within the ER of monocytes from AAT-deficient individuals, as well as increased GRP78 and GRP94 expression (Carroll et al., 2010). 2.5.1. Required materials
Poly-L-lysine coated slides (Sigma) 4% paraformaldehyde (Sigma) diluted in PBS 0.2% Triton X-100 diluted in PBS (permeabilization buffer) 4% BSA/1% gelatin in PBS (blocking buffer) Vectashield (Vector Laboratories)
2.5.2. Colocalization using immunofluorescence This method is used to investigate AAT localization to the ER by doublestaining monocytes with an antibody to AAT and an antibody to ERresident chaperones containing the tetrapeptide KDEL motif. Monocytes are isolated as described and 100 mL of monocyte suspension pipetted onto a poly-L-lysine glass slide (“P” side up). Score the slide with a diamond pen to indicate the position of cells. Poly-L-lysine coated slides should be used as they provide higher adhesion, reducing the chances of tissue or cell loss during processing. The cells are allowed to adhere to slide for 10 min and then fixed in 4% paraformaldehyde. The cell membranes are disrupted in 0.2% Triton X-100. Nonspecific binding of antibodies and fluorescent conjugates are blocked by preincubation in 4% BSA/1% gelatin. Colocalization of AAT and ER-specific chaperones is detected by immunofluorescence using goat polyclonal anti-AAT-FITC (Abcam) and mouse monoclonal anti-KDEL (Stressgen), with an anti-mouse tetramethylrhodamine isothiocyanate (TRITC) secondary conjugate (Abcam) for visualization of the anti-KDEL antibody. PBS washes (3) are performed after each incubation, and ensure that the addition and removal of solutions are performed carefully in the corner of the slides so as not to disturb or dislodge the monocytes. Cells are then mounted in Vectashield, containing 40 ,6diamidino-2-phenylindole di-lactate (DAPI), and examined using a LSM510 Meta laser scanning confocal microscope (Zeiss). Images are captured at 63 magnification and 4 zoom with excitation wavelengths for FITC, TRITC, and DAPI of 488, 543, and 364 nm, respectively (Fig. 5.2).
93
Measuring UPR Activation in the Monocyte
AAT
KDEL
Merge
MM
DAPI
5 mm
5 mm
5 mm
5 mm
5 mm
5 mm
5 mm
ZZ
5 mm
Figure 5.2 Intracellular accumulation of AAT and increased KDEL expression in the ER of ZZ monocytes. The subcellular distribution of AAT in monocytes isolated from MM (normal) and ZZ (AAT-deficient) individuals was determined by immunofluorescence using antibodies for AAT (green) and the ER marker KDEL (red), with colocalization indicated by yellow staining. Nuclei were stained with DAPI (blue). Imaging was acquired using a Zeiss LSM510 Meta confocal microscope and the images presented are single focal plane scans of 1 mm depth at the midsection of the fixed cells.
ACKNOWLEDGMENTS We are thankful to Dr. Warren Thomas and Dr. David Bergin for assistance with confocal imaging and analysis, and all the members of the Department of Medicine, RCSI Beaumont Hospital, both past and present. This work was supported by financial assistance from the Alpha One Foundation (Ireland), the Alpha One Foundation (US), the Health Research Board (HRB), the Medical Research Charities Group, the Children’s Research Centre Crumlin Hospital, the Program for Research in Third Level Institutes (PRTLI), Talecris Biotherapeutics, and the Royal College of Surgeons in Ireland. Confocal imaging experiments were performed on equipment supported by the Higher Education Authority (HEA) of Ireland through the National Biophotonics and Imaging Platform Ireland (NBIPI).
REFERENCES Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254. Calfon, M., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, S. G., and Ron, D. (2002). IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415, 92–96.
94
Toma´s P. Carroll et al.
Carroll, T. P., Greene, C. M., O’Connor, C. A., Nolan, A. M., O’Neill, S. J., and McElvaney, N. G. (2010). Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J. Immunol. 184, 4538–4546. Dale, D. C., Boxer, L., and Liles, W. C. (2008). The phagocytes: Neutrophils and monocytes. Blood 112, 935–945. Harding, H. P., Zhang, Y., and Ron, D. (1999). Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397, 271–274. Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., Sadri, N., Yun, C., Popko, B., Paules, R., Stojdl, D. F., Bell, J. C., et al. (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619–633. Iwakoshi, N. N., Lee, A. H., Vallabhajosyula, P., Otipoby, K. L., Rajewsky, K., and Glimcher, L. H. (2003). Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 4, 321–329. Kaufman, R. J. (1999). Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev. 13, 1211–1233. Komura, T., Sakai, Y., Honda, M., Takamura, T., Matsushima, K., and Kaneko, S. (2010). CD14þ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes. Diabetes 59, 634–643. Li, Y., Schwabe, R. F., DeVries-Seimon, T., Yao, P. M., Gerbod-Giannone, M. C., Tall, A. R., Davis, R. J., Flavell, R., Brenner, D. A., and Tabas, I. (2005). Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: Model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. J. Biol. Chem. 280, 21763–21772. Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) Method. Methods 25, 402–408. Malhotra, J. D., and Kaufman, R. J. (2007). The endoplasmic reticulum and the unfolded protein response. Semin. Cell Dev. Biol. 18, 716–731. Marciniak, S. J., Yun, C. Y., Oyadomari, S., Novoa, I., Zhang, Y., Jungreis, R., Nagata, K., Harding, H. P., and Ron, D. (2004). CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 18, 3066–3077. Medzhitov, R., and Janeway, C., Jr. (2000). Innate immunity. N. Engl. J. Med. 343, 338–344. Mori, K. (2000). Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 101, 451–454. Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529. Smith, J. A., Turner, M. J., Delay, M. L., Klenk, E. I., Sowders, D. P., and Colbert, R. A. (2008). Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1. Eur. J. Immunol. 38, 1194–1203. Tirasophon, W., Welihinda, A. A., and Kaufman, R. J. (1998). A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. Genes Dev. 12, 1812–1824. Travers, K. J., Patil, C. K., Wodicka, L., Lockhart, D. J., Weissman, J. S., and Walter, P. (2000). Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell 101, 249–258. Vij, N., Fang, S., and Zeitlin, P. L. (2006). Selective inhibition of endoplasmic reticulumassociated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and
Measuring UPR Activation in the Monocyte
95
suppresses interleukin-8 levels: Therapeutic implications. J. Biol. Chem. 281, 17369–17378. Yeo, C., Saunders, N., Locca, D., Flett, A., Preston, M., Brookman, P., Davy, B., Mathur, A., and Agrawal, S. (2009). Ficoll-Paque versus Lymphoprep: A comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. Regen. Med. 4, 689–696. Yoshida, H., Haze, K., Yanagi, H., Yura, T., and Mori, K. (1998). Identification of the cisacting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J. Biol. Chem. 273, 33741–33749. Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., and Mori, K. (2001). XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107, 881–891. Zaman, M. M., Gelrud, A., Junaidi, O., Regan, M. M., Warny, M., Shea, J. C., Kelly, C., O’Sullivan, B. P., and Freedman, S. D. (2004). Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin. Diagn. Lab. Immunol. 11, 819–824.
This page intentionally left blank
C H A P T E R
S I X
Assessment of Endurance Exercise Training in Hepatic Endoplasmic Reticulum Stress Natalie Ann Chapados Contents 98 99 99 103 104 105 105 105 106 106
1. Introduction 2. Assessment of an Endurance-Training Program 2.1. Procedures 2.2. Inculcate good running behaviors 3. “Dietary-Inducible” Hepatic ER Stress 4. Assessment of Hepatic ER Stress Molecular Markers 4.1. Procedures: Handling of the liver 5. Required Materials Acknowledgments References
Abstract Hepatic endoplasmic reticulum (ER) stress has recently been associated with several health complications such as obesity, type 2 diabetes, and hepatic steatosis. Exercise training has been recognized for many years to have important beneficial effects in these metabolic complications, however much remains unknown regarding the effects of exercise training on ER stress in the liver. A better understanding of the effects of exercise training on hepatic ER stress response requires studies in which the exercise training protocol is well assessed. Therefore, the purpose of this chapter is to provide detailed description of an endurance-training program and suggest a dietary approach in order to help induce and study changes in ER stress molecular markers expression levels in the liver of rats in response to exercise training.
Institut de Recherche de l’Hoˆpital Montfort/Montfort Hospital, Research Institute, Ottawa, Ontario, Canada Methods in Enzymology, Volume 489 ISSN 0076-6879, DOI: 10.1016/B978-0-12-385116-1.00006-6
#
2011 Elsevier Inc. All rights reserved.
97
98
Natalie Ann Chapados
1. Introduction The endoplasmic reticulum (ER) plays an important role in the folding process of newly synthesized protein in a living organism. Alteration of this process is associated with ER stress appearance and activation of the unfolded protein response (UPR). Briefly, the UPR pathway implicates the activation of three transmembrane proteins (PERK, ATF6, and XBP1) by a cytosolic chaperone protein (BiP/GRP78) in order to establish ER homeostasis (Flamment et al., 2010). Researchers have detected the presence of ER stress in various tissues such as the neuron (Um et al., 2008), the adipose tissue (Xu et al., 2010), and the liver (Ozcan et al., 2004; Wang et al., 2006), providing new insights on ER stress implication in different health complications such as Alzheimer’s disease (Um et al., 2008), diabetes (Ozcan et al., 2004), and hepatic steatosis (Wang et al., 2006). The physiological effects of an exercise training program have been well documented over the years. In fact, exercise training is known to have beneficial metabolic effects in various health complications such as obesity, type 2 diabetes, and hepatic steatosis in humans (Eriksson et al., 2010; Kantartzis et al., 2009) and animals (Marques et al., 2010). These findings imply that the systemic effects of exercise training in the development of these health problems could possibly translate at the cellular level, that is, ER stress. Exercise training programs have been showed to have potential effects on ER stress in tissues such as the skeletal muscle and the brain. For instance, studies have reported two- to threefold increase of GRP78 protein expression in the soleus and extensor digitorum longus in rats following a 3-month treadmill program compared to sedentary rats (Gonzalez et al., 2000). Furthermore, 16 weeks of treadmill training in mice resulted in a significant increase in GRP78 protein expression in the brain of Alzheimer patients (Um et al., 2008). As for the liver, the only evidence is demonstrated by the study of the acute effects of exercise. Gonzalez et al. (Gonzalez and Manso, 2004) reported that rats exposed to a single exercise bout increased GRP78 protein expression by twofold compared to sedentary rats. When investigating the impact of exercise in animal models, just as in humans, the importance of using a well-designed training program must not be overlooked. Only a carefully crafted training protocol is likely to provide relevant and interpretable data. While a plethora of information is available for establishing standard human training regimen, the design of a training program for rodents could be seen as rather challenging. Therefore, the purpose of this chapter is to provide a detailed assessment of an endurance exercise protocol to study molecular changes in hepatic ER stress in rats. Hopefully, this technique will help minimize the difficulties regarding the
99
Endurance Training on Liver ER Stress in Rats
assessment of an adequate training program and induce cellular changes in hepatic ER stress molecular makers in rats.
2. Assessment of an Endurance-Training Program Adopting a fit exercise program to induce changes.
2.1. Procedures The next section consists of three types of exercise training protocol on treadmill: (1) increasing speed, constant slope; (2) increasing slope, constant speed; and (3) increasing speed and slope. 2.1.1. Increasing speed, constant slope The exercise training protocol presented in this section is based on established values of VO2max levels conducted in rats. Shepherd et al. (Shepherd and Gollnick, 1976) assessed VO2max in Sprague–Dawley rats using a motor-driven work wheel equipped with a metabolic chamber. Oxygen uptake measurements were performed during exercise at seven different speeds (16–67 m min 1) when the slope was null (0 of inclination). Values ranged from 6.44 ml (100 g min) 1 when rats ran at 16 m min 1 and increased 30% at 67 m min 1. As shown in Table 6.1, VO2 ml (100 g min) 1 increased linearly with running speed intensity (m min 1) up to a maximal value of 9.51 0.14 ml (100 g min) 1 at 49.5 m min 1. Thereafter, the average VO2 ml (100 g min 1) decreased slightly to 9.39 0.15 ml (100 g min) 1 at a running speed of 67.0 m min 1. In addition, I have included in Table 6.1 Table 6.1 Oxygen uptake in rats during exercise at different speeds (m min 1) Speed (m min 1) VO2 ml (100 g min 1) VO2 (ml kg 1 min 1) % VO2max
0 16.0 22.5 28.5 39.0 49.5 53.5
2.42 6.44 7.26 7.75 8.85 9.51 9.49
0.1 0.16 0.15 0.14 0.14 0.14 0.14
24.2 64.4 72.6 77.5 88.5 95.1 94.9
1.0 1.6 1.5 1.4 1.4 1.4 1.4
Baseline 67.7 76.3 81.5 93.0 100 99.8
Adapted from Shepherd et al. (Shepherd and Gollnick, 1976). Values are expressed by means S.E. Pooled data from three groups of rats, 16 rats per group.
100
Natalie Ann Chapados
120
VO2 (ml kg−1 min−1)
100 80 60 40 20 0
0
10
20
30
40
50
60
m min-1
Figure 6.1 Linear relationship between increasing speed (16–49.5 m min 1) and VO2 (ml kg 1 min 1) in Sprague–Dawley rats. Adapted from Shepherd et al. (Shepherd and Gollnick, 1976). Values are expressed by means S.E. of pooled data from three groups of rats, 16 rats per group.
converted values of VO2 expressed in ml kg 1 min 1 derived from initial values expressed in ml (100 g min) 1 obtained from Shepherd et al. (Shepherd and Gollnick, 1976) as well as % VO2max. Thereafter, VO2 (ml kg 1 min 1) and speed (m min 1) values were plotted and presented in Fig 6.1 in order to obtain Eq. (6.1) derived from the linear relationship between increasing speed (16–49.5) and VO2. y ¼ 0:9169x þ 51:106ðr ¼ 0:98Þ
ð6:1Þ
Equation (6.1) will therefore help to predict VO2 at a given speed (between 16 and 49.5 m min 1) when the slope is constant at 0 . 2.1.2. Increasing slope, constant speed As mentioned earlier, values provided from Shepherd et al. (Shepherd and Gollnick, 1976) presented in Table 6.1 and the Eq. (6.1) derived from the linear relationship between VO2 (ml kg 1 min 1) and speed (m min 1) (Fig. 6.1) were obtained when the slope is constant at 0 . Therefore, it has been reported that an increase of one slope incline increases 0.44 mlO2 kg 1 min 1 in oxygen consumption, representing about 0.5% of VO2max for each slope incline (Norton et al., 1990). Figure 6.2 represents an example of the relationship between the increasing slope ( ) and the VO2 (mlO2 kg 1 min 1) when the speed is constant (e.g., here the
101
Endurance Training on Liver ER Stress in Rats
74.5 74
VO2 (ml kg -1 min-1)
73.5 73 72.5 72 71.5 71 70.5 70 69.5 0
2
4
6
8
10
Incline (⬚)
Figure 6.2 Relationship between speed (m min 1) and VO2 (ml kg 1 min 1) in Sprague–Dawley rats when speed is constant at 20 m min 1. An increase of each inclination of 1 increases 0.5% of VO2max. Here, a speed of 20 m min 1 corresponds to an oxygen uptake of 69.44 ml kg 1 min 1 at 0 incline.
speed is constant at 20 m min 1). Equation (6.2) derived from the relationship presented in Fig. 6.2 is y ¼ 0:4403x þ VO2 mlO2 kg1 min1 ð6:2Þ at 0 slope value (e.g., here VO2 corresponds to 69.44 mlO2 kg 1 min 1 at speed 20 m min 1). The exercise training protocol that I proposed in the following section is an enforced training protocol on a treadmill that is generally used in our laboratory. This type of program ensures a precise control of the training stimulus and therefore could serve as a rigorous model to study the physiological effects of exercise training in rats. 2.1.3. Increasing speed and slope (proposed endurance-training program) The endurance-training program (Table 6.2) consists of a 6-week endurance running program in Sprague–Dawley rats starting when rats are 6 weeks of age. Rats were trained to run 5 days week 1 for 6 weeks on a motor-driven treadmill with 10 individual lanes (Quinton Instruments, Seattle, WA, USA). We kept rats in a 12 h light–dark cycle (6 a.m.–6 p.m. light; 6 p.m.–6 a.m. dark). Since rodents are not normally active during the
102